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Abstract

GLIAL CELL MECHANISMS REGULATE ALCOHOL SEDATION IN DROSOPHILA
MELANOGASTER
Kristen Mary Lee
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2019.
Major Director: Mike Grotewiel, PhD
Assistant Graduate Dean
Associate Professor, Human & Molecular Genetics

Approximately 16 million people in America are diagnosed with Alcohol Use Disorder
(AUD) but no efficacious medical treatments exist. Alcohol-related behaviors can be
studied in model organisms, and changes in these behaviors can be correlated with
either (i) a risk for alcohol dependence or (ii) a symptom/feature of AUD itself. Although
AUD is a disease of the central nervous system, a majority of research has focused on
the neuronal underpinnings, leaving glial contributions largely undescribed. We used
Drosophila melanogaster (fruit fly) to identify genes whose expression in glia regulates
alcohol sedation. Mammals and Drosophila have conserved behavioral responses to
alcohol and functionally similar adult glial cells, especially astrocytes. Since previous
research in mammals and flies has demonstrated that glia respond to alcohol
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administration, we hypothesized that glia are important regulators of alcohol-related
behaviors. To pursue this, we characterized a pan-glial steroid-inducible GeneSwitch
transgenic fly, which allows gene manipulation within glia during adulthood. We
performed a targeted screen and manipulated genes that were known to be expressed
within Drosophila glia and measured their alcohol sedation sensitivity using the ethanol
sedation assay. We identified the genes Cysteine proteinase 1 (Cp1) and Tyramine
decarboxylase 2 (Tdc2). Knocking down Cp1 in cortex glia, as well as all glia during
adulthood, increased alcohol sedation sensitivity and may also enhance rapid tolerance
development. We could not identify what pathway Cp1 was functioning within to
mediate this response, suggesting that Cp1 may have a unique function within glia.
Knockdown or overexpression of Tdc2 in glia increased or decreased alcohol sedation
sensitivity, respectively. Tdc2 functions upstream of the vesicular monoamine
transporter (VMAT) and the SNARE complex to regulate alcohol sedation. These results
were specific to astrocytes, as well as all glia during adulthood. These results suggest
that tyramine synthesis via Tdc2 and its release via vesicular exocytosis regulates
alcohol sedation. Taken together, these results suggest that glia are important
regulators of alcohol-related behaviors in flies. Interestingly, fly cortex glia and
astrocytes are functionally similar to mammalian astrocytes, indicating that these results
may be translatable to mammals.

CHAPTER 1: INTRODUCTION

A. ALCOHOL ABUSE AND ALCOHOL USE DISORDER
Approximately 86% of people have drunk alcohol at some point in their lifetime, and
roughly 2.4 billion people are currently alcohol drinkers worldwide1. While these
statistics may not be surprising, 2.8 million deaths were caused by alcohol use in 2016,
making alcohol the leading cause of premature death of people ages 18-49
worldwide1,2. Continued, problematic and severe alcohol consumption can lead to the
diagnosis of an alcohol use disorder (AUD). Although AUD is a spectrum disorder, it is
largely characterized by a (i) compulsive and uncontrolled use of alcohol and (ii) a
negative emotional state when not using alcohol3. Depending on the number of DSM-5
criteria met, AUDs can be classified as mild, moderate or severe3. In 2015, it was
estimated that 16 million people in the United States were living with AUD. However,
only 7% of this population received any medical treatment1. No new pharmacotherapies
for AUD have been approved in over a decade, and the only Food and Drug
Administration approved drug is naltrexone4. Together, these statistics highlight the
need to better understand the biological progression from alcohol use to AUD so more
efficacious treatments can be discovered.
Alcohol use impacts central nervous system (CNS) function, and AUD is a disease
of the central nervous system5. Since many parallels have been made between alcoholrelated behaviors and alcohol abuse and dependence, there is a continuing effort to use
1

model organisms to identify genes and mechanisms underlying alcohol-related
behaviors to better understand the role of the CNS during alcohol use, abuse and
dependence. Identifying novel genes and mechanisms may facilitate the discovery of
novel treatments for humans with AUD. Although the central nervous system contains
both glia and neurons, the majority of research to date has focused on the role of
neuronal mechanisms in alcohol-related behaviors. Thus, there is likely much to be
learned by investigating the role of glia in behavioral responses to alcohol.
The model organism Drosophila melanogaster is a well-established model for
identifying novel genes and mechanisms that regulate alcohol-related behaviors.
Considering that flies and mammals have conserved behavioral responses to alcohol,
as well as functionally homologous glial cells, we postulate that the fly is an excellent
model to investigate how glial cells influence alcohol-related behaviors (reviewed in
sections B and C). Additionally, previous research has demonstrated that glia in human
alcoholic post-mortem tissue, rodents and flies are altered in the presence of alcohol
(reviewed in section D). While there is still much to be learned, this body of work
supports the notion that glia do respond to alcohol administration and influence alcoholrelated behaviors.

B. DROSOPHILA MELANOGASTER AS A MODEL TO STUDY ALCOHOLRELATED BEHAVIORS
In both humans and flies, lower doses of alcohol produce a stimulant effect,
characterized by hyperactivity6,7. Conversely, higher doses of alcohol lead to
depressant effects, such as motor impairment and sedation7,8. Flies and humans can
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both develop tolerance to alcohol, but rapid tolerance and chronic tolerance are typically
measured in the fly. Flies can develop tolerance in the presence of a brief exposure to a
high, sedating, dose of ethanol (rapid tolerance) or in the presence of a long exposure
to a non-sedative dose of alcohol (chronic tolerance)9. It is largely accepted that chronic
ethanol exposure can result in long term changes in the brain, and this is thought to be
a sign of dependence, and can lead to withdrawal symptoms. In the absence of ethanol,
as a sign of withdrawal, humans experience dysphoria, anxiety, cognitive impairment
and seizures10. By electrically stimulating the brain and recording seizure like activity in
the flight muscle, seizures can be studied in the fly11. The threshold for inducing
seizures is lower in flies previously exposed to ethanol11. Another hallmark feature of
alcohol dependence is uncontrolled use and continued consumption despite aversion7.
Ethanol consumption can be measured in the fly, and when given a choice between
food with or without ethanol, flies develop a preference for the ethanol containing food 12.
This preference persists when the aversive, bitter tasting compound quinine is added to
the ethanol containing food12. Interestingly, by associating ethanol vapor with an odor,
flies will even undergo an electric shock for the alcohol associated cue 13.
Additionally, there are conserved molecular mechanisms regulating alcohol-related
behaviors in flies and mammals. For example, the same alcohol metabolism machinery
exists in flies and mammals and it is essential to avoid ethanol toxicity14,15. Specifically,
alcohol is converted to acetaldehyde by alcohol dehydrogenase (ADH), and
acetaldehyde is converted to acetate by aldehyde dehydrogenase 16. Mutations in the
ADH gene reduce hyperactivity in response to a low dose of ethanol and increase
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sensitivity to a high dose in flies6,17. In humans, ADH variants produce an inactive form
of the enzyme, and protect against AUD development5.
Various neurotransmitters have also been implicated in alcohol abuse, including Aminobutyric Acid (GABA), dopamine and neuropeptide Y. Antagonizing the GABA-B
receptor in flies blunts the loss of postural control associated with a high dose of
alcohol18. Interestingly, the GABA-B receptor has been associated with alcohol
consumption and motivation in rats and alcohol withdrawal and cravings in humans19.
Additionally, knocking out the dopamine D1-like receptor in flies decreases ethanolinduced hyperactivity, suggesting that dopamine contributes to the stimulant effect of
alcohol in flies20. In mammals, dopamine mediates the rewarding properties of drugs of
abuse, including alcohol21 and the stimulating effect of alcohol is reported as
rewarding7. Neuropeptide Y (NPY) has also been implicated in alcohol consumption and
dependence in mammals22. The fly orthologue to NPY is neuropeptide F (NPF), and
flies with decreased NPF signaling are resistant to alcohol sedation23. Together, this
research supports that flies have a conserved behavioral response to alcohol, and that
many genes that alter alcohol-related behavior in flies have also been implicated in
mammalian, and even human, alcohol use and abuse.
Additionally, many tools exist in the fly to manipulate gene expression, which makes
it feasible to screen large sets of genes to determine if any influence alcohol behavior.
For example, the Gal4-UAS system allows constitutive transgene expression in specific
tissues or cell types24. The Gal4 “driver” is expressed via tissue-specific promoters, and
only Gal4 can bind to and activate a specific upstream activator sequence (UAS) that is
followed by a transgene of choice. Once the UAS is activated, that transgene is
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transcribed24. Commercially available UAS-transgenes include RNAi’s to knockdown
specific genes, dominant negatives to functionally silent genes, and duplicate copies to
overexpress a specific gene. Similar systems exist with different “driver” proteins (i.e.
LexA or Q), which recognize their own “UAS” sequences (i.e. LexAop or QUAS) 25,26.
When used together, unique manipulations can be made in different cell types at the
same time27. These systems can also be temporally controlled by temperature shifts
and drug treatments. For example, Gal80 proteins repress Gal4 proteins and can be
temperature sensitive (Gal80ts)28. In the Gal4 restrictive temperature (18°C) the Gal80
protein is activated, and the Gal4 protein is repressed. At the Gal4 permissive
temperature (30°C) the Gal80 protein is inactive and the Gal4 protein is functional.
Additionally, GeneSwitch (GS) drivers are tissue specific, steroid-inducible Gal4 drivers,
which allow temporal control over UAS-transgene induction29. Utilizing this system,
when the steroid is not present, the Gal4 protein is inactive and expression of the UAStransgene is not induced. When the steroid is present, however, the Gal4 protein is
activated and can induce expression of the UAS-transgene. The steroid (RU486 or
mifepristone) can be administered to flies through their food. Therefore, flies with GSand UAS-transgenes fed steroid during adulthood will have the UAS-transgene
expressed during adulthood. Conveniently, many tools exist to manipulate glia and glial
cell subtypes in flies.
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C. DROSOPHILA MELANOGASTER AS A MODEL TO STUDY ADULT CNS
GLIAL CELLS
The adult mammalian CNS has three major glial cell subtypes: oligodendrocytes,
microglia and astrocytes, as well as other glial cells like NG2 cells and polydendrocytes.
A core function of oligodendrocytes is forming myelin sheath around neuronal axons in
the CNS, allowing fast conductance of action potentials and trophic support 30. Microglia
are the primary immune cell in the mammalian brain; they are constantly surveying their
microenvironment for foreign pathogens or danger signals, and can secrete pro- or antiinflammatory molecules in response31. Astrocytes can interact with the blood brain
barrier (BBB), other glia and neurons, and play a role in maintaining overall brain
homeostasis32.
The adult fly CNS contains five glial cell subtypes: subperineural glia, perineural glia,
ensheathing cells, cortex glia and astrocytes. The subperineural and perineural glia
(also termed surface glia) make up the BBB of the fly. While they express similar
proteins found in the mammalian BBB33, they do not share any functional or molecular
similarities with mammalian CNS glia. Like their name implies, ensheathing glia
encapsulate axon bundles34. Ensheathing glia can also regulate neuronal excitability by
metabolizing glutamate35, as well as engulf neuronal debris36-38. Cortex glia surround
neuronal cell bodies and maintain the microenvironment 39. Additionally, fly astrocytes
extend processes into the synapse and maintain the synaptic environment 27. In the fly
CNS, macrophages are the primary immune cell and it is currently believed that flies do
not have microglia40.
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In a healthy brain, fly ensheathing glia and mammalian oligodendrocytes share
some similarities: they are both closely associated with neuronal axons and provide
some support30,35. However, the fly CNS does not contain myelin40 and during trauma,
ensheathing glia become highly phagocytic36, when oligodendrocytes typically become
damaged and can die41-43. This suggests that ensheathing glia and oligodendrocytes
are fundamentally different, and that studies using fly glia may not be translatable to
mammalian oligodendrocytes. However, mammalian astrocytes share many
morphological and functional similarities with fly cortex glia and fly astrocytes,
suggesting that studying these cell types in flies may be translatable to mammals.
Mammalian astrocytes and their fly counterparts will be reviewed in sections 1 and 2
below.

C.1 A FUNCTIONAL OVERVIEW OF MAMMALIAN ASTROCYTES
Astrocytes are the most abundant cell type in the mammalian CNS and tile the entire
CNS with fine processes in a non-overlapping manner44. One astrocyte can contact
approximately 100,000 and 2,000,000 synapses in rodents and humans, respectively45.
This allows astrocytes to function in close proximity with neurons, blood vessels, and
other glial cells, therefore allowing these cells to regulate overall brain homeostasis.
Astrocytes provide support to neurons through ion homeostasis, transmitter clearance
and recycling, direct modulation of neuronal signaling and provide metabolites and
nutrients32. Astrocytes also participate and maintain the BBB, where their perivascular
end feet directly contact blood vessels and transfer metabolites from the blood to
neurons46,47. Additionally, astrocytes function in a network and can communicate with
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each other through gap junctions. In the hippocampus, there are approximately 15
astrocytes per network in the rat48, and 18 astrocytes per network in the mouse49. While
not electrically excitable like neurons, astrocytes display a form of excitability based on
intracellular calcium variations50. Intracellular calcium can be transferred between gap
junctions, allowing one calcium event which originated in one astrocyte to reach
thousands of synapses51. These calcium events are in response to neurotransmitters,
neuromodulators and changes in the extracellular space52, and can lead to the release
of gliotransmitters. Astrocytes also respond to pathological insults, a process known as
astrogliosis, which can alter their functions. Astrocyte functions in a healthy mature
brain, as well as under pathological insults, will be reviewed in detail below.
Among others, two ways astrocytes regulate synaptic activity is through
neurotransmitter uptake and ion homeostasis. One of the defining features of astrocytes
is their enrichment for glutamate and GABA transporters, which efficiently clear the
respective neurotransmitters (NTs) from the extracellular space after neuronal
activity53,54. Astrocyte expression of the excitatory amino acid transporters (EAAT)
glutamate transporter 1 (GLT-1) and glutamate-aspartate transporter (GLAST), as well
as the cysteine glutamate anti-transporter (xCT), prevents glutamate-derived neuronal
excitotoxicity55,56. These transporters also control glutamate spillover outside of the
synapse, allowing glutamate to function solely in the synapse it was released into 57.
Additionally, once glutamate has been transported into the astrocyte, it can be
converted to glutamine via glutamine synthetase and recycled back to the neuron 58.
The GABA transporters (GATs) 1 and 3 are expressed in astrocytes. GAT-1 reduces
GABA spillover outside the synapse and GAT-3 regulates extracellular GABA
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concentrations, consequently regulating tonic synaptic inhibition59. In the hippocampus,
activation of GAT-3 leads to an increase in intracellular sodium (Na+) concentrations,
and a sequential increase in calcium (Ca2+) via Na+/Ca2+ exchangers60.
When neurons are undergoing an action potential, they release a large amount of
potassium (K+) into the extracellular environment. To maintain neuronal activity,
astrocytes engage in K+ buffering. While astrocytes express multiple K+ channels56, the
most studied is the inwardly rectifying K+ (Kir) channel, Kir4.1, which controls the
hyperpolarized resting potential of astrocytes61. Expression of Kir4.1 on astrocyte
processes allows a rapid uptake of K+ from the synapse62 and reduced Kir4.1
expression in astrocytes is associated with elevated extracellular K+ and an increase in
neuronal membrane depolarization63. Interestingly, the aquaporin-4 water channel is
also highly expressed in the same subcellular regions as Kir4.1 on astrocytes. It is
believed that K+ uptake via Kir4.1 generates a parallel water influx through aquaporin-4,
which regulates osmotic changes within the astrocyte64. However, K+ clearance from the
synaptic cleft is not limited to Kir4.1; astrocytic Na+/K+ ATPase activity in the
hippocampus and optic nerve is also important for K+ buffering during neuronal
activity65,66.
Astrocyte membranes also express many calcium channels and exchangers which
are important for Ca2+ mediated events. For example, transient receptor potential (TRP)
channels allow Ca2+ influx in response to various changes in the environment. TRPA1
mediated Ca2+ influx contributes to the astrocytes’ resting cytosolic Ca2+ levels67.
Mechanical stimulation can activate Ca2+ influx via TRPC168, TRPC369 and TRPV4
channels70. In vivo mechanical stimulation of astrocytes can occur in response to blood
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flow, allowing astrocytes to be sensitive to local changes in vasomotion 71. Temperature
changes also activate Ca2+ influx via TRPV1 channels72. Local brain temperature can
change in response to metabolic heat produced by physiological activity or
pathology73,74. Additionally, astrocytes express voltage-gated Ca2+ channels (VGCCs) in
vivo75,76. While VGCCs do not contribute to internal Ca2+ concentrations at rest, they
may be recruited to the membrane to function under depolarizing or pathological
conditions77,78, but this is controversial79. Although TRP channels and VGCCs are
important for Ca2+ influx, the Na+/Ca2+ exchanger is important for Ca2+ efflux. This
exchanger brings three Na+ into, and one Ca2+ out, of the cell. However, when
astrocytic intracellular Na+ is elevated, NCX can function in the opposite mode, and thus
cause Ca2+ influx80.
Astrocytes also express many NT receptors and their activation can lead to
increases in intracellular calcium. These NTs include acetylcholine, ATP, GABA,
endocannabinoids, and glutamate81. There is also evidence that astrocytes respond to
the neuromodulators norepinephrine82,83 and dopamine84 as well as neuroendocrine
molecules85. Activation of the ionotropic N-methyl-D-aspartate (NMDA) glutamate
receptor and ionotropic purinergic P2X(1/5) ATP receptor causes an influx of cations,
such as Ca2+86. Additionally, many of these receptors are G-protein coupled receptors
(GPRC), and activation of Gq GPRCs can lead to increases in intracellular calcium
indirectly through increases in phospholipase C (PLC) production. PLC converts
phosphatidylinositol biphosphate (PIP2) to diacylglycerol (DAG) and inositol
triphosphate (IP3). The endoplasmic reticulum (ER) in astrocytes has IP3 receptors,
which require Ca2+ and IP3 as co-agonists87,88. Upon activation, the IP3 receptors
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release Ca2+ from the ER, thus raising intracellular Ca2+ levels within the astrocyte89.
Gq GPCRs expressed on astrocytes include the metabotropic glutamatergic receptor 5
(mGluR5)90, the purinergic P2Y receptor91, the serotonergic 5HT2A receptor92 and the
adrenergic 1A receptor93.
Outside of the ER, the mitochondria also regulate intracellular Ca2+ in astrocytes
through the mitochondrial H+/Ca2+ exchanger (HCX), the mitochondrial Ca2+ uniporter
(MCU) and the permeability transition pore (PTP)94. Although HCX and MCU both
remove intracellular Ca2+ from the astrocyte cytosol, HCX is sensitive to nanomolar
concentrations of Ca2+95 and MCU is sensitive to micromolar concentrations96. PTP, on
the other hand, can produce spontaneous Ca2+ events when the IP3 receptors are not
activated97.
When the intracellular Ca2+ concentration reaches a certain threshold98,99, the
astrocyte can release gliotransmitters (GTs). The widely accepted and frequently
studied gliotransmitters are glutamate, D-serine, GABA, ATP and adenosine32. While
still debated, evidence suggests that GTs can be released from astrocytes through (i)
Ca2+ dependent vesicle release, (ii) transporters or (iii) the opening of channels,
specifically hemichannels or pannexons. In astrocytes, GT release via vesicular
exocytosis is a relatively slow process and is dependent on Ca2+ and SNARE
proteins100,101. Interestingly, unique elements of the SNARE complex appear to regulate
independent SNARE-dependent vesicular release pathways. Glutamate-containing
vesicles require synaptobrevin II for their release, while neuropeptide Y containing
vesicles require cellubrevin102. These data suggest that there is diversity within the
astrocyte SNARE protein pathways. There is also evidence that transporters may be

11

able to release GTs under pathological and non-pathological conditions. Transporters
can reverse their directionality and release gliotransmitters, specifically glutamate and
GABA, into the synapse101,103. Lastly, astrocytes can release GTs through
hemichannels and pannexons. Hemichannels are channels compromised of connexins,
while pannexons are channels made of pannexins104. Both these channels are found in
similar domains on the astrocyte105 and they both allow ions and small molecules,
including ATP, glutamate, D-serine and possibly other GTs, to pass104,106,107. Despite
these similarities, the two channels have different opening properties. Hemichannels
exhibit a low open probability under resting conditions108, whereas pannexons have a
high open probability under resting conditions109.
Once released, GTs can influence nearby neurons and glial cells. However,
astrocyte communication with each other through GT is temporally limited by GT
diffusion in the extracellular space, and is therefore relatively slow. A faster mechanism
of astrocyte communication with their immediate neighbors is through gap junctions 110.
Gap junctions form from the docking of two hemichannels, creating a pore that connect
the cytoplasm of the two cells106. Thus, ions, second messengers and small molecules
up to 1.8 kiloDalton, including Ca2+, K+, Na+, cyclic adenosine monophosphate, inositol1,4,5 triphosphate, glutamate, ATP and energy metabolites can pass between the
cells111,112. This allows metabolic and electric coupling and coordination of the
astrocytes.
Overall, astrocytes preform these functions to maintain their microenvironment and
promote normal neuronal firing. Due to this, it is not surprising that astrocytes are a
highly heterogeneous cell type. However, it is debated whether astrocyte heterogeneity
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stems from distinct molecular differences during development or adaptations to the
microenvironment. In a healthy adult brain, astrocytes are morphologically distinct
based on their location. Fibrous astrocytes are found in the white matter of the CNS and
have numerous long branches that wrap around neuronal cell bodies and contact nodes
of Ranvier on the axon. They can also extend their end-feet to blood vessels.
Protoplasmic astrocytes are found in the grey matter and typically have shorter and
stubbier processes. These processes surround virtually every synapse, and also
contact blood vessels44. However, astrocytes also display heterogeneity in their protein
expression in normal, healthy adult brains. For example, astrocytes have been identified
as “passive” or “active” based on whether they express glutamate transporters or
receptors. Passive astrocytes express glutamate transporters but not receptors, while
active astrocytes express glutamate receptors but not transporters. Passive and active
astrocytes can be found in the same brain region113.
Research also suggests that layer-specific astrocytes exist as well. For example,
astrocytes from cortical layer 2/3 take up a larger volume compared to astrocytes from
cortical layers 1, 4, 5 and 6114. Likely due to their expansive processes, cortical layer 2/3
astrocytes also surround more synapses than other cortical astrocytes114. In vivo
analysis revealed that cortical layer 1 astrocytes have twice as much Ca 2+ activity
compared to cortical layer 2/3 astrocytes115. Additionally, cortical layer 2/3 and 5
astrocytes express higher levels of the K+ channel Kir4.1 compared to astrocytes in
other cortical layers116. Taken together, these data suggest that astrocyte functions may
reflect the needs of their neighboring neurons and that astrocytes can, therefore,
differentially influence surrounding synapses.
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Astrocytes also differ between brain regions. Astrocytes isolated from mouse
cerebellum, thalamus, brainstem, olfactory bulb and cortex could be separated into five
different subpopulations based on their immunoreactivity to several antibodies117.
Additionally, astrocyte mRNA expression patterns from the cortex, hippocampus,
thalamus, hypothalamus, caudate-putamen and nucleus accumbens revealed three
molecularly distinct subpopulations with different, and sometimes complete opposite,
profiles between regions118. A similar study found astrocyte transcriptome differences to
be region and age dependent119. Besides RNA and protein expression differences,
astrocytes in the hippocampus, striatum and ventral tegmental area also display
difference in their K+ currents, spontaneous and evoked Ca2+ events, morphology and
synapse proximity120,121.
Not surprisingly, astrocytes also actively, and heterogeneously, respond to CNS
insults, diseases and disorders. Under these conditions, astrocytes become activated
and alter their morphology and gene expression, a process termed astrogliosis31.
Activated astrocytes take on an A1 or A2 profile. A1 astrocytes exacerbate disease
progression by killing neurons and oligodendrocytes, resulting in a largely negative
effect on CNS function and recovery. However, A2 astrocytes upregulate neurotrophic
genes and promote neuronal survival122. Interestingly, astrocytes also react uniquely in
different disease states, and this heterogeneity has been heavily studied 123. However,
since this research focuses on alcohol use and AUD, astrocytic contributions to this will
be reviewed below (Section D).
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C.2 A FUNCTIONAL OVERVIEW OF DROSOPHILA MELANOGASTER CORTEX
GLIA AND ASTROCYTES
In Drosophila melanogaster, cortex glia and astrocytes are morphologically and
functionally similar to mammalian astrocytes. These parallels will be highlighted below.
The basic anatomy between the mammalian and fly brain is very different, however.
There are few structural similarities and the fly brain is divided into two major regions:
the cortex and the neuropil. The fly cortex contains neuronal cell bodies and no
synapses. The neuropil, on the other hand, contains neuronal axons and is a synaptic
rich region.
Cortex glia, as their name implies, reside in the cortex region of the Drosophila
CNS124. However, one cortex glia cell can extend its fine processes to surround
approximately 100 neuronal cell bodies125 and make significant contact with the BBB126.
Through their non-overlapping spatial domains, cortex glia surround virtually every
neuronal cell body in the adult fly brain124. Genetic ablation of these cells results in
developmental lethality127 and disruption of cortex glial secretion of the neurotrophin
Spätzle 3 leads to neuronal cell death39, demonstrating that these cells are important for
neuronal health and maintenance, like their mammalian astrocyte counterparts.
Given that cortex glia are positioned between the BBB and neuronal cell bodies,
it has been assumed that cortex glia shuttle important metabolites to neurons 39,128
similarly to mammalian astrocytes, but this relationship has never been experimentally
demonstrated. However, components of the mammalian astrocyte neuron lactate
shuttle are conserved in Drosophila glial cells, but the exact glial cell subtype(s) remain
unidentified. For example, the monocarboxylate transporter (MCT) Chaski, which
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shuttles lactate and pyruvate, is enriched in fly glia but is also expressed in neurons129.
The mammalian MCT1 and MCT2 are also expressed on glia and neurons 129, although
these transporters are known to be expressed on mammalian astrocytes and
oligodendrocytes130-132. Taken together, these data suggest that fly cortex glia may be
equipped to provide trophic support to neurons.
Additionally, like their mammalian counterparts, cortex glia display rapid, near
membrane Ca2+ oscillations133. The change in intracellular Ca2+ is mediated by TRPA1
channels, as well as zydeco, a Na+/Ca2+, K+ exchanger (NCKX)133. This suggests that
cortex glia (i) have similar machinery as mammalian astrocytes to alter intracellular Ca 2+
levels and (ii) can respond to and regulate ion concentrations in the extracellular space.
Drosophila zydeco is homologous to mammalian NCKX2, which regulates intracellular
Ca2+ in astrocytes, oligodendrocytes and neurons134,135. Knockdown of zydeco in cortex
glia decreased Ca2+ influx and increases seizure susceptibility133. Interestingly, several
mammalian studies have correlated astrocyte Ca2+ oscillations with seizure initiation136138,

suggesting that glial Ca2+ dysregulation may be a conserved seizure pathology.

Cortex glial cells also contribute to seizure susceptibility when their plasma membrane
structure is compromised, causing neuronal cell bodies to be abnormally
encapsulated139. While this exact mechanism is unknown, these data further suggest
that cortex glia can regulate neuronal excitability.
Drosophila astrocytes, like their mammalian counterparts, maintain ion
homeostasis, remove neurotransmitters from the synapse, produce Ca 2+ oscillations
and release gliotransmitters40,140. These cells also are morphologically similar; however,
fly astrocytes are unique in that their fine processes are only found in synaptic rich
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regions141. The approximately 4,600 fly astrocytes exist and tile to form a dense
meshwork with very little overlap to cover the entire synaptic space 124,125.
Fly astrocytes express the EAAT1 (also known as GLAST) and GAT for the
uptake of glutamate and GABA from the synapse. As seen in mammals, this allows the
balance of excitatory and inhibitory synapses in the adult fly brain142,143. Previous work
in the fly has demonstrated that EAAT1 and GAT expression on astrocytes is
physiologically relevant. Loss of EAAT1 in fly astrocytes leads to neuronal firing
dysregulation, axon degeneration, and a shortened lifespan 141,144. Additionally, an
increase in EAAT1 on fly astrocytes has been correlated with increased seizure
susceptibility145. Conversely, downregulation of GAT endocytosis in astrocytes, and
therefore an increase in GABA in the synaptic cleft, has been associated with a rapid
onset of paralysis in flies146. Under normal conditions, astrocyte GAT expression on the
plasma membrane is regulated by neuronal activity levels, indicating that flies engage in
glia-neuron crosstalk147. Neuronal activity can increase astrocyte Ca2+ levels, leading to
endocytosis of GAT146. Interestingly, mutations in EAAT’s and GAT have also been
associated with seizures and paralysis in mammals148,149. Moreover, fly astrocytes, like
mammalian astrocytes, express the enzymes and proteins necessary to break down
glutamate and GABA into intermediates and recycle them back to neurons142-144.
In mammals, astrocytes display Ca2+ oscillations, which can modulate the
synaptic environment and neuronal function. Similar processes have been identified and
studied in depth in Drosophila. Fly astrocytes can function in a tripartite synapse150,
display Ca2+ transients 27,40,146, and directly modulate neuronal function27. Under normal
conditions, fly astrocytes display spontaneous Ca2+ transients which are regulated by
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synaptic activity and TRP channels27,146. Specifically, the invertebrate catecholamines
octopamine or tyramine binding to the Octopamine-Tyramine receptor (Oct-TyrR) on
astrocytes leads to an increase in intracellular Ca2+. This Ca2+ transient stimulates
adenosine release from the astrocyte, which binds to the adenosine receptor on a
neighboring dopaminergic neuron to inhibit its function and alter locomotor behavior 27.
Mammalian astrocytes’ Ca2+ levels are modulated by the catecholamine
norepinephrine83,151,152 demonstrating the utility of Drosophila to understand astrocyteneuronal communication and its physiological relevance in vivo.
The Drosophila CNS also expresses innexins, which are structurally and
functionally similar to mammalian pannexins and connexins, and they form
hemichannels and gap junctions153. 8 innexins exist in flies, and innexin-2 and ogre are
strongly expressed in glial cells153. Fly astrocytes can form gap junctions with each
other141 and with cortex glia58. These couplings have been implicated in glutamate
metabolism and sleep58. These data suggest that fly glia may be a useful model to study
the physiological relevance of astrocyte communication through gap junctions.
Fly astrocytes also express multiple inflammatory mediators, such as TNF and
NF- homologues109,154. Due to this, fly models of Alzheimer’s disease, amyotrophic
lateral sclerosis and Huntington’s disease have been developed and research has
implicated astrocyte contributions to disease progression140. While activated profiles of
astrocytes in flies have not been fully characterized, these data begin to suggest that
Drosophila astrocytes can respond to pathology similarly to their mammalian
counterparts.
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As mentioned previously, mammalian astrocytes display robust heterogeneity123.
Recently, fly astrocytes have been proposed as a model to study astrocyte
heterogeneity as well155. For example, within the visual cortex of the adult fly, astrocyte
morphology and orientation vary depending on the depth of the cell in the lamina and 4
specific astrocyte subtypes in this region have been classified 156,157. Additionally,
different Gal4 drivers have been used to induce UAS-transgene expression in unique
astrocyte populations, indicating that certain Gal4 promoters are specific to certain fly
astrocytes24,125.
Drosophila cortex glia and astrocytes are functionally homologous to mammalian
fibrous and protoplasmic astrocytes, respectively39,40. Although heterogeneity within
individual cortex glial cells has yet to be explored, fly astrocytes are emerging as a
diverse cell type155. Taken together, this invites the speculation that Drosophila cortex
glia and astrocytes have a common origin with mammalian astrocytes.

D. GLIAL RESPONSES TO ALCOHOL ADMINISTRATION AND THEIR ROLE IN
ALCOHOL-RELATED BEHAVIORS
To date, the role of glial cells in alcohol use, abuse and dependence is not fully
understood. However, previous literature has demonstrated that mammalian astrocytes,
microglia, oligodendrocytes, as well as fly surface glia, can respond to adolescent and
adult alcohol exposure and influence alcohol-related behaviors. This body of literature
will be reviewed below.
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D.1 MAMMALIAN ASTROCYTES AND ALCOHOL
Astrocytes are robustly altered in human alcoholic post-mortem brain tissue
samples. Increases in glial fibrillary acidic protein (GFAP) in the pre-frontal cortex158, as
well as decreased astrocyte density in the pre-frontal cortex159,160 and hippocampus158
have been observed, along with overall changes in astrocyte morphology161.
Additionally, there is less connexin 43, a hemichannel precursor, in alcoholic brain
tissue162. Microarray data also demonstrated that alcoholic postmortem brain tissue has
upregulated immune-related genes, and microglia and astrocytes are historically major
contributors to the neuroimmune response163-165. These data suggest that astrocytes
are robustly altered in the presence of chronic alcohol.
Studies in the rodent have further demonstrated that astrocytes are altered in the
presence of alcohol. For example, neurotransmitter uptake in astrocytes is influenced by
alcohol administration. Acute ethanol blocks glutamate uptake166-168 and chronic ethanol
downregulates the expression of the glutamate transporter GLT-1 and xCT169,170.
Conversely, chronic ethanol treatment increased GLAST and GLT1 in cultured
astrocytes171. Manipulating glutamate uptake in vivo also influences alcohol related
behaviors. When GLAST was knocked out, mice had reduced voluntary alcohol
consumption and did not exhibit motivation for alcohol172. Pharmacologically blocking
glutamate uptake with dihydrokainic acid reduced binge drinking173, while
pharmacologically enhancing GLT1 and xCT with N-acetylcysteine and clavulanic acid
decreased ethanol consumption, ethanol seeking and ethanol reacquisition after
abstinence174,175. Additionally, upregulation of GLT1, but not GLAST, was seen in the
nucleus accumbens core astrocytes following voluntary ethanol consumption 176,177.
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These results indicate that astrocytes may differentially regulate glutamate uptake as a
response to alcohol.
Transcriptomic data have revealed changes in astrocyte Ca2+ signaling in response
to chronic ethanol consumption178. In cultured astrocytes, the presence of alcohol
increases intracellular Ca2+ transients179,180. Increases in astrocytic Ca2+ are indicative
of GT release32, suggesting that GT may be released in response to alcohol. In support
of this, hemichannels, which release GTs, are also altered by alcohol treatment 104.
Interestingly, hemichannels are opened in the presence of alcohol, specifically,
connexin 43 and pannexin 1 in hippocampal astrocytes181,182. Blocking hemichannels in
the nucleus accumbens core increased ethanol seeking behavior, while activating these
same astrocytes reduced motivation for ethanol after abstinence183.
Research has also implicated that GTs respond to alcohol administration. For
example, ethanol administration increases extracellular levels of the GT adenosine 184.
Increased adenosine activates the astrocyte-specific equilibrate nucleoside transporter,
ENT1, which decreases glutamate uptake by downregulating GLT-1185.
Ethanol also promotes immune signaling, specifically through the toll-like receptor 4
(TLR4) and interleukin 1 receptor (IL1R), which increases expression of inflammatory
cytokines186-190. Microglia and astrocytes regulate the neuroimmune response191 and
this response can also influence alcohol related behaviors. The chemokine C-C motif
ligand 2 (CCL2) is increased in alcohol post-mortem brains163 as well as in mice after
alcohol exposure192,193. Increased CCL2 expression in astrocytes led to increases in
whole-brain CCL2 and reduced ethanol consumption, impaired spatial learning and
improved associative learning in alcohol dependent mice194. However, increasing CCL2
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with transgenics in astrocytes also increases endogenous CCL2 secretion from
microglia, which complicates any conclusions about astrocytes directly modulating
behavior194.
D.2 MAMMALIAN MICROGLIA AND ALCOHOL
Microglia typically become activated when they sense threats, leading to
morphological changes and the secretion of pro- or anti-inflammatory molecules195. In
human alcoholic post-mortem brain tissue, markers of microglia activation are
upregulated, including the Ionized calcium-binding adapter molecule 1 (Iba-1) and the
antigen CD11b196, suggesting that microglia may regulate toxicity and
neurodegeneration associated with chronic alcohol exposure197. Similar results were
seen in the mouse brain following chronic and binge alcohol exposures186,198,199.
Interestingly, after alcohol administration microglia in the prefrontal cortex200 and
hippocampus201 were activated but there was no increase in inflammatory markers,
suggesting that microglia may have a protective or homeostatic role in these brain
regions after alcohol exposure.
Alcohol is predicted to activate microglia through the TLRs. Specifically, alcohol
administration upregulates TLR4 and TLR2 and promotes the release of
neuroinflammatory mediators202. In TLR4 knockout mice, alcohol administration did not
increase Iba-1 and neurotoxicity development was blunted186. Interestingly, microglia
activation is associated with the nuclear factor kappa-light-chain enhancer of activated
B cells (NF-κB) signaling and reactive oxygen species (ROS) production, which has
also been correlated with neurodegeneration following ethanol treatment 203.
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Pharmacologically inhibiting microglial activation with minocycline decreased
alcohol self-administration in mice204 and alcohol relapse after abstinence in rats205.
Chemically depleting microglia with the colony-stimulating factor 1 receptor antagonist,
PLX33397, blocks the expression of anti-inflammatory genes that are typically
unregulated during alcohol withdrawal, but did not alter alcohol induced motor
impairment206. Taken together, these data suggest that microglial activation occurs in
response to alcohol administration, and that this process may mediate alcohol-related
behaviors, as well as ethanol-induced neurodegeneration and toxicity.

D.3 MAMMALIAN OLIGODENDROCYTES AND ALCOHOL
Oligodendrocytes are characterized by forming myelin sheath around axons.
Markers for myelin include myelin basic protein (MBP), proteolipid protein (PLP) and
myelin associated glycoprotein (MAG), among others207. In human alcoholic postmortem brain, mRNA levels for MBP, PLP and MAG were decreased compared to nonalcoholic brain samples163,208. Interestingly, these reductions were also significant in
alcoholics with cirrhosis compared with alcoholics without cirrhosis208, suggesting
nutritional or metabolic impairments caused by chronic alcohol consumption enhance
myelin degeneration.
In adult mice, chronic alcohol exposure is correlated with reduction of myelin
components in multiple brain regions, eventually leading to neurodegeneration.
However, the addition of calpain inhibitors prevented Ca2+ activation of calpain and
significantly blunted myelin reduction and neurodegeneration associated with alcohol
administration209. Another proposed regulator of alcohol-associated myelin loss and
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neurodegeneration is the alcohol metabolite acetaldehyde 210. Although alcohol
administration clearly leads to myelin pathology, more research is needed to determine
how alcohol reduces myelin and how this process influences alcohol-related behaviors.

D.4 DROSOPHILA MELANOGASTER SURFACE GLIA AND ALCOHOL
Two studies using Drosophila as a model organism have demonstrated a causal
relationship between the surface glial cells and alcohol sedation and tolerance 211,212.
The fly blood brain barrier is a layer of two glial cells, also known as the surface glia,
which are comprised of the subperineural and the perineural glia213. The GPCR, Moody,
is expressed in the BBB glia in fly larva and a mutation in the Moody gene blocks
alcohol-induced motor impairments in adult flies211. While interesting, the gene Moody
was never specifically altered in the BBB glia, and the Moody GPCR expression pattern
wasn’t investigated in the adult brain as well as throughout the rest of the body. This is a
concern, given that a mutation in the gene Moody causes a ubiquitous knock down, and
not just reduced expression in the BBB. Taken together, how Moody functions
specifically in the BBB to influence alcohol sedation remains elusive. An additional study
indicated that expression of the A kinase anchoring protein AKAP200 in perineural glia
is required for alcohol tolerance212. Similar results were observed when protein kinase
A, actin and calcium signaling were manipulated in perineural glia, leading to
conclusions that AKAP200 is coordinating these to control alcohol tolerance 212. While
possible, these molecular interactions were not tested formally, making this conclusion
premature. These studies, however, begin to demonstrate the utility of the fly to
manipulate glia in vivo and investigate the resulting behavioral changes to alcohol.
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E. SIGNIFICANCE
Previous research has demonstrated that adult CNS glia robustly respond to alcohol
administration and can influence alcohol related behaviors. This supports our
overarching hypothesis that adult CNS glia are important regulators of alcohol-related
behaviors. However, to date, a causal relationship between any glial cell molecular
pathway and an alcohol related behavior has not been demonstrated fully. Given that
flies and mammals have (i) conserved behavioral responses to alcohol, (ii) conserved
molecular responses to alcohol and (iii) conserved astrocyte function, we decided to use
Drosophila melanogaster as a model to identify novel genes whose expression in glia
regulates alcohol sedation. In pursuit of this, we characterized a novel GeneSwitch
driver, GliaGS, to manipulate gene expression specifically in glia during adulthood
(Chapter 3). Through targeted screens, we identified the genes cysteine proteinase 1
(Cp1) and tyrosine decarboxylase 2 (Tdc2) as novel regulators of alcohol sedation
sensitivity. Cp1 functions in cortex glia to regulate alcohol sedation (Chapter 4). Tdc2 is
involved in the synthesis and release of tyramine in astrocytes, which mediates alcohol
sedation (Chapter 5). This research demonstrates that glia are integral for normal
alcohol-related behaviors, and could therefore be regulating alcohol abuse and
dependence progression.
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CHAPTER 2: MATERIALS AND METHODS

A. UNIVERSAL METHODS
Fly husbandry. All flies were reared under standard conditions as described
previously214,215. Flies were grown on food medium containing 10% sucrose, 3.3%
cornmeal, 2% yeast, 1% agar, 0.2% Tegosept, and antibiotics (0.1 g/L ampicillin, 0.02
g/L tetracycline, 0.125 g/L chloramphenicol) with active dry yeast on top in 6-ounce
polypropylene Drosophila bottles (Fisher Scientific, Hampton, NH). Flies were housed
in an environmental chamber kept at 25°C and 60% relative humidity with a 12-hour
light/dark cycle. All comparisons between groups were based on studies with flies that
were grown, handled, and tested side by side.

Fly stocks. UAS-transgenic and Gal4 driver strains were obtained from either (i) other
laboratories or (ii) one of the following commercial/public resources: Vienna Drosophila
Resource Center (VDRC), Vienna, Austria and Bloomington Drosophila Stock Center
(BDSC), Bloomington, IN. A w1118 reference stock from the VDRC (stock number 60000)
was used to control the genetic background of all flies obtained from this stock center.
Any UAS-transgene marked with y+ was backcrossed to a w1y1 strain (stock number
1495, BDSC) for seven generations to normalize the genetic background. All Gal4
stocks (marked with mini-w) were backcrossed to our standard reference strain, w[A]
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(w1118 in an isogenic background; BDSC, stock number 5905) for seven generations to
normalize the genetic background. All fly strain information is listed below.

Ethanol sedation sensitivity. One day before behavioral studies, adult flies (1-4 days
old) were placed under light CO2 anesthesia and sorted for sex. Eleven adult female
flies were placed into fresh non-yeasted food vials (standard food medium without
active dry yeast on top). Flies recovered in food vials stored upside down (food side up)
overnight at 25°C and 60% relative humidity. Each vial of flies corresponded to n=1; up
to 24 vials were tested in each single ethanol sedation experiment.
Ethanol sedation studies were performed at 23-25°C and 55-65% relative
humidity under standard office lighting as previously described214,215. Flies, after a 1-2
hour acclimation period in the testing room, were transferred to empty polystyrene food
vials (VWR, Radnor, PA) and trapped in the vials with a cellulose acetate Flug (FlyStuff,
San Diego, CA) inserted approximately 2 cm into each vial. The number of inactive flies
was recorded for each vial (typically 0-1 flies/vial). One mL of 85% ethanol (made fresh
weekly) was added to each Flug, and the vials were immediately sealed with a silicone
stopper. Once every 6 minutes, each vial was tapped gently on a table 3 times and the
number of sedated flies (i.e. still on the bottom of the vial) was recorded 30 seconds
later. The ethanol sedation experiments were terminated when all flies were sedated,
typically after 60-90 minutes. The percentage of active flies was calculated for each vial
at each time point, and the time required for 50% of the flies in each vial to become
sedated (sedation time 50, ST50) was interpolated from sigmoidal curve fits using Excel
(Microsoft, Redwood, WA)214,215.
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Internal ethanol. Flies were exposed to vapor from 85% ethanol as described for
measuring ethanol sedation8. After exposure to ethanol vapor for a duration equivalent
to the ST50, flies were transferred to 1.5 mL snap-cap tubes and frozen at -80°C.
Frozen flies were homogenized in 200 µL ice-cold ddH20 and then centrifuged at 14,000
rpm at 4°C for 20 minutes. The internal ethanol concentration of the supernatant was
determined using Alcohol Reagent Set (Pointe Scientific Inc., Canton, MI) according to
the manufacturer’s instructions.

GeneSwitch induction. 100 µl of 1 mM Mifepristone (RU486; Sigma Aldrich, St. Louis,
MO) or vehicle (100% ethanol) was added to the surface of solidified food in vials and
allowed to dry overnight. Flies were provided food medium topped with RU486
(induced) or vehicle (control) for 6 days total. Flies were transferred to fresh drug- or
vehicle-treated food vials after 3 days.

Whole brain imaging and immunodetection. Whole brains from adult (4 day-old) female
flies were dissected in 0.3% Phosphate buffer Triton X-100 (PBT) under a dissecting
microscope. Dissected brains were fixed in 0.5 mL snap cap tubes containing 4%
paraformaldehyde on ice and then for 20 minutes at room temperature on a tube
rotator. Brains were then washed with 0.3% PBT and blocked with 5% normalized goat
serum (NGS). Primary antibodies diluted in 5% NGS were added and brains were
placed on a tube rotator at 4°C for 36-48 h. Brains were washed with 0.3% PBT and
exposed to the secondary antibodies diluted in 5% NGS at 4°C for 36-48 h. Brains were
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then washed with 0.3% PBT and mounted onto glass slides in SlowFade mounting
medium (Invitrogen, Carlsbad, CA)216.

Statistics. All statistical analyses (Student’s t-test, one-way ANOVA, two-way ANOVA
and Bonferroni’s multiple comparison tests) were performed with Prism 6.04 (GraphPad
Software, San Diego, CA, USA). Numerical data are mean ± S.E.M.

B. CHAPTER SPECIFIC METHODS
Chapter 3: GliaGS identification
Fly stocks.

β-Galactosidase activity. β-galactosidase activity was measured in whole body extracts
of flies as previously described217. Three adult (4 day-old) female flies were
homogenized in 250 µL buffer (1 X PBS with 1 X protease inhibitor cocktail (Sigma
Aldrich, St. Louis, MO)). An additional 500 µL of extraction buffer was added, the
extracts were vortexed and then centrifuged at 14,000 rpm for 5 minutes at room
temperature. 100 µL of the resulting supernatant was added to 900 µL of 1 mM
chlorophenol red-β-d-galactopyranoside (Sigma Aldrich, St. Louis, MO). β29

galactosidase activity was observed as the change in absorbance at 562 nm over 6
minutes in a Ultraspec 2000 spectrophotometer (Pharmacia Biotech, Piscataway, NJ).

Chapter 4: Cysteine proteinase 1 regulates Drosophila alcohol sedation by functioning
in adult cortex glia
Fly stocks.
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Trans-species rescue of the Cp1 RNAi in glia. FlyBase and NCBI were used to
determine that D.melanogaster Cp1 and D. pseudoobscura GA25021 were orthologous.
Fly stocks that express D. pseudoobscura GA25021 under UAS control were created
via standard P-element-mediated transgenesis using pUAST218. The D. pseudoobscura
GA25021 cDNA was cloned into the pUAST vector by GenScript (Piscataway, NJ, USA)
and injected in w[A], our standard lab stock, by Rainbow Transgenic Flies (Camarillo,
CA, USA). We mapped the independent UAS-GA25021 insertions to autosomes. Flies
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constitutively expressing the HMS00725 Cp1 RNAi transgene in all glia via repo-Gal4
were generated through standard crosses.

Rapid tolerance. Rapid tolerance to ethanol was assessed as the change in sensitivity
to ethanol sedation due to a prior exposure to the drug. Flies were tested for ethanol
sedation during a first ethanol exposure as described above (E1), returned to food vials
to recover for 4 h, and then tested for ethanol sedation during a second ethanol
exposure (E2)214. The development of rapid tolerance was quantitated as the ratio
between the ST50 during E2 and the ST50 during E1.

Locomotor behavior. Flies were collected as described above for ethanol sedation. On
the test day, flies were transferred to empty polystyrene food vials. The positive control
group vials (Gal4/+) were vortexed for four minutes prior to the experiment. Thereafter
vials were handled as described for ethanol sedation studies, except for the following
changes: (i) no ethanol was placed on the flug and (ii) no plug was used to seal the vial.
The percentage of active flies was calculated for each vial at each time point.

Immunodetection. The following primary antibodies at the indicated concentrations from
the listed sources were used: polyclonal guinea pig anti-cp1 (1:250; donated from
Patrick Dolph, Dartmouth College, NH); monoclonal mouse anti-repo (1:100,
Developmental Studies Hybridoma Bank, Iowa City, IA); polyclonal rabbit anti-LacZ
(1:25, Fisher Scientific). The following secondary antibodies were used: goat anti-
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guinea pig Alexa 568, rabbit anti-mouse Alexa 488 and chicken anti-rabbit Alexa 647
(all at 1:1000; ThermoFisher, Waltham, MA).
All images were collected using a Zeiss LSM 510 multi-photon microscope (Carl
Zeiss Microscopy, LLC, Thornwood, NY) or a Zeiss LSM 700 confocal microscope (Carl
Zeiss Microscopy, LLC, Thornwood, NY) housed in the VCU Department of Anatomy
and Neurobiology Microscope Facility. Confocal images using a pin hole of 1 Airy disc
unit and Nyquist sampling were collected from each adult brain. Images were taken with
a 10X objective with a numerical aperture of 0.3 or a 63X oil-immersion objective with a
numerical aperture of 1.4. The gain and offset values were kept constant for all images
compared within an experiment.
All images taken on the Zeiss LSM 510 multiphoton microscope were processed
using Zeiss LSM Image Browser Version 4,2,0,121 and Inkscape 0.92 was used to
adjust image orientation. All images taken on the Zeiss LSM 700 confocal microscope
were processed using Zeiss Zen 2.3. Colocalization between glia (via endogenous repo
expression) and LacZ was quantified using Volocity™ 3D Image Analysis Software
version 6.3. All thresholds were automatically set and Pearson Correlation was
reported. Mean pixel intensity of Z-stacks was quantified using ImageJ (NIH, Bethesda,
MA, USA).
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Chapter 5: Tyramine decarboxylase 2
Fly stocks.
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Tyramine feeding. 100 mL of 100 mg/mL tyramine (tyramine hydrochloride; Sigma
Aldrich, St. Louis, MO) or vehicle (5% sucrose in diH2O) was added to the surface of
solidified food in vials and allowed to dry overnight in an environmental chamber. Adult
flies were collected and placed on food topped with tyramine or vehicle (control) for 2
days total.

Yohimbine feeding. Adult flies were collected and starved in empty food vials for 17
hours. Whatman #1 filter papers (Cat. No 1001 125; Whatman International Ltd.,
Maidstone, England) were placed at the bottom of empty food vials, and the drug
treatment was administered onto the filter paper. Vials were treated with either 1 mg/mL
yohimhine (yohimbine hydrochloride; Sigma Aldrich, St. Louis, MO) or vehicle (5%
sucrose in diH2O). Starved flies were transferred onto the drug treated vials for 1 hr and
45 min.

Immunodetection. The following primary antibodies at the indicated concentrations from
the listed sources were used: rabbit anti-Tdc2 (1:200; Covalab, Villeurbanne, France),
rabbit anti-VMAT (1:2000, David Krantz, University of California - Los Angeles.). The
following secondary antibody was used: chicken anti-rabbit Alexa 647 (1:1000;
ThermoFisher, Waltham, MA).
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All images were collected using a Zeiss LSM 700 confocal microscope (Carl
Zeiss Microscopy, LLC, Thornwood, NY) housed in the VCU Department of Anatomy
and Neurobiology Microscope Facility. Confocal images using a pin hole of 1 Airy disc
unit and Nyquist sampling were collected from each adult brain. Images were taken with
a 10X objective with a numerical aperture of 0.3. The laser power, gain and offset
values were kept constant for all images compared within an experiment. All images
were processed using Zeiss Zen 2.3. Mean pixel intensity of individual Z-stacks were
quantified using ImageJ (NIH, Bethesda, MA, USA).
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CHAPTER 3: CHARACTERIZATION OF A CNS-GLIA SPECIFIC GENESWITCH FLY
STOCK

A. INTRODUCTION
Development is an extremely sensitive time in any species, including in the fruit fly
Drosophila melanogaster. Molecular expression changes can result in robust alterations
in the neuronal circuitry, which can have an impact on the adult fly lifespan and
behavior27,139,153. Glia are major regulators of neuronal migration and circuitry
assembly27,153. While changes to CNS development are relevant for alcohol use
disorder219-221, we were interested in investigating alcohol-related behavioral changes
due to acute molecular mechanisms within glia, and not due to glia-dependent CNS
developmental changes. Therefore, to bypass any developmental changes associated
with glial gene manipulation, we utilized the GeneSwitch system 29. The GeneSwitch
protein is a steroid-inducible Gal4 driver, and therefore allows temporal control of UAStransgene expression. In the presence of steroid (mifepristone, referred to as RU486
throughout), the GeneSwitch Gal4 driver is changed to an active confirmation, and is
able to bind to the upstream activator sequence (UAS) and induce expression of the
associated transgene. However, when RU486 is not present, the Gal4 driver is in an
inactive confirmation, and therefore cannot bind to the UAS and induce transgene
expression29. To bypass development and manipulate gene expression during
adulthood, flies are fed RU486 during adulthood and not during development. This

38

system has been used extensively previously to manipulate gene expression during
adulthood in ubiquitous and pan-neuronal manners222-224, although when we started this
project no glial-specific GeneSwitch reagent had been characterized. However,
Nicholson and colleagues screened approximately 3,000 publically available
GeneSwitch flies29. Each of these flies had a randomly inserted GeneSwitch p-element,
and therefore the GeneSwitch expression pattern for many lines was unknown. In thirdinstar larvae, 433 GeneSwitch lines induced GFP expression in neurons, glia or
muscles29. Using this expression data, we selected candidate fly lines that induced GFP
expression in larval glia, and not in other tissues. We wanted to determine if (i) the
GeneSwitch induced transgene expression in adult flies fed 1 mM RU486 for 6 days, (ii)
the GeneSwitch induced transgene expression in glia during adulthood and (iii) the
RU486 feeding regimen did not influence alcohol sedation behavior in control flies. In
total, we tested two transgenic lines: 59929 (GeneSwitch ID 7293) and 40262
(GeneSwitch ID 1821).

B. RESULTS
B.1 IDENTIFYING GENESWITCH REAGENTS THAT INDUCE LACZ
TRANSGENE EXPRESSION DURING ADULTHOOD
Given that each GeneSwitch fly is unique, we wanted to determine if the
candidate GeneSwitch transgenic flies were capable of inducing robust transgene
expression. To measure relative amounts of transgene induction, we utilized the galactosidase activity assay to quantify the amounts of LacZ protein produced via UASLacZ transgene induction. To validate this assay, we measured LacZ activity in flies
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expressing a UAS-LacZ transgene ubiquitously (via da-Gal4), in all neurons (via elavGal4) and in all glia (via repo-Gal4). As anticipated, we found that flies with both daGal4 and UAS-LacZ had the most LacZ activity (Fig 1; green line, slope = 0.05). Flies
with both elav-Gal4 and UAS-LacZ had a median amount of LacZ activity (Fig 1; purple
line, slope = 0.03) and flies with both repo-Gal4 and UAS-LacZ had the least amount of
LacZ activity (Fig 1; red line, slope = 0.005). Since the amount of LacZ activity
correlated with size of the tissue represented by each Gal4 driver (i.e. presumably daGal4 induces in the most cells, elav-Gal4 induces in the second highest and repo-Gal4
induces in the smallest population of cells), we felt comfortable using this technique to
measure how much LacZ each GeneSwitch driver induced when flies were fed RU486.
We investigated whether flies expressing a GeneSwitch candidate transgene and
the UAS-LacZ transgene had increased LacZ activity when fed RU486 compared to
controls. For all experiments, flies were fed 1 mM RU486 for 6 days. Flies with the
59929 GeneSwitch transgene and the UAS-LacZ transgene fed RU486 had an increase
in LacZ activity (Fig 2A; black line, slope = 0.03) and control flies had no LacZ activity
(slopes indistinguishable from zero). Control flies either had the 59929 GeneSwitch
transgene and UAS-LacZ transgene and were fed vehicle, the UAS-LacZ transgene
alone fed RU486 or vehicle and the 59929 GeneSwitch transgene alone fed RU486 or
vehicle (Fig 2A). The 59929 GeneSwitch transgene induced LacZ activity well above the
background of the controls, so we decided to characterize this reagent further.
Additionally, flies with the 40262 GeneSwitch transgene and the UAS-LacZ transgene
fed RU486 had an increase in LacZ activity (Fig 2B; black line, slope = 0.003) and
control flies had no LacZ activity (slopes indistinguishable from zero). Control flies either
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had the 40262 GeneSwitch transgene and UAS-LacZ transgene and were fed vehicle,
the UAS-LacZ transgene alone fed RU486 or vehicle and the 40262 GeneSwitch
transgene alone fed RU486 or vehicle (Fig 2B). However, the 40262 GeneSwitch
transgene did not induce LacZ activity above the background of the controls, making
this GeneSwitch transgene unattractive for use in behavioral studies; therefore, we
decided not to move forward with characterizing this reagent.
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Figure 3.1. LacZ induction can be measured in a tissue-size dependent manner.
Using the -galactosidase activity assay, flies expressing UAS-Lacz ubiquitously via daGal4 had the largest amount of LacZ activity (green line: slope = 0.05  0.04, p =
0.0003, n = 3). Flies expressing UAS-LacZ in all neurons via elav-Gal4 had the second
largest amount of LacZ activity (purple line: slope = 0.03  0.01, p = 0.0073, n = 3). Flies
expressing UAS-LacZ in all glia via repo-Gal4 had the least amount of LacZ activity (red
line: slope = 0.005  0.001, p = 0.0021, n = 3). P-values represent how different the
slope is from zero. -galactosidase activity was measured for 6 minutes.

42

Figure 3.2. GeneSwitch transgenes induce different amount of UAS-LacZ. (A)
Using the -galactosidase activity assay, flies expressing the 59929 GeneSwitch
transgene and UAS-LacZ transgene fed 1mM RU486 for 6 days had significant LacZ
activity (black line: slope = 0.03  0.004, p < 0.0001, n = 5). All other groups were
controls and had insignificant slopes, indicating that there was no LacZ activity. (B)
Using the -galactosidase activity assay, flies expressing the 40262 GeneSwitch
transgene and UAS-LacZ transgene fed 1mM RU486 for 6 days had significant LacZ
activity (black line: slope = 0.003  0.0009, p = 0.008, n = 5). All other groups were
controls and had insignificant slopes, indicating that there was no LacZ activity. Pvalues represent how different the slope is from zero. -galactosidase activity was
measured for 6 minutes.
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B.2 THE 59929 GENESWITCH TRANSGENE INDUCES UAS-TRANSGENE
EXPRESSION IN CNS GLIA
Flies with the GeneSwitch 59929 transgene and UAS-LacZ transgene were fed
either RU486 or vehicle during adulthood. After exposure to RU486, we dissected their
brains and labeled endogenous glial cells (in green via anti-repo; Fig 3A) and induced
LacZ (in red via anti-LacZ; Fig 3B). Colocalization is represented in yellow (Fig 3C).
When quantified, approximately 96 percent of green pixels expressed a red pixel,
indicating that approximately 96 percent of glia also expressed LacZ (Mander’s
correlation = 0.957; n = 7). Additionally, flies fed vehicle expressed no LacZ, suggesting
that the 59929 GeneSwitch transgene induces UAS-transgene expression when RU486
is present. Given that the 59929 GeneSwitch transgene induces transgene expression
in glia, we termed this reagent “GliaGS”.
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Figure 3.3. GliaGS drives expression in CNS glia during adulthood. Flies with the
59929 GeneSwitch transgene and the UAS-LacZ transgene were fed 1 mM RU486 for 6
days prior to brain dissection and immunolabeling. (A) Endogenous repo expression
(green) indicating CNS glia (anti-repo 1:100, Alexa 488 1:1000) (B) GliaGS-driven LacZ
expression labeled red (anti-LacZ 1:500, Alexa 568 1:1000) (C) Merged images of
panels A and B; yellow indicates co-localization of repo and LacZ. Representative
images from 10X and 63X oil.
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B.3 THE RU486 FEEDING REGIMENT DOES NOT ALTER ALCOHOL SEDATION
SENSITIVITY IN CONTROL FLIES
To determine if feeding 1 mM RU486 to flies for 6 days altered their behavioral
responses to alcohol in control flies, we measured the ST50’s of flies with the GliaGS
transgene alone fed vehicle or RU486, a universal control for any behavioral experiment
utilizing GliaGS. Compared to vehicle control, GliaGS/+ flies fed RU486 had no change
in ST50, indicating that this regimen of RU486 exposure, which can induce transgene
expression, does not impact ethanol sedation in control animals.
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Figure 3.4. RU486 feeding regiment does not alter alcohol sedation sensitivity.
Flies with the GliaGS transgene (59929) alone were fed vehicle or 1mM RU486 for 6
days. Treatment did not alter ST50 values (student’s t test, p = 0.264, n = 8).
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CHAPTER 4: CYSTEINE PROTEINASE 1 REGULATES DROSOPHILA ALCOHOL
SEDATION BY FUNCTIONING IN ADULT CORTEX GLIA

A. INTRODUCTION
In largely naïve alcohol drinkers, the initial level of response to alcohol correlates
with their likelihood of becoming alcohol dependent225, a significant phenotype
associated with AUD3. For example, men with an initially low sensitivity to alcohol are
four times more likely to be an alcoholic by age thirty225. Therefore, investigating
molecular-genetic mechanisms that influence alcohol sensitivity is a potentially
promising approach for understanding the molecular underpinnings of AUD.
The fruit fly Drosophila melanogaster, the nematode C. elegans and rodents
have been used extensively to investigate the genetics of alcohol-related behaviors,
including alcohol sedation. Numerous genes involved in alcohol-related behaviors in
model organisms have human orthologues that have been implicated in human alcohol
abuse, suggesting mechanistic connections between alcohol-related behaviors in model
organisms and alcohol abuse in humans226,227. A majority of these genes are known or
predicted to function in neurons226, leaving the contribution of glia and glial cell
mechanisms to alcohol-related behavior largely unexplored. To the best of our
knowledge, only three studies have investigated the direct contribution of glia in alcoholrelated behaviors. One study found that activation of calcium signaling in rat nucleus
accumbens core astrocytes via DREADDS decreases motivation for alcohol after a
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three week long alcohol abstenance183. Another study found that Drosophila with a
mutation in the gene moody, a gene expresssed in surface glia as well as other cell
types, have reduced sensitivity to ethanol-induced loss of postural control211. An
additional study in Drosophila found that surface glia also contribute to alcohol
tolerance212. Despite these pioneering studies, our understanding of the role of glia in
alcohol-related behavior is woefully incomplete.
The Drosophila central nervous system (CNS) is compartmentalized into two
gross anatomical regions: an outer cortex (containing neuronal cell bodies) and a more
central neuropil (containing neurites and synapses). Like mammals, the Drosophila
CNS is composed of both neurons and glia. Drosophila CNS glia are functionally and
molecularly similar to mammalian CNS glia27,40,142,228,229. Cortex glia, astrocytes and
ensheathing cells are the main subtypes of CNS glia in adult flies40. Additionally,
perineural and subperineural glia, often referred to as surface glia, surround the entire
CNS and compose the blood brain barrier in flies128,230. Drosophila cortex glia and
astrocytes are intimately associated with neurons in the CNS125. Cortex glia are located
in the cortex region of the brain and encapsulate virtually all neuronal cell bodies with
fine processes124. A single adult cortex glial cell is thought to be able to encapsulate up
to 100 neurons125. Cortex glia aid in gas exchange, neuronal firing and nutrient transfer
to neurons, similarly to mammalian protoplasmic astrocytes40,124,231. Cortex glia also
exhibit calcium transients near membranes close to neurons, which appear to regulate
neuronal cell function133. Physical associations between cortex glia and neurons are
essential for normal nervous system function and behavior in Drosophila39. In contrast
to cortex glia, the cell bodies of astrocytes reside at the cortex-neuropil interface and
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extend processes into the neuropil36. Like mammalian astrocytes, Drosophila astrocytes
are important for synapse formation and maintenance, clearing and recycling
neurotransmitters from the synapse, and modulating neuronal physiology141,232.
Drosophila astrocytes release gliotransmitters, which are regulated by transient
intracellular calcium signaling; this mechanism can directly influence nearby cells and
influence behavior27,143,146. The cell bodies of ensheathing glia are also located at the
interface of the brain cortex and neuropil36. Under normal physiological conditions,
ensheathing glia encase the entire neuropil region in the CNS and occasionally wrap
axonal segments between the neuropil and the periphery34. Ensheathing glia can
regulate neuronal excitability by metabolizing glutamate, and disruptions in this function
can alter behavior35. Under pathological conditions, these cells extend processes into
the neuropil to phagocytize debris36-38. Drosophila surface glia (i.e. subperineural and
perineural glia) are less similar to mammalian glia, but they have been associated with
alcohol-related behavior in flies211,212. Subperineural glia mediate most of the blood
brain barrier chemoprotective functions, similar to mammalian brain vascular endothelial
cells33. Interestingly, subperineural glia can extend processes which function at PNS
synapses150. As their name implies, perineural glia reside on top of the subperineural
glia, and protect against the entrance of larger molecules213. With macrophages, these
cells secrete a dense lamella that covers the CNS and peripheral nerves 213. Despite
being extensively investigated in numerous experimental settings, a role for glia in fly
alcohol-related behavior has not been comprehensively explored.
Here, we demonstrate that RNAi-mediated knockdown and rescue of the gene
cysteine proteinase 1 (Cp1) constitutively in all CNS glia regulates alcohol sedation.
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This behavioral effect appears specific to Cp1 expression in cortex glia, as well as all
glia during adulthood. Cp1 is a hydrolase involved in protein degradation that is
functionally and structurally homologous to mammalian Cathepsin L233. Our data
suggest a novel role for cortex glia and Cp1 in the adult Drosophila CNS: regulation of
sedation in response to acute administration of alcohol.

B. RESULTS
B.1 IDENTIFYING GLIAL GENES THAT INFLUENCE ALCOHOL-RELATED
BEHAVIOR IN DROSOPHILA
To begin exploring the role of central nervous system (CNS) glia in alcohol
behavior, we performed a targeted screen in which we (i) compiled genes previously
reported to be expressed in glia142, (ii) obtained RNAi reagents to manipulate the
expression of those genes, and (iii) determined whether constitutive expression of RNAi
targeting of those genes in glia influenced alcohol sedation. In total, we screened 13
genes by RNAi and identified 5 genes whose expression in glia influenced alcohol
sedation sensitivity (Table 4.1).
Flies with pan-glial Gal4 (via repo-Gal4) driven expression of the Cp1 RNAi #1
transgene had significantly decreased sedation time 50 (ST50) values compared to
control flies containing the Gal4 or an RNAi transgene alone (Fig. 4.1A). Similar results
were obtained with flies containing repo-Gal4 and an RNAi transgene for the genes axo
(Fig 4.1B, 4.1C), Jhl-21 (Fig 4.1D), nemy (Fig 4.1E) and Ent2 (Fig 4.1F).
To characterize the role of these genes in alcohol sedation further, we (i)
determined if expression of RNAi against these genes in glia altered alcohol metabolism
and (ii) determined if expression of RNAi against these genes in neurons influenced
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alcohol sedation. To determine if these genes influenced alcohol metabolism, we
measured the internal alcohol levels in these flies after an 30-minute alcohol exposure
(approximating the ST50). We found no significant difference in the internal alcohol
concentrations between flies expressing an RNAi transgene in glia (via repo-Gal4)
compared to controls that expressed the respective RNAi transgene or repo-Gal4
transgene alone (Table 4.2). These results suggest that Cp1, axo, Jhl-21, nemy and
Ent2 might influence a pharmacodynamic mechanism that impinges on alcohol
sedation. To determine if expression of RNAi against these genes in neurons influenced
alcohol sedation, we compared the ST50 values of flies with both pan-neuronal Gal4
(via elav-Gal4) and an RNAi transgene to control flies that had the elav-Gal4 transgene
or the respective RNAi transgene alone. We found no significant difference in ST50
between flies expressing an RNAi transgene individually for Cp1, axo, Jhl-21, nemy and
Ent2 in neurons (via elav-Gal4) compared to controls (Table 4.3). While not fully
conclusive, these data begin to suggest that expression of Cp1, axo, Jhl-21, nemy and
Ent2 in glia, but not neurons, is important for alcohol sedation.
Lastly, we aimed to determine whether expression of RNAi against these genes
during adulthood influenced alcohol sedation because CNS glia play important roles
during both development229,234,235 and adulthood125,229,236. To express the RNAi
transgenes against Cp1, axo, Jhl-21, nemy and Ent2 in glia during adulthood, we used
the steroid-inducible GeneSwitch (GS) system29. Specifically, we utilized GliaGS, a
driver that induced transgene expression in glia. Flies with both the GliaGS driver and
an RNAi transgene, and control flies with either GliaGS or the respective RNAi
transgene alone, were reared to adulthood in the absence of the steroid mifepristone
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(RU486) and then switched to food medium containing steroid (RU486) or vehicle for 6
days, allowing induced transgene expression exclusively for 6 days during adulthood.
Compared to vehicle control animals of the same genotype, flies containing both GliaGS
and the Cp1 RNAi #1 transgene fed RU486 had significantly decreased ST50 values
(Fig 4.2A). Exposure to RU486 in flies with either the GliaGS alone or the Cp1 RNAi
transgene alone did not alter ST50 values (Fig 4.2A). However, compared to vehicle
control animals of the same genotype, flies containing both GliaGS and an RNAi
transgene against Axo, Jhl-21, nemy or Ent2 transgene fed RU486 had similar ST50
values (Fig 4.2B-F). Taken together, these data suggest a role for Cp1 expression in
adult glia. While follow-up experiments would be needed, our data begin to suggest that
expression of axo, jhl-21, nemy and Ent2 function in glia during development to
influence alcohol sedation.
Since expression of the Cp1 RNAi transgene in glia during adulthood altered
alcohol sedation, we postulated that Cp1 is likely functioning through an acute
molecular pathway in glia to alter alcohol sedation. Due to this, we decided to pursue
research on Cp1 further. Cysteine Proteinase 1 (Cp1) is known to function in Drosophila
midgut, garland cells, salivary glands, macrophages, gonads and PNS neurons233,237-240
and is expressed in glia142, but prior to our results no studies have demonstrated a
functional role for Cp1 in glia. Cp1 is the only Drosophila cysteine proteinase that has
been described and is functionally and structurally homologous to mammalian
Cathepsin L238,241. Although cysteine proteinases play key roles in the lysosomes of
phagocytic cells240 and mammalian Cathepsin L has been associated with multiple
diseases including cancer242,243, Alzheimer Disease244 and retinal degeneration238, no
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previous studies implicate this family of genes in alcohol-related behavior. In
subsequent experiments, we aimed to (i) validate our previous findings by repeating
experiments and/or using different methods to manipulate Cp1, (ii) determine which glial
cell subtype Cp1 expression is required in for normal alcohol sedation and (iii)
investigate whether Cp1 expression in glia is important for any other alcohol related
behaviors.
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Table 4.1. Screen results: expressing RNAi against genes known to be expressed
in glia and measuring alcohol sedation sensitivity.
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Table 4.1. Each gene and the RNAi reagent used to presumably manipulate gene
expression are listed in the first two columns. The ST50 ± SEM are listed for each
genotype: Gal4/+ (repo-Gal4/+), RNAi/+ (the respective RNAi transgene/+) and
Gal4/RNAi (repo-Gal4/RNAi transgene). If the ANOVA is significant, we reported the
Bonferonni multiple comparisons adjusted p-value. To determine if expression of the
RNAi transgene in glia (via repo-Gal4) influences alcohol sedation, we compared the
Gal4/RNAi group to the Gal4/+ group and the RNAi/+. $, #, @, ~, %, ^, + and = symbols
represent common Gal4/+ controls ST50 and ANOVA values, due to multiple genotypes
being tested in the same experiment.
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Figure 4.1. Expression of RNAi against Cp1, axo, Jhl-21, nemy and Ent2 in glia
alters alcohol sedation. (A) ST50 values were reduced in flies expressing the Cp1
RNAi #1 transgene in glia (blue bar: repo-Gal4/Cp1 RNAi #1) compared to control flies
with either repo-Gal4 alone (black bars: repo-Gal4/+) or the RNAi transgenes alone
(black bars: Cp1 RNAi #1/+) (one-way ANOVA, p = 0.0352 ; *Bonferroni's multiple
comparison vs controls, p < 0.05; n = 8). (B, C) ST50 values were reduced in flies
expressing axo RNAi transgenes in glia (blue bars: repo-Gal4/axo RNAi #1, panel B;
repo-Gal4/axo RNAi #2, panel C) compared to control flies with either repo-Gal4 alone
or the respective RNAi transgene alone (black bars) (Panel A: one-way ANOVA, p <
0.0001; *Bonferroni's multiple comparison vs controls, p < 0.05; n = 8; Panel B: one-way
ANOVA, p < 0.0001; *Bonferroni’s multiple comparison vs control, p < 0.05; n = 8). (D)
ST50 values were reduced in flies expressing a Jhl-21 RNAi transgene in glia (blue bar:
repo-Gal4/Jhl-21 RNAi) compared to control flies with either repo-Gal4 alone or the
RNAi transgene alone (black bars) (one-way ANOVA, p = 0.0004; *Bonferroni's multiple
comparison vs controls, p < 0.05; n = 8). (E) ST50 values were reduced in flies
expressing a nemy RNAi transgene in glia (blue bar: repo-Gal4/nemy RNAi) compared
to control flies with either repo-Gal4 alone or the RNAi transgene alone (black bars)
(one-way ANOVA, p = 0.018; *Bonferroni's multiple comparison vs controls, p < 0.05; n
= 8). (F) ST50 values were reduced in flies expressing a Ent2 RNAi transgene in glia
(blue bar: repo-Gal4/Ent2 RNAi) compared to control flies with either repo-Gal4 alone or
the RNAi transgene alone (black bars) (one-way ANOVA, p < 0.0001; *Bonferroni's
multiple comparison vs controls, p < 0.05; n = 8).
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Table 4.2. Expression of RNAi against Cp1, axo, Jhl-21, nemy and Ent2 in glia
does not alter internal alcohol concentrations.

Flies expressing individual RNAi against Cp1, axo, Jhl-21, nemy and Ent2 in glia via
repo-Gal4 (the Gal4/RNAi group) had similar internal alcohol concentrations compared
to controls with either repo-Gal4 alone (the Gal4/+ group) or the respective RNAi
transgene alone (the RNAi/+ group). The mean internal EtOH concentration for each
group is reported  SEM. Results from individual one-way ANOVAs and (when
appropriate) Bonferroni’s multiple comparisons are reported. @ and # represent
common Gal4/+ controls.
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Table 4.3. Expression of RNAi against Cp1, axo, Jhl-21, nemy and Ent2 in neurons
does not alter alcohol sedation sensitivity.

Flies expressing individual RNAi against Cp1, axo, Jhl-21, nemy and Ent2 panneuronally via elav-Gal4 (the Gal4/RNAi group) had similar ST50 values compared to
controls with either elav-Gal4 alone (the Gal4/+ group) or the respective RNAi
transgene alone (the RNAi/+ group). The ST50 for each group is reported  SEM.
Results from individual one-way ANOVAs and (when appropriate) Bonferroni’s multiple
comparisons are reported. $ and # represent common Gal4/+ controls and one-way
ANOVA values, because the genotypes were tested in the same experiment.
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Figure 4.2. Expression of RNAi against Cp1, axo, Jhl-21, nemy and Ent2 in glia
during adulthood. (A) Compared to vehicle, treatment with 1 mM RU486 for 6 days
decreased ST50 values in flies with the GliaGS driver and Cp1 RNAi #1 transgene
(GliaGS/Cp1 RNAi #1), but not in control flies with either GliaGS or the RNAi transgene
alone (two-way ANOVA; RU486, p = 0.019; genotype, p < 0.0001; interaction, p =
0.089; *Bonferroni's multiple comparisons between vehicle and RU486, p < 0.05; n = 8).
(B-F) Compared to vehicle, treatment with 1 mM RU486 for 6 days did not alter ST50
values in flies with the GliaGS driver and an RNAi transgene against either axo (Panels
B, C), Jhl-21 (Panel D), nemy (Panel E) or Ent2 (Panel F) (tested individually). There
were also no differences in ST50 between vehicle and drug treated control flies
(GliaGS/+ and RNAi/+). (Panel B: two-way ANOVA; RU486, p = 0.03; genotype, p <
0.0001; interaction, p = 0.62; Bonferroni's multiple comparisons between vehicle and
RU486, p > 0.05; n = 8; Panel C: two-way ANOVA; RU486, p = 0.68; genotype, p =
0.029; interaction, p = 0.16; Bonferroni's multiple comparisons between vehicle and
RU486, p > 0.05; n = 8; Panel D: two-way ANOVA; RU486, p = 0.84; genotype, p =
0.51; interaction, p = 0.65; n = 8; Panel E: two-way ANOVA; RU486, p = 0.75; genotype,
p = 0.005; interaction, p = 0.17; Bonferroni's multiple comparisons between vehicle and
RU486, p > 0.05; n = 8; Panel F: two-way ANOVA; RU486, p = 0.13; genotype, p <
0.0001; interaction, p = 0.91; Bonferroni's multiple comparisons between vehicle and
RU486, p > 0.05; n = 8).
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B.2 Cp1 KNOCKDOWN IN ALL CNS GLIA ALTERS ALCOHOL SEDATION
WITHOUT INFLUENCING INTERNAL ALCOHOL LEVELS
Flies with pan-glial Gal4 (repo-Gal4) driven expression of two different Cp1 RNAi
transgenes (Cp1 RNAi #1 (v13959) and Cp1 RNAi #2 (HMS00725), tested individually)
had significantly decreased sedation time 50 (ST50) values compared to control flies
containing the Gal4 or the respective RNAi transgene alone (Fig 4.3A, 4.3B). For
reasons that are unclear, constitutive expression of a third RNAi transgene (Cp1 RNAi
#3 (v110619)) in all glia did not consistently alter alcohol sedation (Fig 4.4A). To
determine if Cp1 influenced alcohol metabolism, we measured the internal alcohol
levels in these same genotypes after a 30-minute alcohol exposure (approximating the
ST50). We found no significant difference in the internal alcohol concentrations between
flies expressing Cp1 RNAi transgenes in glia compared to controls (Fig 4.3C, 4.3D),
indicating that Cp1 might influence a pharmacodynamic mechanism that impinges on
alcohol sedation. Interestingly, despite Cp1 being endogenously expressed in
neurons239, pan-neuronal expression (via elav-Gal4) of the Cp1 RNAi #1 transgene did
not alter ST50 values compared to Gal4 and RNAi transgene controls (Fig 4.5A). Taken
together, these results suggest that Cp1 influences alcohol sedation via a role in glia.
Although our studies are consistent with the hypothesis that Cp1 function in neurons
might not play a major role in alcohol sedation, further studies would be required to
formally assess this possibility.
The principal RNAi transgenes used in this study (Cp1 RNAi #1, #2) are
predicted to target all four mRNA transcripts of Cp1 (Fig 4.6) and have no predicted offtarget effects245-247. We used whole brain immunofluorescence to address whether the
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RNAi transgenes knockdown Cp1 expression in specific tissues. Overall Cp1
immunofluorescence was substantially reduced (Cp1 RNAi #1: 55%; Cp1 RNAi #2:
62%) in brains from flies with pan-glial expression of Cp1 RNAi transgenes (Fig 4.3F,
4.3H) compared to brains from flies with the Cp1 RNAi transgenes alone (Fig 4.3E,
4.3G). The remaining Cp1 immunofluorescence is consistent with Cp1 expression in
neurons, which should not be impacted by expression of Cp1 RNAi in glia. Additionally,
overall Cp1 immunofluorescence was reduced 29% in brains expressing the Cp1 RNAi
#1 transgene pan-neuronally (Fig 4.5C) compared to brains containing the Cp1 RNAi #1
transgene alone (Fig 4.5B). The remaining Cp1 immunofluorescence is consistent with
Cp1 expression in glia. These results confirm that expression of the Cp1 RNAi
transgenes knocked down Cp1 as expected in both glia and neurons.
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Figure 4.3. Cp1 knockdown in CNS glia alters ethanol sedation sensitivity without
affecting internal ethanol levels. (A, B) ST50 values were reduced in flies expressing
Cp1 RNAi transgenes in glia (blue bars: repo-Gal4/Cp1 RNAi #1, panel a; repoGal4/Cp1 RNAi #2, panel b) compared to control flies with either repo-Gal4 alone (black
bars: repo-Gal4/+) or the RNAi transgenes alone (black bars: Cp1 RNAi #1/+ and Cp1
RNAi #2/+) (Panel A: one-way ANOVA, p = 0.0352 ; *Bonferroni's multiple comparison
vs controls, p < 0.05; n = 8; Panel B: one-way ANOVA, p < 0.0001; *Bonferroni’s
multiple comparison vs control, p < 0.05; n = 8). (C, D) Expression of Cp1 RNAi
transgenes in CNS glia (blue bars: Cp1 RNAi #1, panel C; Cp1 RNAi #2, panel D) did
not alter internal ethanol levels compared to controls with either repo-Gal4 or the RNAi
transgenes alone (black bars) (individual one-way ANOVAs, p > 0.05; n = 8). (E-H)
Whole mount brain images immunolabeled for Cp1 expression. Whole brain Cp1
detection was reduced in flies expressing Cp1 RNAi transgenes in glia (F,H) compared
to brains from RNAi transgene control animals (E,G). (Anti-Cp1 1:250, Alexa 568
1:1000). Representative images, 10X.
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Figure 4.4. Ethanol sedation sensitivity in flies expressing Cp1 RNAi #3 in glia. (A)
ST50 values were influenced by overall genotype and reduced in flies expressing the
Cp1 RNAi #3 transgene in all CNS glia (blue triangles: repo-Gal4/Cp1 RNAi #3)
compared to one control group (black squares: Cp1 RNAi #3/+), but not the other
control group (black circles, repo-Gal4/+) (one-way ANOVA, p = 0.0465; *Bonferroni's
multiple comparisons, Cp1 RNAi #3/+ vs. repo-Gal4/Cp1 RNAi #3, p < 0.05; n = 8). (B)
ST50 values were influenced by overall genotype (one-way ANOVA, p = 0.0015, n=8)
but were not detectably different in planned comparisons between flies expressing Cp1
RNAi #3 transgene in cortex glia (blue triangles: NP2222-Gal4/Cp1 RNAi #3) and
control flies containing the NP2222-Gal4 alone (black circles) or the RNAi transgene
alone (black squares) (C) Expression of Cp1 RNAi in CNS glia during adulthood
increased ethanol sedation sensitivity. Compared to vehicle-treated controls, treatment
with 1 mM RU486 for 6 days decreased ST50 values in flies with the GliaGS driver and
Cp1 RNAi #3 transgene (GliaGS/Cp1 RNAi #3), but not in control flies with either
GliaGS or the RNAi transgene alone (two-way ANOVA; RU486, p = 0.0341; genotype, p
< 0.0001; interaction, n.s.; *Bonferroni's multiple comparisons between vehicle and
RU486, p < 0.05; n = 8).
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Figure 4.5. Expression of Cp1 RNAi in neurons did not influence ethanol sedation
sensitivity. (A) ST50 values were not changed in flies expressing the Cp1 RNAi #1
transgene in neurons (blue triangles: elav-Gal4/Cp1 RNAi #1) compared to control flies
with either elav-Gal4 alone (black circles: elav-Gal4/+) or the RNAi transgene alone
(black squares: Cp1 RNAi/+) (one-way ANOVA, p = 0.6508; n = 8). (B, C) Whole mount
brains immunolabeled for Cp1 detection (Anti-Cp1 1:250, Alexa 568 1:1000). Cp1
fluorescence was reduced 29% in flies with the Cp1 RNAi #1 transgene expressed panneuronally (via elav-Gal4) (panel C) compared to flies that had the Cp1 RNAi transgene
alone (panel B). Microscope settings were optimized for Cp1 RNAi #1/+ brains. Mean
fluorescence intensity was calculated using Image J, n = 5. 10X, representative images.
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Figure 4.6. The Cp1 region. Transcription is from left to right. Complementary
sequences for UAS-Cp1 RNAi transgenes - Cp1 RNAi #1 (labeled as GD5803), Cp1
RNAi #2 (labeled as HMS00725) and Cp1 RNAi #3 (labeled as KK107765) - are shown
below the predicted transcripts. All 3 RNAis are predicted to cleave all 4 Cp1 transcripts.
Image taken from the FlyBase genome browser (www.FlyBase.org).
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B.3 EXPRESSION OF DROSOPHILA PSEUDOOBSCURA Cp1 RESCUES
ALCOHOL SEDATION SENSITIVITY DUE TO KNOCKDOWN OF ENDOGENOUS
DROSOPHILA MELANOGASTER Cp1 IN GLIA
When expressed in glia, both of the main Cp1 RNAi transgenes used in our
studies (Cp1 RNAi #1 and #2) make flies sensitive to alcohol sedation and knockdown
Cp1 expression (Fig 4.3). The target sequence of Cp1 RNAi #2 is wholly encompassed
by that of Cp1 RNAi #1 (Fig 4.6), raising the possibility that the sensitivity to alcohol
sedation in flies expressing Cp1 RNAi might be due to knockdown of Cp1 or another,
unidentified, gene. To address this possibility, we determined whether expression of a
Cp1 orthologue from Drosophila pseudoobscura in glia could rescue the alcohol
sedation sensitivity in flies expressing RNAi against endogenous melanogaster Cp1
also in glia218. We choose the Drosophila pseudoobscura Cp1 orthologue (GA25021)
for these studies because (i) its primary amino acid sequence is 70-92 % similar to the
four Drosophila melanogaster Cp1 isoforms and (ii) the Cp1 RNAi #2 siRNA target
sequence is poorly conserved between Cp1 and GA25021 – there are 6 base pair
mismatches (Fig 4.7). Taken together, these findings suggested that GA25021 protein
would have a similar function to Cp1, but importantly the GA25021 mRNA would largely
escape RNAi-mediated degradation by Cp1 RNAi #1. We therefore postulated that
expression of GA25021 might rescue the alcohol sedation sensitivity observed in flies
expressing RNAi against melanogaster Cp1 in glia.
We generated UAS-GA25021 transgenic flies via P-element transgenesis and
screened seven lines (i.e. flies with UAS-GA25021 inserted into different locations in the
genome) to determine whether or not the expression of the individual UAS-GA25021
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transgenes in glia altered ST50. Out of the seven lines screened, expression of UASGA25021 #1, #3, #5, #6 and #7 in glia (via repo-Gal4) did not alter ST50 compared to
control flies with either the respective UAS-GA25021 transgene or the repo-Gal4
transgene alone (Fig 4.8). However, expression of UAS-GA25021 #2 and #4 in glia (via
repo-Gal4) significantly decreased ST50 compared to control flies with either the
respective UAS-GA25021 transgene or the repo-Gal4 transgene alone (Fig 4.8). We
moved forward with the five transgenic lines (UAS-GA25021 #1, #3, #5, #6, #7) that
didn’t impact ST50 values in the absence or presence of repo-Gal4.
We assessed whether expression of UAS-GA25021 transgenes rescued alcohol
sensitivity in constitutive glial Cp1 knockdown flies. repo-Gal4/+ flies were used as a
representative control in our subsequent rescue experiments because their ST50 values
were not significantly different from other control flies that had the RNAi transgene
alone, the UAS-GA25021 transgene alone, or repo-Gal4 driven expression of a UASGA25021 transgene (Fig 4.8; Fig 4.9A, 4.9C). Consistent with the data in Figure 4.3B,
flies that constitutively expressed the Cp1 RNAi #2 transgene in all glia (via repo-Gal4)
had significantly decreased ST50 values compared to control flies with repo-Gal4 alone
(Fig 4.9B, 4.9D). In contrast, flies with pan-glial expression of both the Cp1 RNAi #2
transgene and a UAS-GA25021 transgene had (i) significantly increased ST50 values
compared to flies expressing only the Cp1 RNAi #2 transgene and (ii) statistically
indistinguishable ST50 values compared to control flies with repo-Gal4 alone (Fig 4.9B,
4.9D). In total, we tested five UAS-GA25021 transformants. The transgenes in four of
the transformants rescued the glial Cp1 RNAi alcohol sedation phenotype, while one of
the transgenes did not (Fig 4.9; Fig 4.10A-C). Additionally, we determined whether this
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behavioral rescue was due to the Gal4 dilution phenomenon, which theorizes that a
Gal4 driver cannot express two UAS-transgenes as efficiently as one UAS-transgene. If
this were true, we would hypothesize that the addition of any UAS-transgene in the
presence of repo-Gal4 and the Cp1 RNAi #2 transgene would lead to behavioral
rescue. However, flies with pan-glial expression of both the Cp1 RNAi #2 transgene and
a UAS-LacZ transgene had (i) similar ST50 values compared to flies expressing only
the Cp1 RNAi #2 transgene and (ii) significantly decreased ST50 values compared to
control flies with repo-Gal4 alone (Fig 4.10D). Taken together, these data demonstrate
the ability of Drosophila pseudoobscura Cp1 to rescue alcohol sedation sensitivity due
to knockdown of melanogaster Cp1, and strongly supports a role for Cp1 in glia in
alcohol sedation.
We used whole brain immunofluorescence to address whether the UASGA25021 transgenes expressed detectable levels of immunoreactive Cp1-like protein.
Endogenous Cp1 was readily detectable in control repo-Gal4/+ brains (Fig. 4.9E). This
signal was reduced substantially by expression of the Cp1 RNAi #2 transgene in all glia
(Fig. 4.9F; decreased 68%) and increased by expression of UAS-GA25021 transgene
#1 in all glia (Fig. 4.9G; increased 37%). Expression of this same UAS-GA25021
transgene concurrently with the Cp1 RNAi #2 transgene substantially increased the Cp1
signal compared to brains that expressed only Cp1 RNAi #2 in all glia (Fig. 4.9H;
increased 331%). Similarly, expression of UAS-GA25021 transgene #3 in all glia
increased the Cp1 signal (Fig. 4.9I; increased 32% compared to repo-Gal4 alone) and
expression of this same UAS-GA25021 transgene concurrently with the Cp1 RNAi #2
transgene substantially increased the Cp1 signal compared to brains that expressed
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only Cp1 RNAi #2 in all glia (Fig. 4.9J; 188%). Although we were surprised by— and do
not at this time understand—the difference in Cp1 signal in flies with concurrent
expression of GA25021 and Cp1 RNAi #2, these data indicate that the UAS-GA25021
transgenes are functional and expressed at the protein expression level in the presence
of the Cp1 RNAi transgene.
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Figure 4.7. Cp1 RNAi #2 siRNA target region on Drosophila melanogaster Cp1 and
Drosophila pseudoobscura GA25021 alignment. The Drosophila melanogaster Cp1
transcript is “Query 1” and the Drosophila pseudoobscura GA25021 transcript is “Sbjct
1”. The Cp1 RNAi #2 siRNA target sequence on the Cp1 transcript is boxed in red.
Comparing this region between Cp1 and GA25021, 6 base pairs are mismatched.
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Figure 4.8. Expression of the Drosophila pseudoobscura UAS-GA25021
transgenes in glia. (A) ST50 values were not changed in flies expressing both the
UAS-GA25021 #1 transgene and repo-Gal4 (blue bar: repo-Gal4/UAS-GA25021 #1)
compared to control flies with either repo-Gal4 alone (black bar: repo-Gal4/+) or the
UAS-GA25021 #1 transgene alone (black bar: UAS-GA25021 #1/+). ST50 values were
decreased in flies expressing both the UAS-GA25021 #4 transgene and repo-Gal4 (red
bar: repo-Gal4/UAS-GA25021 #4) compared to control flies with either repo-Gal4 alone
(black bar: repo-Gal4/+) or the UAS-GA25021 #4 transgene alone (UAS-GA25021 #4/+)
(one-way ANOVA, p = 0.0008; *Bonferroni's multiple comparison vs controls, p < 0.05; n
= 8). (B) ST50 values were decreased in flies expressing both the UAS-GA25021 #2
transgene and repo-Gal4 (red bar: repo-Gal4/UAS-GA25021 #2) compared to control
flies with either repo-Gal4 alone (black bar: repo-Gal4/+) or the UAS-GA25021 #2
transgene alone (UAS-GA25021 #2/+) (one-way ANOVA, p = 0.022; *Bonferroni's
multiple comparison vs controls, p < 0.05; n = 8). (C, D) ST50 values were not changed
in flies expressing both a UAS-GA25021 transgene and repo-Gal4 (Panel C, blue bar:
repo-Gal4/UAS-GA25021 #5, red bar: repo-Gal4/UAS-GA25021 #7; Panel D, blue bar:
repo-Gal4/UAS-GA25021 #3, red bar: repo-Gal4/UAS-GA25021 #6) compared to
control flies with either repo-Gal4 alone or the respective UAS-GA25021 transgene
alone (black bars). (Panel C: one-way ANOVA, p = 0.12; n = 8; Panel D: two-way
ANOVA, p = 0.57; n = 8).
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Figure 4.9. Cross-species rescue of alcohol sedation in Cp1 RNAi flies. (A, C)
Ethanol sedation in flies with repo-Gal4 alone, Cp1 RNAi #2 alone, UAS-GA25021
transgenes alone, and repo-Gal4 with UAS-GA25021. Genotype did not impact ST50
values (Panel A: one-way ANOVA, p = 0.4855, n = 8; Panel C: one-way ANOVA, p =
0.1683, n = 8). (B, D) Ethanol sedation in flies with concurrent expression of Cp1 RNAi
and UAS-GA25021. ST50 values were decreased in flies constitutively expressing the
Cp1 RNAi #2 transgene in all glia via repo-Gal4 (blue squares) compared to control flies
containing repo-Gal4 alone (black circles). ST50 values in flies that expressed a UASGA25021 transgene and Cp1 RNAi #2 transgene in all glia via repo-Gal4 (grey
triangles: UAS-GA25021 #1, Panel B; UAS-GA25021 #3, Panel D) were significantly
elevated compared to flies expressing only Cp1 RNAi #2 in glia (blue squares: UASGA25021 #1, Panel B; UAS-GA25021 #3, Panel D), but were not different than control
flies containing repo-Gal4 alone (black circles) (Panel B: one-way ANOVA, p <0.0001,
n=8, *Bonferroni's multiple comparison vs repo-Gal4;Cp1 RNAi #2 flies, p<0.05; Panel
D: one-way ANOVA, p = 0.0019; *Bonferroni's multiple comparison vs repo-Gal4;Cp1
RNAi #2 flies, p<0.05). (E-J) Whole mount brain images immunolabeled for Cp1. Whole
brain fluorescence was reduced in flies constitutively expressing the Cp1 RNAi #2
transgene in all glia via repo-Gal4 (F) compared to brains that contained repo-Gal4
alone (E). Compared to brains that contained repo-Gal4 alone (E), whole brain
fluorescence was increased when a UAS-GA25021 transgene was expressed in all glia
via repo-Gal4 (UAS-GA25021 #1, panel G; UAS-GA25021 #3, panel I). Compared to
brains that expressed the Cp1 RNAi #2 transgene in all glia via repo-Gal4 (F), whole
brain fluorescence was increased when a UAS-GA25021 transgene was expressed with
the Cp1 RNAi #2 transgene in all glia via repo-Gal4 (UAS-GA25021 #1, panel H; UASGA25021 #3, panel J). Representative images from middle sections of adult brains, 10X
(Anti-Cp1 1:250; Alexa 568 1:1000).
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Figure 4.10. Cross-species rescue of alcohol sedation in Cp1 RNAi flies. (A, B)
ST50 values were decreased in flies constitutively expressing the Cp1 RNAi #2
transgene in all glia via repo-Gal4 (blue bar) compared to control flies containing repoGal4 alone (black bar). ST50 values in flies that expressed a UAS-GA25021 transgene
(Panel A: UAS-GA25021 #5; Panel B: UAS-GA25021 #6) and Cp1 RNAi #2 transgene
in all glia via repo-Gal4 (grey bar) were significantly elevated compared to flies
expressing only Cp1 RNAi #2 in glia (blue bar), but were not different than control flies
containing repo-Gal4 alone (black bar) (Panel A: one-way ANOVA, p <0.0001;
*Bonferroni's multiple comparison vs repo-Gal4;Cp1 RNAi #2 flies, p<0.05; n = 8; Panel
B: one-way ANOVA, p = 0.003; *Bonferroni's multiple comparison vs repo-Gal4;Cp1
RNAi #2 flies, p<0.05; n = 8). (C) ST50 values were decreased in flies constitutively
expressing the Cp1 RNAi #2 transgene in all glia via repo-Gal4 (blue bar) compared to
control flies containing repo-Gal4 alone (black bar). ST50 values in flies that expressed
the UAS-GA25021 #7 transgene and Cp1 RNAi #2 transgene in all glia via repo-Gal4
(grey bar) were similar to flies expressing only Cp1 RNAi #2 in glia (blue bar), and were
decreased compared to control flies containing repo-Gal4 alone (black bar) (one-way
ANOVA, p = 0.0003; *Bonferroni's multiple comparison vs repo-Gal4;Cp1 RNAi #2 flies,
p<0.05; n = 8). (D) ST50 values were decreased in flies constitutively expressing the
Cp1 RNAi #2 transgene in all glia via repo-Gal4 (blue bar) compared to control flies
containing repo-Gal4 alone (black bar). ST50 values in flies that expressed the UASLacZ transgene and Cp1 RNAi #2 transgene in all glia via repo-Gal4 (grey bar) were
similar to flies expressing only Cp1 RNAi #2 in glia (blue bar), and were decreased
compared to control flies containing repo-Gal4 alone (black bar) (one-way ANOVA, p <
0.0001; *Bonferroni's multiple comparison vs repo-Gal4;Cp1 RNAi #2 flies, p<0.05; n =
8).
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B.4 Cp1 EXPRESSION SPECIFICALLY IN CORTEX GLIA REGULATES ALCOHOL
SEDATION
Adult Drosophila have five CNS glial subtypes: astrocytes, ensheathing cells,
cortex glia, subperineural glia and perineural glia40. To address the possibility that Cp1
influences alcohol sedation by functioning within one or more specific glial subtypes, we
determined whether expression of Cp1 RNAi transgenes in individual glial subtypes (via
a series of Gal4 drivers) altered alcohol sedation sensitivity. Flies expressing Cp1 RNAi
#1 or Cp1 RNAi #2 transgenes in cortex glia (via NP2222-Gal436 or CtxGlia Split-Gal439)
had significantly decreased ST50 values compared to control flies with the Gal4 and
RNAi transgenes alone (NP2222-Gal4: Fig 4.11A, 11B; CtxGlia Split-Gal4: Fig 4.12).
Flies expressing the Cp1 RNAi #3 transgene in cortex glia (via-NP2222-Gal4) had
inconsistent results (Fig 4.4B). Additionally, ST50 values were not altered by expression
of Cp1 RNAi #1 in the four other CNS glial subtypes (astrocytes, ensheathing cells,
subperineural glia and perineural glia via Alrm-Gal440, TIFR-Gal436, mz0709-Gal436, GliGal4248 and Indy-Gal4212) (Table 4.4). The simplest interpretation of these data is that
Cp1 influences alcohol sedation by functioning in cortex glia.
We used whole brain immunofluorescence to determine if Cp1 is expressed in
adult Drosophila cortex glia. Utilizing flies that constitutively express mCD8::GFP in
cortex glia via NP2222-Gal4, we found that Cp1 immunofluorescence colocalized with
GFP (Fig 4.11C-D). When quantified using Volocity™ 3D image analysis software,
greater than 60% of the red and green pixels overlapped (average Pearson’s correlation
= 0.622; n = 6). This result indicated that endogenous Cp1 is expressed in cortex glia,
consistent with a role for Cp1 in acute alcohol sedation sensitivity.
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Figure 4.11. Cp1 expression in cortex glia is required for normal ethanol sedation.
(A,B) ST50 values were decreased in flies expressing Cp1 RNAi transgenes in cortex
glia (blue bars: NP2222-Gal4/Cp1 RNAi #1, panel A; NP2222-Gal4/Cp1 RNAi #2, panel
B) compared to control flies containing either the cortex glia Gal4 driver (black bars:
NP2222-Gal4/+) or the RNAi transgenes (black bars: Cp1 RNAi #1/+ or Cp1 RNAi #2/+)
alone (individual one-way ANOVAs, p ≤ 0.0001; *Bonferroni's multiple comparisons vs
controls, p < 0.05; n = 8). (C-E) Cp1 is expressed in cortex glia. (C) Whole brain
expression of UAS-GFP (green) driven by NP2222. (D) Endogenous Cp1 expression
labeled red (anti-Cp1 1:250, Alexa 568 1:1000). (E) Merged image of panel C and panel
D; GFP and Cp1 co-localization is yellow. Representative images from whole brain at
10X (i) and 63X oil immersion (ii).
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Figure 4.12. Cp1 expression in cortex glia is required for normal ethanol sedation.
(A, B) ST50 values were decreased in flies expressing Cp1 RNAi transgenes in cortex
glia (blue triangles: CtxGlia Split-Gal4/Cp1 RNAi #1, panel A; CtxGlia Split-Gal4/Cp1
RNAi #2, panel B) compared to control flies containing either the cortex glia Gal4 driver
(black circles: CtxGlia Split-Gal4/+) or the RNAi transgenes (black squares: Cp1 RNAi
#1/+ or Cp1 RNAi #2/+) alone (Panel A: one-way ANOVA, p = 0.0029; *Bonferroni's
multiple comparisons vs controls, p < 0.05; n = 16; Panel B: one-way ANOVA, p =
0.0156; Bonferroni's multiple comparisons vs controls, p < 0.05; n = 8).
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Table 4.4. Expression of Cp1 RNAi in each glial cell subtype individually.

Expression of the Cp1 RNAi #1 transgene in ensheathing cells (via TIFR-Gal4 and
mz0709-Gal4), subperineural glia (via Gli-Gal4), astrocytes (via Alrm-Gal4) and
perineural glia (via Indy-Gal4) did not consistently alter alcohol sedation compared to
both Gal4 driver (Gal4/+) and RNAi transgene (RNAi/+) controls. Results from individual
one-way ANOVAs and (when appropriate) Bonferroni’s multiple comparisons are
reported. $ and # represent common RNAi/+ controls.
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B.5 Cp1 IN RAPID TOLERANCE DEVELOPMENT
Flies develop rapid tolerance to alcohol, defined as increased ST50 values
during a second alcohol exposure after recovering from a first alcohol exposure 214. To
determine whether Cp1 influences this aspect of alcohol behavior through its function in
CNS glia, we expressed the Cp1 RNAi #1 transgene in all glia (via repo-Gal4) and then
assessed rapid tolerance development. As anticipated, pan-glial knock down of Cp1 via
the Cp1 RNAi #1 transgene significantly decreased ST50 values during the first ethanol
exposure (black bars, E1) as compared to Gal4 and RNAi transgene alone controls (Fig
4.13A). In contrast, ST50 values during the second alcohol exposure (grey bars, E2)
were not affected by Cp1 knockdown (Fig 4.13A). When quantified as the ratio between
the second and first ST50 values214, flies with Cp1 knocked down in all glia had an
increase in the development of rapid tolerance compared to controls (Fig 4.13B). As we
found during the first alcohol exposure (Fig 4.3C), there was no effect of knocking-down
Cp1 in all glia on internal alcohol levels during the second alcohol exposure (Fig 4.13E).
Knockdown of Cp1 specifically in cortex glia (via NP2222-Gal4) also reduced ST50
values during the first, but not the second, alcohol exposure (Fig 4.13C), leading to an
apparent increase in development of rapid tolerance compared to controls (Fig 4.13D).
Given that Cp1 knockdown does not significantly impact ST50 values during the second
alcohol exposure (Fig 4.13A and 4.13C), the most parsimonious interpretation of these
data is that the increased development of rapid tolerance is likely a mathematical
product of the enhanced sensitivity to alcohol during the first exposure. We therefore did
not further investigate the potential role of Cp1 in rapid tolerance.
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Figure 4.13. Cp1 in rapid tolerance development. (A) ST50 values from the first (E1)
and second (E2) ethanol exposure when Cp1 is knocked down in all CNS glia.
Compared to controls (repo-Gal4/+ and Cp1 RNAi #1/+), expression of Cp1 RNAi in
CNS glia (repo-Gal4/Cp1 RNAi #1) decreased ST50 values during E1, but not during E2
(two-way ANOVA; genotype, n.s.; ethanol exposure, p < 0.0001; interaction, p = 0.015;
*Bonferroni’s multiple comparisons vs controls for each ethanol exposure, p < 0.05; n =
8). (B) Development of rapid tolerance (fold change in ST50 from E1 to E2) quantified
from the data in panel A. Expression of Cp1 RNAi in glia (blue bar: repo-Gal4/Cp1 RNAi
#1) increased rapid tolerance development compared to controls (black bars: repoGal4/+, Cp1 RNAi #1/+) (one-way ANOVA, p = 0.0014; *Bonferroni’s multiple
comparisons vs controls, p < 0.05; n = 8). (C) ST50 values from the first (E1) and
second (E2) ethanol exposure when Cp1 is knocked down in cortex glia. Compared to
controls (NP2222-Gal4/+ and Cp1 RNAi #1/+), expression of Cp1 RNAi in cortex glia
(NP2222-Gal4/Cp1 RNAi #1) decreased ST50 during E1, but not during E2 (two-way
ANOVA; ethanol exposure, p < 0.0001; genotype, p = 0.0034; interaction, p = 0.0001;
*Bonferroni’s multiple comparisons vs controls for each ethanol exposure, p < 0.05; n =
8). (D) Development of rapid tolerance (fold change in ST50 from E1 to E2) quantified
from the data in panel C. Expression of Cp1 RNAi in cortex glia (blue bar: NP2222Gal4/Cp1 RNAi #1) increased rapid tolerance development compared to controls (black
bars: NP2222-Gal4/+, Cp1 RNAi #1/+) (one-way ANOVA, p = 0.0009; *Bonferroni’s
multiple comparisons vs controls, p < 0.05; n = 8). (E) Expression of Cp1 RNAi
transgenes in CNS glia (blue triangles: repo-Gal4/Cp1 RNAi #1) did not alter internal
ethanol levels compared to controls with either repo-Gal4 alone (black circles: repoGal4/+) or the RNAi transgenes alone (black squares: Cp1 RNAi #1/+) (one-way
ANOVA, p = 0.85; n = 6).
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B.6 Cp1 KNOCKDOWN IN CNS GLIA DURING ADULTHOOD ALTERS ALCOHOL
SEDATION
To determine if Cp1 expression in glia during adulthood is important for alcohol
sedation, we used the steroid-inducible pan-glial driver, GliaGS29. Flies with both the
GliaGS driver and a Cp1 RNAi transgene, and control flies with either GliaGS or the
RNAi transgene alone, were reared to adulthood in the absence of the steroid
mifepristone (RU486) and then switched to food medium containing steroid (RU486) or
vehicle for 6 days. In this experimental design, the Cp1 RNAi transgene should be
induced in RU486-exposed adult flies harboring both a GeneSwitch Gal4 driver and an
RNAi transgene29, thereby allowing Cp1 knockdown during adulthood. Compared to
vehicle control animals of the same genotype, flies expressing the GliaGS transgene
and a Cp1 RNAi transgene fed RU486 had significantly decreased ST50 values (Cp1
RNAi #1 and #2: Fig. 4.14A and 4.14B; Cp1 RNAi #3: Fig. 4.4C). Exposure to RU486 in
flies with either the GliaGS alone or the respective Cp1 RNAi transgenes alone did not
alter ST50 values (Fig. 4.14A, 4.14B; Fig. 4.4C). Manipulation of Cp1 in glia during
adulthood was therefore sufficient to increase alcohol sedation. Interestingly, substantial
overexpression of Cp1238 (87%, quantified via immunofluorescence) in glia during
adulthood did not change ST50 values (Fig. 4.15). These results are consistent with a
model in which endogenous, physiological levels of Cp1 in glia are required and
sufficient for normal alcohol sedation in flies, suggesting that biologically relevant levels
of Cp1 in glia contribute to alcohol behaviors.
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Figure 4.14. Cp1 knockdown in CNS glia during adulthood increased ethanol
sedation sensitivity. Compared to vehicle, treatment with 1 mM RU486 for 6 days
decreased ST50 values in flies with the GliaGS driver and a Cp1 RNAi transgene
(GliaGS/Cp1 RNAi #1, panel A; GliaGS/Cp1 RNAi #2, panel B), but not in control flies
with either GliaGS or an RNAi transgene alone (Panel A: two-way ANOVA; RU486, p =
0.0247; genotype, n.s.; interaction, n.s.; *Bonferroni's multiple comparisons between
vehicle and RU486, p < 0.05; n = 8; Panel B: two-way ANOVA; RU486, n.s.; genotype,
n.s.; interaction, p = 0.0411; *Bonferroni’s multiple comparisons between vehicle and
RU486, p < 0.05; n = 16).
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Figure 4.15. Over-expression of Cp1 in CNS glia during adulthood did not alter
ethanol sedation sensitivity. (A) Over-expression of Cp1 in CNS glia during adulthood
via UAS-Cp1 did not change ethanol sedation sensitivity. Compared to vehicle-treated
controls, treatment with 1 mM RU486 for 6 days did not alter ST50 values in flies with
the GliaGS driver and a UAS-Cp1 transgene (GliaGS/UAS-Cp1). Control flies with the
UAS-Cp1 transgene alone also had no change in ST50 between vehicle and RU486
treatment (UAS-Cp1/+) (two-way ANOVA; RU486, n.s.; genotype, n.s.; interaction, n.s;
all Bonferroni's multiple comparisons between vehicle and RU486, p > 0.05; n = 8). (B,
C) Whole mount brains immunolabeled for Cp1 (Anti-Cp1 1:250, Alexa 568 1:1000).
Brains from flies with the UAS-Cp1 and repo-Gal4 transgenes had increased
fluorescence (89%) compared to brains from flies with the UAS-Cp1 transgene alone.
Microscope settings were optimized for repo-Gal4/UAS-Cp1 brains to avoid oversaturation in the image analysis. Mean fluorescence intensity was calculated using
Image J, n = 5-6. 10X, representative images.
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C. DISCUSSION
Our understanding of the molecular-genetic basis for alcohol-related behavior in
Drosophila and other model systems is based primarily on the results of studies that
have focused on neuronal genes and mechanisms226. The nervous systems of flies and
mammals also contain numerous classes of glia with conserved cellular-molecular
activities. Given that mammalian glia respond to alcohol administration 249-251, that rodent
astrocytes in the nucleus accumbens influence the motivation for alcohol consumption,
and that surface glia influence alcohol sedation and tolerance in flies183,211,212, it is likely
that glia play direct—but underappreciated—roles in behavioral responses to alcohol.
Here, we used tissue specific RNAi-mediated knock down and trans-species
rescue of RNAi to explore this possibility. Pan-glial Cp1 knockdown via RNAi
significantly increased alcohol sedation. Expression of an orthologous gene, Drosophila
pseudoobscura GA25021, in all glia rescued the alcohol sedation phenotype due to
knockdown of endogenous Cp1. Taken together, these results indicate that Cp1
expression in glia regulates alcohol sedation. Additionally, our studies found that Cp1
expression specifically in cortex glia, and probably not other CNS glia, influences
alcohol sedation. The magnitude and direction of change in alcohol sedation observed
when Cp1 was knocked down in all glia versus only cortex glia were similar, suggesting
that cortex glia are the principal cell type in which Cp1 functions to regulate alcohol
sedation. These results reveal a novel role for Cp1 and cortex glia in Drosophila alcohol
sedation. Thus, perineural glia211,212 and cortex glia (our results) influence behavioral
responses to alcohol in Drosophila.
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Glia have prominent roles in nervous system development in flies39,234. Major
changes in Drosophila nervous system development—in response to altered glial cell
function—could, in principle, alter alcohol sedation sensitivity. Our data indicate that
manipulation of Cp1 in glia during adulthood is sufficient to alter alcohol sedation in flies.
Our findings are therefore consistent with a model in which Cp1 dynamically regulates
adult glial cell function, and those changes in adult glial cell function influence the
response of the nervous system to alcohol.
To date, a few studies have investigated the role of Drosophila cortex glia in
behavior. One study suggests that innexin2 expression in cortex glia is required for
normal sleep patterns58, and two studies have indicated that cortex glia function
contributes to seizures133,139. Additionally, cortex glia morphology influences larval
locomotor behaviors39. The results reported here add to the emerging literature on
cortex glia and behavior by showing that cortex glia, via Cp1 function, influence alcohol
sedation. It could be important to explore the role of cortex glia, in conjunction with Cp1
and other candidate pathways, in behavioral responses to other drugs of abuse.
Cp1 knockdown in glia, specifically cortex glia, appeared to enhance alcohol
rapid tolerance development. However, glial Cp1 knock down influenced sedation
during the first exposure to alcohol only. These results suggest that Cp1 function in glia
selectively influences alcohol sedation during an initial exposure to the drug and any
interpretations regarding the role of Cp1 in rapid tolerance should be made with
considerable caution. Importantly, though, since Cp1 knock down in glia did not
influence alcohol sedation during a second alcohol exposure or alter locomotor abilities
in the absence of alcohol (Fig. 4.16), it seems unlikely that the initial sedation sensitivity
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of flies with Cp1 knockdown in glia is related to global sluggishness, a lack of overall
behavioral fitness, or other experimental artifacts. We therefore posit that glial Cp1
plays a direct role in response of the central nervous system to alcohol.
Cp1 cleaves, and thereby activates, the transcription factor cut239. Additionally,
the protein crammer binds to and inactivates the Cp1 protein233. We consequently
predicted that altered expression of cut or crammer might alter sedation sensitivity.
Surprisingly, constitutive expression of RNAi against cut or crammer in cortex glia or
adult-specific expression of RNAi in all glia failed to substantively alter alcohol sedation
(Fig. 4.17 and 4.18). Additionally, a recent study identified that Cp1 is required for
synaptic vesicle degradation, and that this Cp1-mediated degradation was dependent
on neuronal synaptobrevin (n-syb)252. Therefore, we tested whether expression of RNAi
against n-syb in all glia altered alcohol sedation to investigate whether Cp1 and n-syb
may be functioning similarly in glia to mediate alcohol sedation. Constitutive expression
of n-syb RNAi in glia did not alter alcohol sedation (Fig 4.19), suggesting that Cp1 and
n-syb are not functioning together in glia to influence alcohol sedation. However, it is
possible that Cp1 and a glial version of syb may be functioning together, and this
possibility would have to be investigated further. Although additional follow-up studies
would be required to formally rule out a role for cut, crammer and n-syb in Cp1dependent alcohol sedation, our data suggest that Cp1 influences alcohol sedation
independently of these three known genes.
Cp1 is structurally and functionally homologous to mammalian Cathepsin L240.
Cathepsins are powerful hydrolytic cysteine proteases and are inactively stored in the
lysosomes of most tissues in mammalian cells253. When released from lysosomes in
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their active form, they play roles in many physiological processes253. Although
Cathepsin L has not been directly implicated in alcohol-related behaviors in mammals,
Cathepsin L contributes to alcohol-induced cellular and/or organ damage. For example,
Cathepsin L mediates alcohol-induced pancreatic damage and alcoholic liver
fibrosis254,255. Following alcohol administration, Cathepsin L is activated in pancreatic
lysosomes254,256 and down-regulated in the cellular matrix in the liver255, contributing to
disease pathologies. However, it is unlikely that altered alcohol sedation in Cp1
knockdown flies is caused by over-all cathepsin-related glial cell damage because (i)
flies with Cp1 knockdown have normal locomotor responses in the absence of alcohol
(Fig. 4.16), (ii) Cp1 knockdown selectively alters alcohol sedation during a first, but not a
second, exposure to the drug (Fig. 4.13) and (iii) Cp1 overexpression in all glia during
adulthood does not alter alcohol sedation (Fig. 4.15). Although our results do not rule
out the possibility that Cp1 is involved in glial cell damage, they do suggest that alcohol
sedation sensitivity in Cp1 knockdown animals is unrelated to cellular damage that
potentially may be occurring.
Cathepsin L also functions in secretory vesicles as a proneuropeptide
processing257. Cathepsin L knockdown resulted in an 80-90% reduction of Neuropeptide
Y (NPY) production in mammals257. Interestingly, NPY is synthesized in glia during
development and adulthood in mammals. During adulthood, glial NPY is postulated to
provide trophic support to neurons258. Mammalian NPY is homologous to Drosophila
Neuropeptide F (NPF), which influences alcohol sedation in Drosophila23,259. While a
role for Cp1 in NPF maturation in flies is possible, it seems unlikely that glial Cp1
influences alcohol sedation via processing of NPF. When NPF synthesis was ablated in
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all NPF-producing cells, alcohol sedation was blunted23, whereas knockdown of Cp1,
which would also be predicted to decrease NPF production, increased alcohol sedation
in our studies. These contradictory results make it very unlikely that Cp1 and NPF are
working in conjunction to mediate alcohol sedation in Drosophila. Thus, additional
studies, potentially involving approaches grounded in proteomics, are required to begin
elucidating the molecular mechanisms involved in Cp1-dependent modulation of alcohol
sedation in flies.
In summary, our results indicate a novel and potentially direct role for Drosophila
glia in alcohol-related behaviors and that Cp1 represents a functional entry point for
further understanding of cortex glial mechanisms that underlie alcohol sedation. Given
that Drosophila Cp1 is orthologous to mammalian Cathepsin L, and that fly cortex glia
are functionally similar to mammalian protoplasmic astrocytes, our findings have the
potential to be translatable to mammalian systems. Our findings also raise the
possibility that glial cysteine proteinases might mediate behavioral responses to other
drugs of abuse in both flies and mammals.
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Figure 4.16. Expression of Cp1 RNAi in CNS glia did not alter locomotion.
Expression of the Cp1 RNAi #1 transgene in CNS glia (via repo-Gal4) did not alter the
percentage of active flies compared to controls with either repo-Gal4 or the RNAi
transgene alone. Vortexing the repo-Gal4 control for 4 minutes reduced the percentage
of active flies compared to the other groups (one-way ANOVA, p< 0.001; * Bonferronni’s
multiple comparison, p < 0.05; n = 8)
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Figure 4.17. Expression of cut RNAi in cortex glia and CNS glia during adulthood
did not alter alcohol sedation sensitivity. (A, B) ST50 values were not changed in
flies expressing cut RNAi transgenes in cortex glia (blue triangles: NP2222-Gal4/cut
RNAi #1, panel A; blue triangles: NP2222-Gal4/cut RNAi #2, panel B) compared to
control flies containing either the cortex glia Gal4 driver (black circles: NP2222-Gal4/+)
or the RNAi transgenes (black squares: cut RNAi #1/+ or cut RNAi #2/+) alone (Panel
A: one-way ANOVA, p > 0.05; n = 8; Panel B: one-way ANOVA, p = 0.0041; all
Bonferroni’s multiple comparisons vs controls, p > 0.05; n = 8). (C, D) Expression of cut
RNAi in CNS glia during adulthood did not alter ethanol sedation sensitivity. Compared
to vehicle-treated controls, treatment with 1 mM RU486 for 6 days did not change ST50
values in flies with the GliaGS driver and a cut RNAi transgene (GliaGS/cut RNAi #1,
panel C; GliaGS/cut RNAi #2, panel D). Control flies with the RNAi transgene alone also
had no change in ST50 between vehicle and RU486 treatment (individual two-way
ANOVAs; RU486, n.s.; genotype, n.s.; interaction, n.s.; all Bonferroni's multiple
comparisons between vehicle and RU486, p > 0.05; n = 8).
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Figure 4.18. Expression of crammer RNAi in cortex glia and CNS glia during
adulthood did not alter alcohol sedation sensitivity. (A) ST50 values were
significantly decreased between flies expressing the crammer RNAi #2 transgene in
cortex glia (blue triangles: NP2222-Gal4/crammer RNAi #2) compared to the RNAi
alone (crammer RNAi #2/+) control. However, ST50 values were not changed in flies
expressing crammer RNAi transgenes in cortex glia (blue triangles diamonds: NP2222Gal4/crammer RNAi #1; green diamonds: NP2222-Gal4/crammer RNAi #2) compared
to control flies containing either the cortex glia Gal4 driver (black circles: NP2222Gal4/+) or the appropriate RNAi transgene alone (one-way ANOVA, p < 0.0001;
*Bonferroni's multiple comparisons vs controls, p < 0.05; n = 8). (B, C) Expression of
crammer RNAi in CNS glia during adulthood does not alter ethanol sedation sensitivity.
(B) Compared to vehicle-treated controls, treatment with 1 mM RU486 for 6 days did
not alter ST50 values in flies with the GliaGS driver and the crammer RNAi #1
transgene (GliaGS/crammer RNAi #1). Control flies with either GliaGS or the RNAi
transgene alone also had no differences in ST50 between vehicle and RU486 treatment
(two-way ANOVA; interaction, n.s.; genotype, p = 0.0302; RU486, n.s.; all Bonferroni's
multiple comparisons between vehicle and RU486, p > 0.05; n = 3-8). (C) Compared to
vehicle-treated controls, treatment with 1 mM RU486 for 6 days did not alter ST50
values in flies with the GliaGS driver and the crammer RNAi #2 transgene
(GliaGS/crammer RNAi #2). (Student’s t-test, p > 0.05; n = 8).
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Figure 4.19. Expression of n-syb RNAi in all glia did not alter alcohol sedation
sensitivity. (A) ST50 values were significantly decreased between flies expressing the
syb RNAi #1 transgene in all glia via repo-Gal4 (blue triangles: NP2222-Gal4/syb RNAi
#1) compared to control flies expressing repo-Gal4 alone (black circles: repo-Gal4/+).
However, ST50 values were not changed in flies expressing syb RNAi #1 transgene in
all glia via repo-Gal4 (blue triangles) compared to control flies expressing the RNAi
transgene alone (black squares: syb RNAi #1/+) (one-way ANOVA, p = 0.003;
*Bonferroni's multiple comparisons vs controls, p < 0.05; n = 6-8). (B) ST50 values were
similar between flies expressing the syb RNAi #2 transgene in all glia via repo-Gal4
(blue triangles: syb RNAi #2/repo-Gal4) compared to control flies that had either the
Gal4 alone (black circles: repo-Gal4/+) or the RNAi transgene alone (black squares: syb
RNAi #2/+) (one-way ANOVA, p = 0.34; n = 7-8).
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CHAPTER 5: TYRAMINE SYNTHESIS, VESICULAR PACKAGING AND THE SNARE
COMPLEX FUNCTION COORDINATELY IN ASTROCYTES TO REGULATE
DROSOPHILA ALCOHOL SEDATION

A. INTRODUCTION
Alcohol abuse impacts and is impacted by central nervous system (CNS)
function5. There is consequently a large, continuing effort to use model organisms to
identify mechanisms underlying alcohol-related behaviors to better understand the role
of the CNS in alcohol abuse. Although the central nervous system contains both glia
and neurons as principal cell types, the preponderance of research to date has focused
on the role of neuronal mechanisms in alcohol-related behaviors. Thus, there is likely
much to be learned by investigating the role of glia in behavioral responses to alcohol.
Despite the somewhat limited focus on glia and alcohol, several studies offer
intriguing insights into the effect of alcohol on these cells and the roles these cells play
in alcohol-related behavior. For example, calcium signaling genes are upregulated in
astrocytes after chronic alcohol administration in mice178, expression of the glial
cytoskeletal protein GFAP can be altered by alcohol exposure in rodents and
humans159,260, cultured astrocytes, in the presence of alcohol, can induce interferon
expression in neurons190 and alcohol exposure correlates with increased hemichannel
opening in mouse hippocampal astrocytes182. These studies indicate that glia are
responding to alcohol administration and suggest that these responses might be
required for normal alcohol-related behaviors. Consistent with the possibility that glia
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are directly involved in behavioral responses to alcohol, increasing intracellular calcium
in astrocytes via designer receptors exclusively activated by designer drugs
(DREADDs) decreased motivation for alcohol after a 3-week abstinence period in
rats183, mutation of the gene moody in flies, which is expressed in surface glia, blunts
alcohol-induced loss of postural control211, and Drosophila perineural glia influence
alcohol tolerance212. Thus, there is good evidence that glia respond to and are involved
in the behavioral responses to alcohol.
Here, we report the results of studies using the fruit fly, Drosophila melanogaster,
to further explore the role of glia in alcohol-related behavior. Flies are a leading model
for investigating the molecular-genetics of behavioral responses to alcohol for many
reasons including (i) they have conserved behavioral responses to alcohol13, (ii) there is
a large suite of genetic tools available to manipulate gene expression in flies24,261, and
(iii) many genes that impact fly alcohol behavior have been implicated in various
aspects of alcohol abuse in humans16,226. Flies are also emerging as a powerful model
for studying the contribution of glia to physiology and disease. Flies have several glial
cell subtypes in the central nervous system (astrocytes, cortex glia, ensheathing cells,
perineural glia and subperineural glia) that collectively share many morphological and
functional attributes of mammalian glia. For example, fly astrocytes maintain ion
homeostasis, remove neurotransmitters from the synapse, have hemichannels and gap
junctions, produce Ca2+ oscillations and release gliotransmitters like their mammalian
counterparts40,140,153. Flies are therefore well-suited for investigating the contribution of
astrocytes to behavioral responses to alcohol.
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We identified the gene tyramine decarboxylase 2 (Tdc2) as a regulator of alcohol
sedation in flies. Tdc2 is a brain-specific enzyme that converts the amino acid tyrosine
to the catecholamine tyramine in invertebrates262. Manipulation of Tdc2 expression in all
glia, selectively in astrocytes, or conditionally in glia during adulthood altered ethanol
sedation. Additionally, manipulation of the vesicular monoamine transporter (VMAT) and
the SNARE complex in all glia, astrocytes and in adult glia also influenced ethanol
sedation by functioning downstream of Tdc2. Our studies support a model in which
Tdc2 produces tyramine in astrocytes which is packaged into vesicles and released via
the SNARE complex, thereby mediating alcohol sedation in Drosophila.

B. RESULTS
B.1 Tdc2 FUNCTIONS IN CNS GLIA, SPECIFICALLY ASTROCYTES, TO
REGULATE ALCOHOL SEDATION SENSITIVITY
To identify candidate genes that could influence alcohol-related behaviors by
functioning in glia, we compiled a list of genes known to be expressed in Drosophila
CNS glial cells263,264. We then determined whether manipulation of 33 of these genes
individually in all CNS glia influenced alcohol sedation in Drosophila (Table 5.1). Flies
with pan-glial Gal4 (via repo-Gal4) driven expression of two unique Tdc2 RNAi
transgenes (Tdc2 RNAi #1 and #2) had significantly decreased sedation time 50 (ST50)
values compared to control flies containing the Gal4 or RNAi transgene alone (Fig.
5.1A, 5.1B), suggesting that Tdc2 might regulate alcohol sedation by functioning in glia.
Tdc2 could, in principle, influence alcohol sedation through the collective effect of
its role in all CNS glia or by a role in a single glial cell subtype. We consequently
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assessed whether manipulating Tdc2 expression individually in astrocytes, ensheathing
cells, cortex glia, perineural glia and subperineural glia impacted ST50 values. We
found that expression of Tdc2 RNAi in astrocytes (via alrm-Gal4) significantly decreased
ST50 values compared to controls (Fig. 5.1C, 5.1D; Table 5.2). Expression of Tdc2
RNAi in other glial cell subtypes did not alter ST50 values (Table 5.2). Additionally, Tdc2
RNAi expression in neurons did not alter ST50 values compared to controls (Fig. 5.2).
Taken together, these data suggest that Tdc2 plays a role in alcohol sedation by
functioning within astrocytes, but not other glial cell subtypes or neurons.
We performed immunofluorescence studies to determine (i) whether the Tdc2
RNAi transgenes we used knocked down expression of Tdc2 and (ii) whether Tdc2 is
expressed in CNS glia. Consistent with a previous report265, we found that Tdc2 is
robustly expressed throughout the brain (Fig. 5.3A, 5.3B). Additionally, the Tdc2
immunofluorescence signal was significantly decreased by pan-neuronal elav-Gal4driven expression of Tdc2 RNAi transgenes (Figs. 5.3), confirming that Tdc2 is
expressed in neurons265 and that the RNAi transgenes knockdown expression of Tdc2.
Tdc2 is known to be expressed in astrocytes, as characterized by TRAP-seq
studies264. To confirm these results, we labeled astrocytes through mCD8:GFP
expression driven by alrm-Gal4 and detected endogenous Tdc2 via
immunofluorescence. GFP driven by alrm-Gal4 was found in astrocytes throughout the
brain (Fig. 5.4A), as expected40. Endogenous Tdc2 was also expressed throughout the
brain as expected (Fig. 2B). Using Manders colocalization coefficient266, we found that
approximately 12% of the GFP (astrocytes) and red (Tdc2) pixels were colocalized (n =
6), indicating that a subpopulation of astrocytes express Tdc2 (Fig 5.4). Collectively, the
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data in Figs. 5.1, 5.3 and 5.4 indicate that Tdc2 influences alcohol sedation in
Drosophila by functioning in astrocytes.
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Table 5.1. Identifying glial genes that regulate alcohol sedation

Genes were manipulated either by over-expression (UAS), dominant negative or RNAi
transgenes. Manipulations were made in all glia during adulthood using GliaGS. ST50
values for the GliaGS/transgene either fed RU486 or vehicle are reported. #, $, %, &, ~
and + represent genotypes that were tested together, and were therefore statistically
compared in the two-way ANOVA. When appropriate, Bonferonni multiple comparisons
adjusted p-values are reported.
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Figure 5.1. Manipulating Tdc2 expression constitutively in all glia or specifically
in astrocytes alters alcohol sedation. (A, B) ST50 values were reduced in flies with
the pan-glial driver repo-Gal4 and a Tdc2 RNAi transgene (blue bars: repo-Gal4/Tdc2
RNAi #1, panel A; repo-Gal4/Tdc2 RNAi #2, panel B) compared to control flies with
either repo-Gal4 alone (black bars: repo-Gal4/+) or the respective RNAi transgene
alone (black bars: Tdc2 RNAi #1/+ and Tdc2 RNAi #2/+) (Panel A: one-way ANOVA, p
< 0.0001; *Bonferroni’s multiple comparison vs controls, p < 0.05; n = 8; Panel B: oneway ANOVA, p < 0.0001; *Bonferroni’s multiple comparison vs controls, p < 0.05; n =
16). (C, D) ST50 values were decreased in flies expressing the astrocyte-specific driver
alrm-Gal4 and a Tdc2 RNAi transgene (blue bars: alrm-Gal4/Tdc2 RNAi #1, panel C;
alrm-Gal4/Tdc2 RNAi #2, panel D) compared to control flies containing either the
astrocyte Gal4 driver (black bars: arlm-Gal4) or the respective RNAi transgene (black
bars: Tdc2 RNAi #1/+, panel C; Tdc2 RNAi #2, panel D) alone (Panel C: one-way
ANOVA, p < 0.0001; *Bonferroni’s multiple comparison vs controls, p < 0.05; n = 8;
Panel D: one-way ANOVA, p < 0.0001; *Bonferroni’s multiple comparison vs controls, p
< 0.05; n = 16).
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Table 5.2. Manipulating expression of Tdc2 in each glial cell subtype individually

Expression of the Tdc2 RNAi #1 transgene in astrocytes (via alrm-Gal4) consistently
altered alcohol sedation compared to both the Gal4 driver (Gal4/+) and RNAi transgene
(RNAi/+) controls. Expression of the Tdc2 RNAi #1 transgene in ensheathing cells (via
TIFR-Gal4 and mz0709-Gal4), cortex glia (via NP2222-Gal4), subperineural glia (via
Gli-Gal4) and perineural glia (via Indy-Gal4) did not consistently alter alcohol sedation
compared to both the Gal4 driver (Gal4/+) and RNAi transgene (RNAi/+) controls.
Results from individual one-way ANOVAs and (when appropriate) Bonferroni’s multiple
comparisons are reported. $ represent common RNAi/+ controls.
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Figure 5.2. Tdc2 knockdown in neurons does not alter alcohol sedation. ST50
values were not altered in flies containing both the pan-neuronal driver elav-Gal4 and
the Tdc2 RNAi #1 transgene (blue bar: elav-Gal4/Tdc2 RNAi #1) compared to control
flies containing either elav-Gal4 or the Tdc2 RNAi #1 transgene alone (black bars) (oneway ANOVA, p = 0.189, n = 8).
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Figure 5.3. Tdc2 RNAi knocks down Tdc2 expression. Whole mount brain images
immunolabeled for Tdc2 expression (anti-Tdc2 1:200, Alexa-647 1:1000). All
representative images, 10X. (A, B) Tdc2 expression in brains of flies with a Tdc2 RNAi
transgene alone. (C, D) Tdc2 expression in brains of flies with the pan-neuronal driver
elav-Gal4 and a Tdc2 RNAi. (E, F) Brains with both the elav-Gal4 and a Tdc2 RNAi
transgene had significantly lower pixel intensity compared to control flies with the Tdc2
RNAi transgene alone (Panel E: students t test, p = 0.0059, n = 4-5; Panel F: students t
test, p = 0.0002, n = 4).
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Figure 5.4. Tdc2 expression in astrocytes. (A) Expression of UAS-GFP (green)
driven by alrm-Gal4. (B) Endogenous Tdc2 expression labeled red (anti-Tdc2 1:200,
Alexa 647 1:1000). (C) Overlay and colocalization. Column i and ii are representative
10X Z-stack slices from the same whole brain. Column iii is representative 63X oil
immersion.
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B.2 Tdc2 REGULATES ALCOHOL SEDATION SENSITIVITY IN CNS GLIA DURING
ADULTHOOD THROUGH A PHARMACODYNAMIC MECHANISM
To determine if Tdc2 expression in glia during adulthood is important for alcohol
sedation, we used GliaGS to conditionally express UAS-transgenes. GliaGS is a steroid
(mifepristone, RU486)-inducible pan-glial Gal4 driver29. Compared to vehicle, induction
of the two independent Tdc2 RNAi transgenes in all glia during adulthood (i.e. in flies
with GliaGS and a Tdc2 RNAi transgene fed RU486) significantly decreased ST50
values (Fig. 5.5A, 5.5B). Conversely, conditional overexpression of Tdc2 via two
independent, previously validated267, transgenes in all glia during adulthood (i.e. in flies
with GliaGS and a UAS-Tdc2 transgene fed RU486) significantly increased ST50 values
(Fig. 5.5C). Treatment with RU486 did not significantly alter ST50 values in control flies
with either the GliaGS driver, the Tdc2 RNAi transgenes or the UAS-Tdc2 transgenes
alone (Fig. 5.5). Additionally, internal alcohol levels were not altered by adult-specific
Tdc2 knockdown or over-expression in glia (Fig. 5.6A). Thus, knocking down or
overexpressing Tdc2 in glia during adulthood respectively decreased or increased ST50
values without altering the net uptake or metabolism of alcohol. Therefore, the level of
Tdc2 expression in adult glia is a key regulator of alcohol sedation in flies.
Interestingly, overexpressing Tdc2 (via UAS-Tdc2) constitutively in all glia (via repoGal4) and constitutively in astrocytes (via alrm-Gal4) caused developmental lethality. To
determine if Tdc2 overexpression in astrocytes alters alcohol sedation, we utilized
Gal80ts, an inducible temperature sensitive Gal4 repressor28, to express UAS-Tdc2 in
astrocytes during adulthood. Flies developed in the Gal80ts permissive temperature
(18°C), repressing UAS-Tdc2 expression during development (i.e. Gal80ts on, alrm-

117

Gal4 off, UAS-Tdc2 off). During adulthood, flies were switched to the Gal80ts restrictive
temperature (30°C), which allows UAS-Tdc2 to be expressed in astrocytes via alrmGal4 (i.e. Gal80ts off, alrm-Gal4 on, UAS-Tdc2 on). Switching flies to the restrictive
temperature (30°C), and consequently overexpressing Tdc2 in astrocytes during
adulthood, significantly increased ST50 compared to control flies that experienced the
same temperature shift (30C, Fig 5.7). However, for reasons that we do not understand,
rearing flies in the permissive temperature (18°C), and not switching temperatures (no
30°C exposure), differentially altered flies behavioral responses to alcohol (18C, Fig
5.7). While difficult to fully interpret, these data begin to suggest that overexpressing
Tdc2 in astrocytes during adulthood also alters alcohol sedation in flies.
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Figure 5.5. Manipulating Tdc2 expression in all glia during adulthood influences
alcohol sedation. (A, B) Compared to vehicle, treatment with RU486 decreased ST50
values in flies with the GliaGS driver and a Tdc2 RNAi transgene (GliaGS/Tdc2 RNAi
#1, panel A; GliaGS/Tdc2 RNAi #2, panel B), but not in control flies with either GliaGS
or the respective RNAi transgene alone (Panel A: two-way ANOVA; RU486, p = 0.059;
genotype, p < 0.0001; interaction, p = 0.13; *Bonferroni’s multiple comparisons between
vehicle and RU486, p < 0.05; n = 8; Panel B: two-way ANOVA; RU486, p = 0.4;
genotype, p < 0.0001; interaction, p = 0.045; *Bonferroni’s multiple comparisons
between vehicle and RU486, p < 0.05; n = 8). (C) Compared to vehicle, treatment with
RU486 increased ST50 values in flies with the GliaGS driver and a UAS-Tdc2
transgene (GliaGS/UAS-Tdc2 #1 and GliaGS/UAS-Tdc2 #2), but not in control flies with
either GliaGS or the UAS-Tdc2 transgene alone (two-way ANOVA; RU486, p = 0.0012;
genotype, p = 0.0004; interaction, p = 0.0003; *Bonferroni’s multiple comparisons
between vehicle and RU486, p < 0.05; n = 6-7).
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Figure 5.6. Internal ethanol concentrations. (A) Compared to vehicle, treatment with
RU486 did not alter internal ethanol levels in flies with the GliaGS driver and the Tdc2
RNAi transgenes (GliaGS/Tdc2 RNAi #1; GliaGS/Tdc2 RNAi #2) or in flies with the
GliaGS driver and the UAS-Tdc2 transgenes (GliaGS/UAS-Tdc2 #1; GliaGS/UAS-Tdc2
#2) (two-way ANOVA; RU486, p = 0.871; genotype, p < 0.0001; interaction, p = 0.286;
Bonferroni’s multiple comparisons between vehicle and RU486, p = 0.66-0.9999; n = 56). (B) Compared to vehicle, treatment with RU486 did not alter internal ethanol levels
in flies with the GliaGS driver and the VMAT RNAi #1 transgene (GliaGS/VMAT RNAi
#1), but RU486 treatment decreased internal ethanol levels in flies with the GliaGS
driver and the VMAT RNAi #2 transgene (GliaGS/VMAT RNAi #2) (two-way ANOVA;
RU486, p = 0.035; genotype, p < 0.0001; interaction, p = 0.022; *Bonferroni’s multiple
comparisons between vehicle and RU486, p < 0.05; n = 5-6). (C) Compared to vehicle,
treatment with RU486 did not alter internal ethanol levels in flies with the GliaGS driver
and the UAS-TeTx transgene (GliaGS/UAS-TeTx) (student’s t test, p = 0.126; n = 5).
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Figure 5.7. Tdc2 overexpression in astrocytes alters alcohol sedation. Gal80ts
represses Gal4 in 18C and is permissive to Gal4 in 30C. Compared to controls within
the same temperature treatment, exposure to 30C significantly increased ST50 values
in alrm-Gal4/Gal80ts, UAS-Tdc2 flies (blue bars). A second group of flies, which did not
experience a temperature shift, also served as a control (labeled 18C). UAS-Tdc2/+
(dark grey bar) and Gal80ts, UAS-Tdc2/+ (light grey bar) flies had significantly
increased ST50 values compared to alrm-Gal4/Gal80ts (black bars) and alrmGal4/Gal80ts, UAS-Tdc2 flies (blue bars) (two-wat ANOVA; temperature, p < 0.0001;
genotype, p < 0.0001; interaction, p < 0.0001; *Bonferroni’s multiple comparisons
between vehicle and RU486, p < 0.05; n = 8).
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B.3 MANIPULATION OF TYRAMINE SYNTHESIS IN ASTROCYTES IMPACTS
ALCOHOL SEDATION
Tyrosine is converted to tyramine by Tdc2 and to dopamine by tyrosine
hydroxylase (Th). Tyramine produced by Tdc2 can be converted to octopamine by
tyramine -hydroxylase (Tbh)262 (Fig 5.8). We postulated that manipulation of Tdc2
might influence alcohol sedation by impacting tyramine levels directly or through
secondary effects on dopamine or octopamine synthesis. To test this, we targeted Tbh
and Th expression in glia during adulthood using GliaGS and previously validated RNAi
and UAS transgenes109,268-272. Induction of Tbh RNAi or UAS transgenes (Fig. 5.9) and
induction of Th RNAi or UAS transgenes (Fig. 5.10) individually in all glia during
adulthood did not alter ST50 values. While follow-up studies would be needed to fully
rule out a role for glial Tbh and Th in alcohol sedation, our results support the
hypothesis that manipulation of Tdc2 expression in glia influences alcohol sedation by
altering tyramine levels.
If Tdc2 impacts alcohol sedation through tyramine synthesis, we predicted that
alcohol sedation sensitivity in Tdc2 knockdown flies might be rescued by
supplementation with dietary tyramine. In vehicle-fed (i.e. no tyramine supplementation)
flies, expression of Tdc2 RNAi in astrocytes via alrm-Gal4 decreased ST50 values (Fig.
5.11A, 5.11B), consistent with our previous studies (Fig. 5.1C, 5.1D). Providing flies with
a diet supplemented with tyramine eliminated (Fig. 5.11A) or partially reversed (Fig.
5.11B) the effect of Tdc2 knockdown in astrocytes on ST50 values. Collectively, the
data in Figs. 5.9, 5.10 and 5.11 are consistent with a model in which tyramine produced
in astrocytes by Tdc2 regulates alcohol sedation.
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Figure 5. 8. The invertebrate catecholamine synthesis pathway. The amino acid
tyrosine can be converted to L-Dopa by tyramine hydroxylase (Th, also known as pale).
L-Dopa is converted to dopamine by dopamine decarboxylase (Ddc). Tyrosine can also
be converted to tyramine by tyramine decarboxylase 2 (Tdc2). Tyramine can be
converted to octopamine by tyramine β hydroxylase (Tbh). Adapted from Cole, 2005 262.
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Figure 5.9. Manipulation of Tbh in glia does not alter normal alcohol sedation. (A,
B) Compared to vehicle, treatment with RU486 did not alter ST50 values in flies with the
GliaGS driver and a Tbh RNAi transgene (panel A: GliaGS/Tbh RNAi #1, GliaGS/Tbh
RNAi #2; panel B: GliaGS/Tbh RNAi #3, GliaGS/Tbh RNAi #4) or in control flies with
either GliaGS or the Tbh RNAi transgene alone (Panel A: two-way ANOVA; RU486, p =
0.003; genotype, p < 0.0001; interaction, p = 0.875; Bonferroni’s multiple comparisons
between vehicle and RU486, p = 0.15-0.9999; n = 8; Panel B: two-way ANOVA; RU486,
p = 0.147; genotype, p < 0.0001; interaction, p = 0.48; Bonferroni’s multiple
comparisons between vehicle and RU486, p = 0.55-0.9999; n = 6). (C) Compared to
vehicle, treatment with RU486 did not alter ST50 values in flies with the GliaGS driver
and the UAS-Tbh transgene (GliaGS/UAS-Tbh) or in control flies with either GliaGS or
the UAS-Tbh transgene alone (two-way ANOVA; RU486, p = 0.005; genotype, p =
0.0009; interaction, p = 0.81; Bonferroni’s multiple comparisons between vehicle and
RU486, p = 0.16-0.77; n = 8).
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Figure 5.10. Manipulation of Th in glia does not alter alcohol sedation. (A, B)
Compared to vehicle, treatment with RU486 did not alter ST50 values in flies with the
GliaGS driver and a Th RNAi transgene (panel A: GliaGS/Th RNAi #1; panel B:
GliaGS/Th RNAi #2, GliaGS/Th RNAi #3, GliaGS/Th RNAi #4) or in control flies with
either GliaGS or the Th RNAi transgene alone (Panel A: two-way ANOVA; RU486, p =
0.16; genotype, p < 0.0001; interaction, p = 0.902; Bonferroni’s multiple comparisons
between vehicle and RU486, p = 0.86-0.9999; n = 8; Panel B: two-way ANOVA; RU486,
p = 0.885; genotype, p = 0.007; interaction, p = 0.503; Bonferroni’s multiple
comparisons between vehicle and RU486, p > 0.9999; n = 6). (C) Compared to vehicle,
treatment with RU486 did not alter ST50 values in flies with the GliaGS driver and the
UAS-Th transgene (GliaGS/UAS-Th) or in control flies with either GliaGS or the UAS-Th
transgene alone (two-way ANOVA; RU486, p = 0.23; genotype, p = 0.749; interaction, p
= 0.504; n = 6).
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Figure 5.11. Tyramine feeding rescues Tdc2 RNAi-associated alcohol sedation
sensitivity. (A) ST50 values were decreased in vehicle-fed flies expressing the
astrocyte specific driver alrm-Gal4 and the Tdc2 RNAi #1 transgene (blue bar: alrmGal4/Tdc2 RNAi #1) compared to vehicle-fed control flies containing either the astrocyte
Gal4 driver (black bar: arlm-Gal4) or the RNAi transgene (grey bar: Tdc2 RNAi #1/+)
alone. ST50 values were not different in tyramine-fed flies expressing alrm-Gal4 and
Tdc2 RNAi transgene #1 (blue bar: alrm-Gal4/Tdc2 RNAi #1) compared to tyramine-fed
control flies containing either the astrocyte Gal4 driver (black bar: arlm-Gal4) or the
Tdc2 RNAi transgene alone (grey bar: Tdc2 RNAi #1/+) (two-way ANOVA; tyramine
treatment, p = 0.77; genotype, p = 0.029; interaction, p = 0.28; *Bonferroni’s multiple
comparisons within treatments, p < 0.05; n = 14-16). (B) ST50 values were decreased
in vehicle-fed flies expressing the astrocyte specific driver alrm-Gal4 and the Tdc2 RNAi
#2 transgene (blue bar: alrm-Gal4/Tdc2 RNAi #2) compared to vehicle-fed control flies
containing either the astrocyte Gal4 driver (black bar: arlm-Gal4) or the RNAi transgene
(grey bar: Tdc2 RNAi #2/+) alone. ST50 values were not different in tyramine-fed flies
expressing alrm-Gal4 and the Tdc2 RNAi transgene #2 (blue bar: alrm-Gal4/Tdc2 RNAi
#2) compared to tyramine-fed control flies containing the Tdc2 RNAi transgene alone
(grey bar: Tdc2 RNAi #2/+). ST50 values were higher in tyramine-fed control flies with
the astrocyte Gal4 driver alone (black bar: alrm-Gal4/+) compared to tyramine-fed flies
containing the Tdc2 RNAi transgene alone (grey bar: Tdc2 RNAi #2/+) and flies
containing both alrm-Gal4 and Tdc2 RNAi transgene (blue bar: alrm-Gal4/Tdc2 RNAi
#2) (two-way ANOVA; tyramine treatment, p = 0.57; genotype, p < 0.0001; interaction, p
= 0.02; *Bonferroni’s multiple comparisons within treatments, p < 0.05; n = 8).
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B.4 ALCOHOL SEDATION IS INFLUENCED BY VESICULAR PACKAGING AND
RELEASE MACHINERY IN GLIA
In fly neurons, tyramine is released into the synapse through vesicular exocytosis
and then functions as a neurotransmitter27,267,273. If tyramine production in glia mediates
alcohol sedation, we predicted that manipulating the vesicular packaging machinery
might have the same effect on alcohol sedation as Tdc2 knockdown. We therefore
assessed whether the vesicular monoamine transporter (VMAT) in glia regulates
alcohol sedation because this transporter (i) packages monoamines, including tyramine,
into vesicles in neurons274, (ii) is expressed in mammalian astrocytes76 and (iii) is
expressed in fly glia275,276. Constitutive expression of two unique VMAT RNAi
transgenes individually in all glia via repo-Gal4 significantly decreased ST50 (Fig.
5.12A, 5.12B). Similarly, flies expressing VMAT RNAi in astrocytes (via alrm-Gal4) had
significantly decreased ST50s compared to controls (Fig. 5.12C, 5.12D). RU486induced expression of VMAT RNAi in all glia during adulthood significantly decreased
ST50s, whereas treatment with RU486 had no effect in control genotypes (Fig. 5.12E,
5.12F). Internal alcohol levels were not consistently altered by expression of VMAT
RNAi transgenes (Fig. 5.6B), indicating that that VMAT is mediating alcohol sedation
through a pharmacodynamic mechanism. Expression of the RNAi transgenes used in
these experiments in neurons significantly decreased the detection of VMAT in whole fly
brains (Fig 5.13), indicating that the transgenes are capable of knocking down VMAT
expression. Thus, knocking down Tdc2 (Figs. 5.1 and 5.5) and VMAT (Fig. 5.12), using
three different expression strategies targeting all glia, astrocytes or adult glia, have
similar effects on alcohol sedation.
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Given that manipulation of Tdc2 and VMAT in glia produced similar changes in
alcohol sedation, we postulated that they might function in the same pathway. To
address this possibility, we assessed alcohol sedation in flies with Tdc2 over-expressed
and VMAT knocked down using three approaches: pan-glial expression via repo-Gal4,
astrocyte-specific expression using alrm-Gal4, and adult-induced expression in all glia
using GliaGS. Over-expression of Tdc2 in all glia and in astrocytes was lethal (missing
bars in Fig. 5.14A, 5.14B). Expression of VMAT RNAi in all glia (Fig. 5.14A) or in
astrocytes (Fig. 5.14B) significantly decreased ST50 values as described above (Fig.
5.12). Interestingly, expression of only the VMAT RNAi, and not a UAS-GFP transgene,
suppressed the lethality associated with Tdc2 over-expression (quantified for repo-Gal4
in Table 5.3). More importantly, the ST50 values in flies over-expressing Tdc2 in
conjunction with the VMAT RNAi were statistically indistinguishable from flies
expressing only VMAT RNAi (Fig. 5.14A, all glia; Fig. 5.14B, astrocytes). Similarly,
RU486-induced over-expression of Tdc2 during adulthood increased ST50 values,
expression of VMAT RNAi decreased ST50 values, and flies with concomitant overexpression of Tdc2 and VMAT RNAi had decreased ST50s that were comparable to
ST50s in flies expressing only VMAT RNAi (Fig. 5.14C). Taken together, these data
strongly support a model in which knockdown of VMAT is epistatic to over-expression of
Tdc2, thereby placing VMAT biochemically downstream of Tdc2 and suggesting that
alcohol sedation might be influenced by tyramine packaging into vesicles within glia.
Synaptic vesicles loaded with transmitters dock to the plasma membrane prior to
releasing their contents into the synapse102. This process is, in part, mediated by the
SNARE complex in both glia and neurons102,252,277. We therefore reasoned that the
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SNARE complex in glia might be required for normal alcohol sedation and that this
complex might function downstream of Tdc2. We used two expression strategies to test
these possibilities: constitutive expression in astrocytes via alrm-Gal4 and RU486induced expression in glia during adulthood via GliaGS. Additionally, we used tetanus
toxin, which cleaves synaptobrevin, to inhibit the SNARE complex and block synaptic
transmission278. Expression of tetanus toxin (UAS-TeTx) in astrocytes (Fig. 5.15A) and
adult glia (Fig. 5.15B) decreased ST50 values. Internal ethanol levels were not altered
by expressing UAS-TeTx in glia during adulthood (Fig. 5.6C), suggesting that the
SNARE complex in glia influences alcohol sedation through a pharmacodynamic
mechanism. However, ST50 was not altered when RNAi expression for individual
components of vesicular release machinery was induced in glia during adulthood (Table
5.4). While surprising, this may suggest that compensatory mechanisms occur in
response to the RNAi expression to keep vesicular exocytosis in glia occurring.
Nonetheless, the effect of expressing the tetanus toxin in astrocytes and in adult glia
was similar to that of knocking down Tdc2 (Figs. 5.1, 5.5), suggesting that the SNARE
complex might function in the same pathway as Tdc2. To formally address this
possibility, we assessed alcohol sedation in flies with Tdc2 over-expression and tetanus
toxin expression. Expression of tetanus toxin in astrocytes suppressed the lethality due
to Tdc2 over-expression and these flies had significantly decreased ST50s. Additionally,
the ST50 value of these flies was indistinguishable from flies that expressed tetanus
toxin alone in astrocytes (Fig. 5.15C). Similarly, RU486-induced over-expression of
Tdc2 in adult glia increased ST50s, expression of tetanus toxin decreased ST50s, and
flies with concomitant over-expression of Tdc2 and expression of tetanus toxin had
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decreased ST50s that were indistinguishable from that of flies expressing tetanus toxin
alone (Fig. 5.15D). Taken together, these data strongly support a role for the SNARE
complex regulating alcohol sedation by functioning within astrocytes and adult glia.
Additionally, these data argue that SNARE-dependent vesicle-mediated release is
functionally downstream of Tdc2 in glia within the context of alcohol sedation.
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Figure 5.12. VMAT expression in glia is required for normal alcohol sedation. (A,
B) ST50 values were reduced in flies with the pan-glial driver repo-Gal4 and a VMAT
RNAi transgene (blue bars: repo-Gal4/VMAT RNAi #1, panel A; repo-Gal4/VMAT RNAi
#2, panel B) compared to control flies with either repo-Gal4 alone (black bars: repoGal4/+) or the respective RNAi transgene alone (black bars: VMAT RNAi #1/+ and
VMAT RNAi #2/+) (Panel A: one-way ANOVA, p = 0.003; *Bonferroni’s multiple
comparison vs controls, p < 0.05; n = 8; Panel B: one-way ANOVA, p = 0.002;
*Bonferroni’s multiple comparison vs controls, p < 0.05; n = 8). (C, D) ST50 values were
decreased in flies expressing the astrocyte-specific driver alrm-Gal4 and a VMAT RNAi
transgene (blue bars: alrm-Gal4/VMAT RNAi #1, panel C; alrm-Gal4/VMAT RNAi #2,
panel D) compared to control flies containing either the astrocyte Gal4 driver (black
bars: arlm-Gal4) or the respective RNAi transgene (black bars: VMAT RNAi #1/+, panel
C; VMAT RNAi #2, panel D) alone (Panel C: one-way ANOVA, p < 0.001; *Bonferroni’s
multiple comparison vs controls, p < 0.05; n = 8; Panel D: one-way ANOVA, p = 0.0001;
*Bonferroni’s multiple comparison vs controls, p < 0.05; n = 8). (E, F) Compared to
vehicle, treatment with RU486 decreased ST50 values in flies with the GliaGS driver
and a VMAT RNAi transgene (GliaGS/VMAT RNAi #1, panel E; GliaGS/VMAT RNAi #2,
panel F), but not in control flies with either GliaGS or the respective RNAi transgene
alone (Panel E: two-way ANOVA; RU486, p = 0.04; genotype, p = 0.23; interaction, p =
0.003; *Bonferroni’s multiple comparisons between vehicle and RU486, p < 0.05; n = 8;
Panel F: two-way ANOVA; RU486, p = 0.051; genotype, p = 0.284; interaction, p =
0.018; *Bonferroni’s multiple comparisons between vehicle and RU486, p < 0.05; n = 8).
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Figure 5.13. VMAT RNAi knocks down VMAT expression. Whole mount brain
images immunolabeled for VMAT expression (anti-VMAT 1:2000, Alexa-647 1:1000). All
representative images, 10X. (A, B) VMAT expression in brains of flies with a VMAT
RNAi transgene alone. (C, D) VMAT expression in brains of flies with the pan-neuronal
driver elav-Gal4 and a VMAT RNAi. (E, F) Brains with both the elav-Gal4 and a VMAT
RNAi transgene had significantly lower pixel intensity compared to control brains of flies
with the VMAT RNAi transgene alone (Panel E: students t test, p = 0.0005, n = 5-6;
Panel F: students t test, p = 0.0448, n = 4).
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Figure 5.14. VMAT functions downstream of Tdc2. (A) ST50 values were decreased
in flies with the pan-glial driver repo-Gal4 and a VMAT RNAi transgene (blue bar: repoGal4/VMAT RNAi #1) and in flies with repo-Gal4, the VMAT RNAi and the UAS-Tdc2
transgenes (red bar: repo-Gal4/VMAT RNAi #1; UAS-Tdc2 #1) compared to control flies
(black bars). ST50 values were not different between flies with the repo-Gal4 and the
VMAT RNAi transgenes (blue bar: repo-Gal4/VMAT RNAi #1) and flies with the repoGal4, the VMAT RNAi and the UAS-Tdc2 transgenes (red bar: repo-Gal4/VMAT RNAi
#1; UAS-Tdc2 #1) (one-way ANOVA, p = 0.003; *Bonferroni’s multiple comparison vs
controls, p < 0.05; n = 8). Flies with both the pan-glial driver repo-Gal4 and the UASTdc2 transgene did not emerge as adults (no bar: repo-Gal4/UAS-Tdc2 #1). (B) ST50
values were decreased in flies with the astrocyte-specific driver alrm-Gal4 and the
VMAT RNAi transgene (blue bar: alrm-Gal4/VMAT RNAi #1) and in flies with alrm-Gal4,
the VMAT RNAi transgene and the UAS-Tdc2 transgene (red bar: alrm-Gal4/VMAT
RNAi #1; UAS-Tdc2 #1) compared to control flies (black bars). ST50 values were not
different between flies with the alrm-Gal4 and the VMAT RNAi transgenes (blue bar:
alrm-Gal4/VMAT RNAi #1) and flies with the alrm-Gal4, the VMAT RNAi and the UASTdc2 transgenes (red bar: alrm-Gal4/VMAT RNAi #1; UAS-Tdc2 #1) (one-way ANOVA,
p < 0.0001; *Bonferroni’s multiple comparison vs controls, p < 0.05; n = 8). Flies
expressing both alrm-Gal4 and UAS-Tdc2 transgenes did not emerge as adults (no bar:
alrm-Gal4/UAS-Tdc2 #1). (C) Compared to vehicle, treatment with RU486 increased
ST50 values in flies with the GliaGS driver and a UAS-Tdc2 transgene (GliaGS/UASTdc2 #1), decreased ST50 values in flies with the GliaGS driver and a VMAT RNAi
transgene (GliaGS/VMAT RNAi #1) and decreased ST50 values in flies with the GliaGS
driver, a VMAT RNAi transgene and a UAS-Tdc2 transgene (GliaGS/VMAT RNAi #1;
UAS-Tdc2 #1). Treatment with RU486 did not alter ST50 in control flies with GliaGS
alone (GliaGS/+) or both the VMAT RNAi and the UAS-Tdc2 transgenes (VMAT RNAi
#1; UAS-Tdc2 #1/+) compared to controls (two-way ANOVA; RU486, p = 0.543;
genotype, p = 0.006; interaction, p = 0.0007; *Bonferroni’s multiple comparisons
between vehicle and RU486, p < 0.05; n = 8).
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Table 5.3. Lethality associated with UAS-Tdc2 expression in glia

Progeny from the indicated crosses were counted and recorded as the “observed n”.
The “observed genotype percentage” was calculated by dividing the number of flies of
each genotype by the total number of flies from the indicated cross. The “expected n”
was used for the comparison between that group (observed) and the group indicated in
the “Group Compared to” column (expected). It was calculated by multiplying the total
number of progeny by the expected percentage of the genotype from the cross being
compared to. The chi-square statistic compared the “expected n” and the “observed n”
to determine if they were different. All chi-square values and their associated p-values
are reported (df = 3). Driving VMAT RNAi with repo-Gal4 (Group B) did not impact
lethality, whereas expression of Tdc2 (Group C) was 100% lethal. Expression of VMAT
RNAi significantly suppressed the lethality due to Tdc2 expression (Group D).
Expression of UAS-GFP did not suppress the lethality due to Tdc2 expression (Group
E)
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Figure 5.15. Expression of tetanus toxin in glia alters alcohol sedation and is
epistatic to of Tdc2. (A) ST50 values were decreased in flies expressing the astrocytespecific driver alrm-Gal4 and the UAS-TeTx transgene (blue bar: alrm-Gal4/UAS-TeTx)
compared to control flies containing either the astrocyte Gal4 driver (black bar: arlmGal4/+) or the UAS-TeTx transgene (black bar: UAS-TeTx/+) alone (one-way ANOVA, p
= 0.0004; *Bonferroni’s multiple comparison vs controls, p < 0.05; n = 15-16). (B)
Compared to vehicle, treatment with RU486 decreased ST50 values in flies with the
GliaGS driver and the UAS-TeTx transgene (GliaGS/UAS-TeTx), but not in control flies
with either GliaGS or the UAS-TeTx transgene alone (two-way ANOVA; RU486, p =
0.0002; genotype, p < 0.0001; interaction, p = 0.0009; *Bonferroni’s multiple
comparisons between vehicle and RU486, p < 0.05; n = 8) (C) ST50 values were
decreased in flies with the astrocyte-specific driver alrm-Gal4 and the UAS-TeTx
transgene (blue bar: alrm-Gal4/UAS-TeTx) and in flies with alrm-Gal4, the UAS-TeTx
transgene and the UAS-Tdc2 transgene (red bar: alrm-Gal4/UAS-TeTx; UAS-Tdc2 #1)
compared to control flies (black bars). ST50 values were not different between flies
containing the alrm-Gal4 and the UAS-TeTx transgenes (blue bar: alrm-Gal4/UASTeTx) and flies containing the alrm-Gal4, the UAS-TeTx and the UAS-Tdc2 transgenes
(red bar: alrm-Gal4/UAS-TeTx; UAS-Tdc2 #1) (one-way ANOVA, p < 0.0001;
*Bonferroni’s multiple comparison vs controls, p < 0.05; n = 8). Flies expressing both
alrm-Gal4 and UAS-Tdc2 transgenes did not emerge as adults (no bar: alrm-Gal4/UASTdc2 #1). (D) Compared to vehicle, treatment with RU486 increased ST50 values in
flies with the GliaGS driver and a UAS-Tdc2 transgene (GliaGS/UAS-Tdc2 #1),
decreased ST50 values in flies with the GliaGS driver and the UAS-TeTx transgene
(GliaGS/UAS-TeTx) and decreased ST50 values in flies with the GliaGS driver, the
UAS-TeTx transgene and a UAS-Tdc2 transgene (GliaGS/UAS-TeTx; UAS-Tdc2 #1).
Compared to vehicle, treatment with RU486 did not alter ST50 in control flies with
GliaGS alone (GliaGS/+) or both the UAS-TeTx and the UAS-Tdc2 transgenes (UASTeTx; UAS-Tdc2 #1/+) (two-way ANOVA; RU486, p = 0.036; genotype, p < 0.0001;
interaction, p < 0.0001; *Bonferroni’s multiple comparisons between vehicle and RU486,
p < 0.05; n = 6-8).
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Table 5.4. Expressing RNAi against individual components of the vesicular
release machinery in adult glia does not alter alcohol sedation
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Manipulations were made in all glia during adulthood using GliaGS. ST50 values for the
GliaGS/transgene either fed RU486 or vehicle are reported. @, #, $, %, &, ~, +, =
represent genotypes that where tested together, and therefore were statistically
compared in the two-way ANOVA. When appropriate, Bonferonni multiple comparision
adjusted p-values are reported
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B.5 THE TYRAMINE RECEPTOR IS IMPORTANT FOR ALCOHOL SEDATION
When tyramine is released from neurons, it binds to a tyramine receptor on a
post-synaptic membrane273. Three tyramine receptor subtypes exist in the fly: TyrR,
TyrRII and TAR1 (also known as Oct-TyrR)279. If tyramine production in glia mediates
alcohol sedation, we predicted that pharmacologically antagonizing the tyramine
receptors might have the same effect on alcohol sedation as Tdc2 knockdown. We
utilized the drug Yohimbine, which efficiently blocks all tyramine receptors 280. Flies fed
Yohimbine had a decreased ST50 compared to vehicle fed flies, suggesting that the
tyramine receptors are important for alcohol sedation (Fig 5.16). Thus knocking down
Tdc2 (Fig 5.1) and antagonizing tyramine receptors (Fig 5.16) have similar effects on
alcohol sedation.
Tyramine could, in principle, influence alcohol sedation through the collective
effect of binding to each tyramine receptor subtype or by a role in a binding to an
individual receptor subtype. Since the tyramine receptors are expressed on both
neurons and glia279, we consequently expressed RNAi against each tyramine receptor
individually in neurons and glia via elav- and repo-Gal4, respectively. Expression of
multiple RNAi against TyrR, TyrRll and TAR1 in neurons (via elav-Gal4) did not alter
alcohol sedation and expression of one RNAi (identifier 27670) against TyrRII
significantly increased ST50 compared to controls (Table 5.5). Given that Tdc2
knockdown in glia decreased ST50 (Fig 5.1), these data suggest that (i) the tyramine
receptors on neurons are not regulating alcohol sedation or (ii) TyrRII may be regulating
alcohol sedation independently of glial tyramine. Interestingly, expression of RNAi
against TAR1 (identifier v26876) in glia (via repo-Gal4) significantly decreased ST50
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compared to controls, while expression of a second RNAi (identifier 28332) did not alter
ST50 values (Table 5.6). Glial expression of RNAi against TyrR either significantly
decreased, significantly increased, or did not alter ST50 compared to control (Table
5.6). Expression of RNAi against TyrRII in glia did not alter ST50 compared to controls
(Table 5.6). Taken together, these data suggest that expression of TAR1 on glia may
regulate alcohol sedation, while the expression of TyrR and TyrRII on glia may not
mediate alcohol sedation. Since individual expression of RNAi against Tdc2 and TAR1
in glia (via repo-Gal4) lead to significant decreases in ST50, it is possible that glial
tyramine is binding to a glial TAR1 receptor to mediate alcohol sedation. Additional
studies are needed to formally assess this possibility.
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Figure 5.16. Antagonizing tyramine receptors with Yohimbine alters alcohol
sedation sensitivity. Our labs standard fly, w[A], was fed Yohimbine or vehicle (5%
sucrose). Flies fed Yohimbine (blue bar) had a significantly decreased ST50 compared
to vehicle control (black bar) (Students t test, p = 0.039, n = 8).

149

Table 5.5. Pan-neuronal expression of RNAi’s against each tyramine receptor
subtype

Expression of RNAi against TyrR, TyrRII and TAR1 in neurons (via elav-Gal4) did not
consistently alter alcohol sedation compared to both the Gal4 driver (Gal4/+) and RNAi
transgene (RNAi/+) controls. Only expression of the 27670 RNAi transgene against
TyrRII had a significantly increased ST50 compared to controls. Results from individual
one-way ANOVAs and (when appropriate) Bonferroni’s multiple comparisons are
reported. @, # and % represent common Gal4/+ controls.
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Table 5.6. Pan-glial expression of RNAi’s against each tyramine receptor subtype

Expression of RNAi against TyrR, TyrRII and TAR1 in glia (via repo-Gal4) did not
consistently alter alcohol sedation compared to both the Gal4 driver (Gal4/+) and RNAi
transgene (RNAi/+) controls. Expression of the TyrR RNAi 25857 significantly
decreased ST50 compared to controls, while expression of the TyrR RNAi 57496
significantly increased ST50 compared to controls. Expression of the TAR1 RNAi
v26876 significantly decreased ST50 compared to controls. Results from individual oneway ANOVAs and (when appropriate) Bonferroni’s multiple comparisons are reported.
@ and # represent common Gal4/+ controls.

151

C. DISCUSSION
A more detailed understanding of the genes and mechanisms that influence
behavioral responses to alcohol could ultimately facilitate the development of novel
diagnostic and treatment options for individuals that abuse the drug. Understandably,
much of the genetic analysis of alcohol behavior in model organisms (mainly mice, flies
and worms) has focused on genes that function in neurons, leaving mechanisms driven
by other cell types largely unexplored. Our studies on Tdc2, glia and fly alcohol sedation
help fill this gap. Here, we show that (i) knockdown and overexpression of Tdc2 in glia
makes flies sensitive and resistant, respectively, to alcohol sedation, (ii) feeding flies
tyramine can rescue the ethanol sedation sensitivity in Tdc2 knockdown flies, (iii) VMAT
and the SNARE complex influence alcohol sedation by functioning in glia, (iv) VMAT
and the SNARE complex impact alcohol sedation by functioning downstream of Tdc2 in
glia, and (v) these findings map to astrocytes and adulthood. Our data support a model
in which astrocytes, during adulthood, influence alcohol sedation by synthesizing and
releasing tyramine into the synapse through SNARE-dependent vesicular exocytosis.
Given that resistance to alcohol responses is linked to the propensity to abuse it 225, our
findings raise the possibility that astrocytes may be key contributors to AUD and
problematic alcohol consumption through their role in mediating alcohol sensitivity
through synthesis and release of transmitters.
Although synaptic vesicle exocytosis is a slower process in astrocytes than in
neurons, the SNARE complex is used by both cell types to release synaptic vesicle
contents101. Whether vesicular exocytosis is a physiologically relevant mechanism in
astrocytes, however, is somewhat controversial. Our studies on VMAT and the SNARE
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complex strongly suggest that synaptic vesicle loading and release within astrocytes are
required for normal alcohol sedation in flies, thereby supporting the hypothesis that
synaptic vesicle exocytosis in astrocytes could have important physiological roles.
Our data suggest that a small fraction of astrocytes expresses Tdc2 and
synthesize/release tyramine, potentially as a gliotransmitter. The presence of or level of
expression of Tdc2 could therefore represent astrocyte heterogeneity, which could be
relevant for normal behavioral responses to alcohol. Given that the fly brain contains
approximately 4,600 astrocytes total 125, it is intriguing to speculate how a minor fraction
of such a small number of cells could impact alcohol sedation in an organism whose
brain contains roughly 100,000 neurons 281. One possibility is that the astrocytes
engaged in tyramine synthesis are physically associated with numerous neurons
involved in regulating alcohol sedation, and the tyramine released from the astrocytes
binds to G protein-coupled tyramine receptors on neurons 279, thereby influencing the
response of those neurons to alcohol. Another possibility is that tyramine released from
a minor fraction of astrocytes permeates the brain as a whole, thereby influencing the
physiological properties of nearby, as well as distant, neurons. However, these
possibilities seem unlikely since expression of RNAi again the tyramine receptors in
neurons did not produce a consistent alcohol sedation response (Table 5.5).
Additionally, tyramine released from a minor fraction of astrocytes could function as an
autocrine/paracrine factor to alter calcium signaling within nearby astrocytes, influencing
their physiology, which can lead to altered responses of neurons to alcohol. This
possibility is supported by our findings, since expressing TAR1 RNAi in glia significantly
decreased ST50 (Table 5.6). Yet another possibility is that astrocytes contain direct
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pharmacological targets of alcohol, and the binding of ethanol to these targets alters the
release of tyramine which influences alcohol sedation. Although these models are
speculative (and not mutually exclusive), they emphasize the need for additional studies
to better understand the role of astrocytes in behavioral responses to ethanol.
Glia in flies and rodents, as well as in human alcoholic post-mortem tissue, are
molecularly and morphologically altered by the presence of alcohol

158,159,211,212,249,282.

In

flies, surface glia can regulate initial alcohol sedation and rapid tolerance development
211,212.

In rodents, blocking astrocyte hemichannels, increasing astrocyte intracellular

calcium, and increasing astrocyte cytokine release has been associated with changes in
alcohol related behaviors 183,194. This study, however, is the first to identify an astrocyte
molecular pathway that directly influences any alcohol-related behavior in any model
organism. While research has demonstrated that astrocytes respond to alcohol
administration and can influence behavioral responses after alcohol administration
182,183,190,194,

but none of these identify a molecular pathway responsible for the

changes. Given that astrocytes are major regulators of the synaptic environment, this
finding is not particularly surprising. However, since alcohol use disorder is a disease of
the central nervous system 5, our data stress the importance to consider both neurons
and glia when investigating the genetic and molecular contributions to alcohol-related
behaviors.
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CHAPTER 6: DISCUSSION

A. SUMMARY AND FUTURE DIRECTIONS
Studies in model organisms, such as the worm, fly and rodents, have led to the
discovery of many novel genes and pathways that regulate alcohol-related behaviors226.
A majority of this work has focused on neurons, leaving glial contributions to alcoholrelated behaviors overlooked. However, previous research using human alcohol postmortem tissue, as well as rodents and flies, has demonstrated that glial cells do respond
to alcohol administration and can influence alcohol related behaviors. For this reason,
we hypothesized that glia are important and direct regulators of alcohol related
behavior. Since flies and mammals have conserved behavioral responses to alcohol, as
well as conserved glial cell function, we used Drosophila melanogaster as a model to fill
this gap in the alcohol field13. Drosophila have an expansive toolkit to manipulate genes
in specific tissues and cell types, including all glia as well as each glial cell subtype
individually24,125. However, prior to this research, no pan-glial steroid-inducible
GeneSwitch transgenic fly had been characterized. By measuring B-galactosidase
activity, and using immunohistochemistry, we characterized a fly that induces robust
transgene expression in adult CNS glia, and termed it GliaGS (Chapter 3). Using these
glial gene manipulation methods, we conducted targeted screens to identify genes
whose expression in glia is important for the alcohol-related behavior, sedation. From
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these screens, we investigated the genes Cysteine proteinase 1 (Chapter 4) and
Tyramine decarboxylase 2 (Chapter 5) further.
Our data suggests that expression of Cp1 in cortex glia during adulthood
regulates alcohol sedation sensitivity and possibly rapid tolerance development to
alcohol. This was the first research to associate Cp1, as well as cortex glia, with an
alcohol-related behavior. Although the role of Cp1 in glia had not been studied
previously, Cp1 function in neurons had. We used this data to try to identify pathways
Cp1 was functioning within to mediate alcohol sedation, and specifically screened the
transcription factor cut, the Cp1 inhibitor crammer, and the synaptic vesicle marker
neuronal-synaptobrevin233,239,252. Unfortunately, manipulating these genes in glia did not
alter alcohol sedation, suggesting that they were not functioning in the same pathway as
Cp1 to mediate this response. Given that Cp1 is involved in protein degradation 241, it is
possible that Cp1 is interacting with different proteins in cortex glia to regulate alcohol
sedation. To identify these proteins, future studies should utilize mass spectrometry.
Additionally, our data suggests that Tdc2 is synthesizing tyramine in astrocytes
during adulthood, and that tyramine is being release through vesicular exocytosis to
regulate alcohol sedation. This was the first research to identify a molecular pathway
within astrocytes that directly influences an alcohol related behavior. Additionally, these
data suggest that astrocyte vesicular exocytosis is physiologically relevant, and that
astrocyte heterogeneity may exist within the fly. Interestingly, our preliminary data
suggests that a tyramine receptor on astrocytes (TAR1, also referred to the Oct-TyrR)
may be involved in this pathway. While additional studies are necessary, this result
invites the speculation that astrocytic tyramine may be functioning in an
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autocrine/paracrine loop to regulate alcohol sedation, since it is known that astrocytes
can communicate with each other through GTs32. Future studies should investigate this,
as well as determine how glial TAR1 is regulating alcohol sedation. Previous literature
has demonstrated that activating TAR1 on astrocytes leads to an increase in
intracellular calcium and adenosine release, which inhibits nearby dopaminergic
neurons27. Since dopamine is heavily involved in addiction, and has been previously
implicated in fly alcohol-related behaviors5,6, this may be an interesting pathway to
pursue.

B. TRANSLATABILITY TO MAMMALS
Cp1 is orthologous to mammalian Cathepsin L, which has been previous implicated
in alcohol-induced tissue damage and is known to be expressed in astrocytes and
microglia283,284. Our data suggest that glial Cathepsin L may have a role in mediating the
behavior response to an acute dose of alcohol. Interestingly, chronic alcohol
administration leads to neurodegeneration191, and Cathepsin L is involved in alcoholinduced cell damage outside the CNS253. Given that glial cell damage or death can lead
to neurodegeneration32, future studies in mammals should investigate whether glial
Cathepsin L contributes to alcohol-induced neurodegeneration, which is a hallmark
feature in severe alcoholic brains163. If true, then glial Cathepsin L may mediate both
acute behavioral responses to alcohol, as well as CNS changes due to chronic alcohol
administration.
Invertebrate tyramine is functionally homologous to mammalian norepinephrine, and
the tyramine receptors are closely related to the vertebrate adrenergic receptors279.
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Both molecules have been associated with the “fight or flight” or arousal response,
which can be measured as aggression and courtship in flies285. To date, norepinephrine
has not been identified as a GT, but it has been implicated in alcohol dependence.
Specifically, norepinephrine is elevated during alcohol withdrawal in mice and
humans286, and blocking norepinephrine neurotransmission also blunts alcohol
withdrawal symptoms in mice. This result suggests that norepinephrine may regulate
the negative emotional state associated with alcohol dependence, which is a criteria for
AUD diagnosis in humans287. In our research, overexpressing Tdc2, and presumably
overexpressing tyramine, leads to alcohol sedation resistance. Given that there is an
inverse correlation between initial sensitivity and risk of alcohol dependence in
humans225, our data suggests that increases in tyramine, and therefore norepinephrine,
may correlate with alcohol dependence development. Taken together, this suggests that
increased norepinephrine levels are associated with alcohol dependence risk and
progression.
Interestingly, tyramine is a trace amine in mammals. Trace amines are
endogenously found monoamines in mammals, and are approximately 100-fold less
abundant than catecholamines288. Trace amines have been implicated in many
disorders, such as schizophrenia, bipolar disorder, depression, addiction and
narcolepsy289. However, the invertebrate and mammalian receptors for tyramine are
evolutionarily distinct, suggesting that tyramine in invertebrates and mammals is also
functionally distinct289. For this reason, tyramine research in invertebrates is not
translatable to tyramine function in mammals.
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The principle cell types implicated in this research are Drosophila cortex glia and
astrocytes. As described earlier, these cell types are morphologically and functionally
similar to mammalian astrocytes (Chapter 1C). While previous literature has
demonstrated that the mammalian orthologue of Cp1 functions in astrocytes 283, it is
unknown whether the enzyme responsible for norepinephrine synthesis does. However,
utilizing human RNA-sequencing data, this enzyme, Dopamine β-hydroxylase (DBH), is
expressed in mature astrocytes290. Taken together, this suggests that our results
studying Cp1 and Tdc2 in fly cortex glia and astrocytes may be translatable to
mammalian astrocytes.
Based on the assumption that our studies in the fly are wholly translatable to
mammals, it is possible that DBH and Cathepsin L may be functioning together in
mammalian astrocytes to regulate alcohol-related behaviors. Our studies suggest that
astrocytes contain synaptic vesicles that release norepinephrine, and that the release of
these vesicles is important for alcohol sedation. Previous literature has demonstrated
that Cp1 is required for synaptic vesicle degradation252. Therefore, it is possible that the
synthesis and release of norepinephrine via DBH and the degradation of the vesicles
that contain norepinephrine via Cathepsin L are functioning together in astrocytes to
influence alcohol sedation. Degraded synaptic vesicles can be processed into new
synaptic vesicles252, therefore allowing norepinephrine to be released from the astrocyte
though vesicular exocytosis. In flies, knocking down Cp1 (i.e. blocking synaptic vesicle
degradation) and knocking down Tdc2 (i.e. blocking tyramine synthesis) produced the
same behavioral effect: decreased ST50, or increased alcohol sedation sensitivity. It is
possible that the studies looking at a relationship between Cp1 and neuronal-
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synaptobrevin in cortex glia did not work because fly cortex glia do not have synaptic
vesicles. However, in mammals, Cp1 (i.e. Cathepsin L) would be expressed in a cell
type where this interaction could occur. Future studies in mammals would be needed to
test this possibility.
Our data suggests that glia are important regulators of alcohol sedation in
Drosophila melanogaster. Given that alcohol use, abuse and dependence effects the
central nervous system, future research within the field should consider both neuronal
and glial contributions. Since glia and neuron function is reliant on the other, it seems
likely that differences in behavioral responses to alcohol may, in part, be due to
impairments in the synchrony of glia and neurons. This impairment can lead to overall
CNS dysfunction, which over time may contribute to alcohol dependence development.
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APPENDIX

Basic Fly Handling and Husbandry
A. Standard Fly Lab Lingo:
1. Stock or strain: a culture of flies with a particular genotype. Balanced stocks have a
special chromosome called a balancer that is marked with a dominant phenotype and
suppresses recombination on the corresponding sister chromosome. Balanced stocks
are often weak (i.e. grow poorly).
2. Seeding: putting adult flies into a new bottle or vial. Also called ‘setting-up’.
3. Transfer: moving flies without anesthesia from one vial or bottle to another. One-toone transfer means moving flies from one bottle/vial to one new bottle/vial. Two-to-one
transfer means moving flies from 2 vials/bottles to 1 new vial/bottle. Also called ‘flipping’.
4. Clearing: removing all of the adults from a bottle or vial. Can be done with or without
anesthesia.
5. Anesthesia: CO2 used to temporarily immobilize flies.
6. Brood: refers to the number of times a set of adults has been used to seed bottles.
Using flies for 2 broods is common, with 3 broods being possible in some cases.
7. white plus (w+): indicates eye color. white minus (w-) flies have white eyes. w+ flies
have eyes that can vary from light peach to deep red.
8. Food: All of our fly food currently has antibiotics on it (ampicillin, tetracycline and
chloramphenicol, ATC). Yeasted (Y) food vials and bottles have live yeast on added.
Yeasted food should be used for seeding new vials and bottles for growing flies.
Nonyeasted (NY) food has no yeast on it and should be used to house flies prior to
behavioral studies and for storing virgin females and males prior to setting-up crosses.
B. Standard Fly Husbandry
1. Remove necessary number of yeasted bottles or vials from the cold room. Use
bottles to grow lots of flies for behavioral, stress or other large experiments. Use vials
for smaller numbers of flies in limited scale crosses or other small scale experiments.
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2. Before putting in new flies, bottles and vials must be dried 2 hours to overnight in the
environmental chamber so that all condensation on the walls evaporates. The food will
pull away from the wall of the bottle or vial if they are over-dried. It is poor practice to
use over-dried food.
3. Turn on the CO2. Clean microscope, CO2 pad and counter with ethanol. Clean before
starting, between each genotype and after you are finished. Be sure the CO 2 is on
before putting ethanol on the pad.
4. Open CO2 to pipette, invert bottle or vial, insert pipette along cotton plug and tap
bottle/vial gently. Flies will become anesthetized quickly and should fall onto the plug
and/or the neck of the bottle/vial.
5. Clic off CO2 to pipette, remove CO2 pipette from vial/bottle. Hold inverted bottle/vial
over CO2 pad. Remove plug and gently shake/tap flies onto pad into a pile. Return plug
to bottle/vial and set aside.
6. Place anesthetized flies in a row and sort flies according to needs. Short CO2 times
are important. For collecting flies that will be used in behavioral studies, goals are (1) all
genotypes experience the same CO2 exposure and (2) all flies are anesthetized for less
than 5 minutes.
7. Set-up new bottles/vials by putting sorted flies from step 6 into dried bottles/vials.
Anesthetized flies should be kept on the wall of the bottle/vial. If they fall into the food,
many of them will stick there and die. Robust strains such as w[A], CS, etc. will do well
with 10 females (♀, see below) per bottle or 3 females per vial. It is good practice to
include a comparable number of males (♂, see below). Weaker stocks will need more
females, up to as many as 50 per bottle and 15 per vial. When working with a stock that
is new to you it is good practice to seed bottles or vials with a range of females (1025/bottle for example) and then use an optimum number thereafter based on how the
various bottles/vials grow.
8. Insert cotton plug, invert new bottle/vial and tap anesthetized flies onto the plug. Lay
the bottle/vial on its side, label with genotype and date. First broods (i.e. bottles or vials
in which the flies are new parents) are marked with a single slash.
9. Wait for flies to regain locomotor activity. Turn bottles/vials upright and place in
environmental chamber to grow.
10. Beginning at around 4 days after seeding, check bottles/vials daily for larval activity.
When larval activity is obvious, transfer adults to new bottles/vials (dried appropriately).
Label second brood with genotype, date and two slashes.
11. Beginning at around 4 days after seeding the second brood, check bottles/vials daily
for larval activity. Discard adults when larval activity is obvious. If necessary, a third
brood is possible in some cases.
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12. You should expect to see obvious larval activity 4 to 7 days after seeding and
obvious pupae 5-10 days after seeding. New adults should begin emerging ~10 days
after seeding. Some strains, especially balanced strains, can take up to 4 additional
days to emerge. Perfectly seeded bottle/vials will have robust larval activity followed by
large numbers of pupae that populate the bottom three-fourths of the wall. Pupae will
not typically be in the food or on the plug in these bottles. Large numbers of healthy
adults suitable for experiments will emerge from perfectly seeded bottles/vials.
13. Common Problems: If your bottles/vials are too dry or wet (as described below), the
resulting adults should not be used for behavioral, stress or gene expression studies.
The resulting adults are fine genotype-wise and reproduction-wise, though, and can be
used to set-up new bottles/vials as necessary.
a. Food too dry after 4-7 days of new adults in bottle/vial: The food should not be
so dry that it detaches from the wall of the bottle of vial and the pupae are in the food. In
cases like this, the food was either over-dried, there were not enough females placed in
the bottle/vial, or possibly both. If this occurs across several strains that have grown well
in the past, it is likely due to over-drying. If it occurs with a subset of strains, it is more
likely due to insufficient numbers of females being used for those specific strains. The
appropriate fixes are to decrease drying time, add more females, or both.
When you transfer flies from the first to second brood or when clearing the second
brood, note the quality of the culture and food. If the food in some bottle/vials is
detached from the wall after 7 days, go ahead and transfer/clear the adults and then
add ddH2O (NOT ETHANOL!) to the bottle/vial until the gap between the food and the
wall is filled. In many cases this will help the larvae quite a lot and you still might get a
decent yield of adults, although they might be delayed a few days due to lack of water.
b. Food too wet after 4-7 days of new adults in bottle/vial: The food should not be
so wet that it runs down the wall of the bottle/vial when it is inverted and the pupae are
on the plug. If this happens, the food was not dried sufficiently before adults were
added, too many adults were added, or possibly both. If this occurs across several
strains that have not had this problem in the past, it is likely due to under-drying the
food. If it occurs with only a subset of strains, it is more likely due to too many females
being added in those specific strains. The fixes are to increase the drying time for
bottles/vials, decrease the number of females used, or both.
If you notice that your bottles are too wet when transferring from the first to
second brood or when clearing the second brood, you can put a folded Kim wipe in the
bottle/vial so that it touches both the food and the plug. This will not result in a
miraculous drying of the bottle/vial, but it can convert a bottle/vial that is far too wet into
one that can be managed with some care.
C. The Basics of Setting-Up Crosses
1. You will need males (♂, mated or unmated) and females (♀ with a ‘v’ on top,
unmated or virgin) for your crosses. Grow bottles or vials as above for strains required
to generate males and virgin females. For planning purposes, you can comfortably
collect 100 males and/or 50 virgin females from a robust bottle. Likewise, you can
probably count on collecting 20 males and 10 virgin females from each well-seeded vial.
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2. Around day 10 after seeding, begin to collect virgin females, identified by their light
body pigmentation and female genitalia (see below). Typically, one would collect virgin
females first thing in the morning, again around noon, and again last thing before
leaving for the day.
3. Keep virgin females in nonyeasted vials with no more than 25 females/vial. Label
each vial with genotype, date and number collected. Keep collected females in
environmental chamber until ready to use. One will often collect virgin females over
several days or until a sufficient number of virgin females has been collected. Also, it is
convenient to store virgin females in upside-down vials.
4. When sufficient numbers of virgin females have been collected (~10% more than you
plan to use) or when it is obvious that you will be able to collect all the virgin females
you will need, collect all males into nonyeasted vials needed for your crosses. Males are
identified by their male genitalia (see below).
5. Set-out yeasted bottles or vials to warm and dry as described above. On the day of
the cross, check all virgin female vials for larvae using the microscope. Any vials with
larvae MUST be discarded because at least one of the females has mated. Use only
virgin females from vials with no larvae.
6. To set-up a cross, anesthetize the males and check them, anesthetize the virgin
females on the same plate and check them, and put appropriate numbers of males and
females into yeasted bottles/vials as described in steps B7-B9 above. Handle them
thereafter as described in B10-B12 above.
7. Make sure that you know what progeny to expect from your crosses before you set
them up.
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Simple Ethanol Sedation Assay
A. Day before assay
1. Collect flies (reared for behavioral assays) in groups of 11 (single sex) under brief
CO2 following standard procedures for behavioral assays.
2. Allow flies to recover overnight in non-yeasted food vials in the environmental
chamber. It is possible to test a maximum of 24 vials of flies in a single experiment.
3. Dilute ethanol solution as necessary (85% is our standard concentration). ~250 ml of
ethanol solution can be stored in a sealed 500ml bottle or other sealed container for a
week without a problem. Make ethanol fresh weekly. Diluted ethanol is exothermic and
should be stored overnight at room temperature before use.
B. Day of assay
1. For each vial of flies to be tested, you will need (a) a clean, empty food vial; i.e.
testing vial, (b) a new Flug, (c) a silicone #4 stopper and (d) 0.9 ml of ethanol solution
(85% ethanol is our standard concentration).
2. Turn on humidifier and allow relative humidity in testing room to rise to 55-65%.
3. Have someone else in the lab assign a unique code to each group of vials for each
genotype and—IMPORTANTLY—record the code for later. Place coded vials with flies
in testing room to acclimate.
3. Label empty testing vials with tape to match codes on fly vials from B.3.
4. Construct a testing log by entering the code for each vial into the Test Log E sheet
within the Excel Sedation file SA E EE 6 min SIGMOIDAL 2015.03.02. Use a random or
cycling order. Add other pertinent information (% ethanol, sex, etc.) to the Test Log
worksheet and print for use during testing.
5. Using the Test Log as a guide, arrange coded food vials with flies and empty testing
vials into matching arrays in the testing room. I have found that it is possible to test 6
sets of 4 vials simultaneously, so arrange 24 vials (maximum) in 6 sets or rows
containing 4 vials each.
6. Transfer all flies from all food vials into matched/labeled testing vials one at a time
and immediately insert Flugs into testing vials until Flugs are a uniform distance below
the vial tops. Use the Fluginator to push Flugs down into vials.
7. Time 0 assessment: For each vial individually, grasp with thumb and forefinger, tap
gently on the table three times to knock flies to the bottom of the vial, wait 30 seconds
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and then count the number of flies that are immobile. Typically, this is 0 or 1 at time 0.
Record the number of immobile flies for each vial at time 0 in the printed Testing Log.
8. Hereafter, each row of four vials will be handled as a set at staggered one-minute
intervals.
Start timer counting up at time 0 and immediately begin adding 1 ml of ethanol to the
Flug in the vials for the first row/set of 4 vials. Add ethanol to the vials at 5 second
intervals in the order they will be tested. Add ethanol to the Flugs in a circular motion so
that all ethanol is absorbed. When ethanol has been added to all four testing vials in the
set, insert a silicone #4 plug in each vial to seal it.
At times 1, 2, 3, 4 and 5 minutes, add 1 ml of ethanol to the second, third, fourth and
fifth sets of 4 vials, respectively. Continue inserting #4 stoppers after adding ethanol to
each set of 4 vials.
9. At time 6 minutes, test the first set of 4 vials by grasping each vial with thumb and
forefinger, tapping gently on the table three times to knock flies to the bottom of the vial,
waiting 30 seconds and then counting and recording the total number of flies that are
sedated. Flies are scored as sedated if they do not appear to have productive
locomotion.
Handle each vial within the set at 5 second intervals. The specific schedule is:
Vial
Tap
Assess
1
6 min 0 s
6 min 30 s
2
6 min 5 s
6 min 35 s
3
6 min 10 s
6 min 40 s
4
6 min 15 s
6 min 45 s
At times 7, 8, 9, 10 and 11 minutes, test the second, third, fourth, fifth and sixth sets of
vials, respectively, as done for the first set.
10. At time 12 minutes, test the first set of 4 vials again as described in B9 and continue
testing the second, third, fourth, fifth and sixth sets of vials at 13, 14, 15, 16 and 17
minutes, respectively.
Continue testing flies as described in B9 and B10 for 60 minutes (single ethanol
exposure) or 90 min (2 ethanol exposures, rapid tolerance).
Clean-up is (a) turn off humidifier, (b) remove #4 plugs for washing and reuse, (c)
discard Flugs containing ethanol, (d) dispose of flies in morgue, (e) place testing vials
on sink to be washed, (f) remove any trash from and straighten up testing room and (g)
turn off light in testing room.
11. Enter the total number of flies in each vial in the Test Log within the Excel
worksheet. Percent Active flies will be automatically calculated and graphed below the
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Test Log. Press ‘Ctrl + s’ to calculate ST50s for each vial and sort the data by group in
the Sorted Data worksheet.
12. Note any flagged data in Sorted Data worksheet. Consider excluding data that looks
qualitatively poor.
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Internal Ethanol Content
**Use pre-chilled solutions throughout assay for consistency**
1. Grow/collect flies and prepare Flugged vials as you normally would for eRING
assays. Use 11 flies/vial and typically 1 vial/genotype with 3-5 vials total per test.
Expose one group to ddH2O (0 minutes) and other groups to ethanol during SSAs for
15-45 minutes or other times as appropriate.
2. After each water or ethanol exposure, transfer flies to labeled 1.5 ml snap-cap tubes
and store at -70C. Continue water and ethanol exposures until you have a complete
set of frozen flies from each genotype at each time-point.
3. Homogenize frozen flies with drill/pestle in 200 μl ice-cold ddH2O for 30 seconds.
Keep flies on ice before and after homogenization.
4. Centrifuge homogenized flies at maximum speed at 4C for 20 minutes. Prepare 25
mM standard by adding 4.37 μl of 100% ethanol (17.16 M) to 2996 μl ice-cold ddH2O.
Prepare remaining standards using the table below. Store standards on ice.
5. Transfer 100 μl of clear supernatant to new labeled 1.5 ml snap-cap tube. Lipid or
other crud will stick to the outside of the pipette tip. DO NOT TOUCH PIPPETTE TIP
TO NEW TUBE! Store 100 μl supernatants on ice.
6. Add 300 μl of cold ethanol reagent to 1.5 ml snap-cap tubes for each sample (in
triplicate, 3 tubes/sample) and standard (in duplicate, 2 tubes/standard).
7. Add 10 μl of each sample supernatant and standard to the corresponding tube from
step 6. Mix by single pulse vortexing.
8. Incubate at 30C in heat block for 5 minutes.
9. Read absorbance of 100 μl of each reaction at 340 nm and print out results.
10. Final ethanol concentration in samples determined in Internal Ethanol BLANK Excel
sheet as:
mM interpolation x (200 µl + [# flies x µl/fly])/(# flies x μl/fly)
Fly water volume in µl is determined as indicated on next page. Each vial of flies is an
N of one.
Notes:
1. Standards
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Standard
0 mM
2 mM
4 mM
6 mM
8 mM
10 mM

Volume of ddH2O
1000 μl
920 μl
840 µl
760 μl
680 µl
600 μl

Volume of 25 mM
0
80 μl
160 µl
240 μl
320 µl
400 µl

2. Alcohol Reagent: Dilute per manufacturer’s instructions. Good for at least 2 weeks
at 4C.
3. Reaction is maximal at ~2 minutes and has a stable product (i.e. A340) out to at
least 12 minutes.
4. Use all cold reagents for consistency.
5. A 30 minute exposure to vapor from 2 mL of 50% ethanol in a SSA should lead to a
final internal ethanol concentration of 100-150 mM in control flies.
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Fixation Protocol for whole adult Drosophila brains
Dissection:
1. Anesthetize flies and place adults of the appropriate age, genotype and gender into a three
well dish on ice
2. Fill another three well dish with PBT and place it under the dissecting microscope
3. Place a 0.5mL snap cap tube containing 500µL of freshly prepared 4% paraformaldehyde
on ice
4. With gentle, SHARP forceps, remove the brain from the head cuticle in the PBT solution.
Place it into the 4% paraformaldehyde on ice
5. Repeat for the remaining flies
Staining: 1-20 tubes at a time
Day 1 (~3 hours)
1. Place the 0.5mL tube containing brains in 4% paraformaldehyde onto a nutator. Allow the
brains to fix for 20 min at room temperature
2. Remove the tube from the nutator and place it into a tube rack at room temperature. Allow
the brains to settle to the bottom of the tube. Use a P-200 pipet to remove the
paraformaldehyde. Dispose appropriately.
3. Add 0.5mL PBT to the tube. Close and invert the tube. Allow the brains to settle to the
bottom. Remove the PBT. Repeat once more (=2 quick washes at room temp)
4. Add 0.5mL PBT to the tube. Place on nutator to wash for 20 min. Repeat twice (=3 20min
washes at room temp)
5. Remove the PBT from the brains and add 0.5mL block solution (5% NGS). Place brains on
nutator to block for atleast 30 min at room temp
6. Remove block solution from the brains. Add the primary antibody solution. Place on nutator
at 4°C for 2 nights.
** can be increased to 1 week
Day 3 (~1.5 hours)
7. Remove primary antibody and store it at 4°C. The antibody can be reused roughly three
more times
8. Add 0.5mL PBT to the tube. Close and invert the tube. Allow the brains to settle to the
bottom. Remove the PBT. Repeat once more (=2 quick washes at room temp)
9. Add 0.5mL PBT to the tube. Place on nutator to wash for 20 min. Repeat twice (=3 20min
washes at room temp)
10. Remove PBT. Add secondary antibody. Place on nutator at 4°C for 2 nights.
** can be increased to 1 week
Day 5 (~1.5 hours)
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11. Remove the secondary antibody and discard
12. Add 0.5mL PBT to the tube. Close and invert the tube. Allow the brains to settle to the
bottom. Remove the PBT. Repeat once more (=2 quick washes at room temp)
13. Add 0.5mL PBT to the tube. Place on nutator to wash for 20 min. Repeat twice (=3 20min
washes at room temp)
** DAPI can be added to one of the 20 min washes to stain nuclei for analyses such as counting
cell numbers
14. Remove PBT and add 200µL SlowFade. Allow brains to settle in SlowFade at 4°C
** brains can be left at this stage for up to 1 week at 4°C
Mount brains:
1. Use a P-200 pipet tip to transfer the brains from the tube and transfer them onto a mounting
slide. Avoid adding excess SlowFade. Excess SlowFade can be removed with a P-200 pipet
or kimwipe.
2. Using forceps, carefully align the brains for ease of imaging.
3. Arrange two broken coverslips on the microscope slide to form a bridge around the brains.
This prevents the brains from becoming too compressed under the top coverslip. For adult
brains, use broken no. 2 coverslips
4. Gently place a no. 1 coverslip on top of the bridge to cover the brains
5. Slowly pipet SlowFade, starting from one side of the coverslip, until the sample is covered.
6. Seal the edges of the coverslip with nail polish. Store at 4°C in a dark slide holder
** mounted slides are good for several months at 4°C and several years (3+) at -20 or -80°C
7. Image using multi-photon confocal microscope
Notes:
0.3% (vol/vol) PBT solution:
Add 1.5 Triton-X 100 to 498.5mL 1 X PB. Store at room temperature
4% (vol/vol) paraformaldehyde:
In a 0.5mL snap cap tube, add 100µL 20% w/v paraformaldehyde to 400µL PBT. Prepare fresh
and place on ice.
5% (vol/vol) normal goat serum (NGS): Add 50µL normal goat serum to 950µL PBT. Store this
block solution for short periods at 4°C (24 hour max)
Primary antibody: Dilute the primary antibody in freshly prepared 5% NGS. A 0.5mL tube
requires 400µL of diluted antibody. Diluted primary antibodies can be reused up to 3 times.
Store in 4°C for up to 1 month

Secondary antibody: Dilute the secondary antibody in freshly prepared 5% NGS. A
0.5mL tube required 400µL of diluted antibody. Prepare fresh and discard after use
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Primary Antibody Information


Stored in -80°C

Primary Antibody
Mouse Anti-Repo
Mouse Anti-GFP
Rat Anti-axotactin
Guinea pig Anti-Cp1
Rabbit Anti-Cp1
Mouse anti-lacZ
Rabbit anti-lacZ
Rabbit anti-Tdc2
rabbit anti-VMAT
rabbit anti-Tbh
mouse anti-Th
rabbit anti-Mef2

Mono/Poly?
Monoclonial
Monoclonial
Monoclonial
Polyclonal
Polyclonal
Monoclonial
Polyclonal
Polyclonal
??
??
Monoclonial
polyclonal

mouse anti-elav

Monoclonial

Source
Developmental Studies Hybridoma Bank
Fischer
Barry Ganetzky (1999)
Dolph
Kuo
Developmental Studies Hybridoma Bank
Fischer
Covalab (Pech,2013)
Krantz (Romero-Calderon, 2008)
Budnik (Koon, 2011)
Developmental Studies Hybridoma Bank
Bruce Paterson
Developmental Studies Hybridoma Bank
(supernant)

Secondary Antibody Information


Stored in 4°C

Secondary Antibody
Rabbit Anti-Mouse
Goat Anti-Guinea Pig
Chicken Anti-Rabbit
Goat anti-mouse

Fluorophore
Alexa 488 (Green)
Alexa 568 (red)
Alexa 647 (red)
Alexa 647 (red)

Source
ThermoFisher
ThermoFisher
ThermoFisher
ThermoFisher
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Cat. Number
A-11059
A-21450
A-21235

Dilution whole brain
1:100
1:100
??
1:250
1:20
1:20
1:25
1:200
1:2000
1:500
??
1:10,000
1:500

Quantitative measurement of β-gal activity in flies

1) Homogenize (with drill/pestle in 1.5 ml snap-cap tubes) 10 lacZ-expressing flies of
desired age and gender in 250 µl of extraction buffer (1X PBS with 1X protease
inhibitor cocktail) for 25 seconds.


if using rotating spec, can only test 6 samples at a time
(1 every 10 seconds for a minute)

2) Add 500 µl extraction buffer to each tube from step 1, mix by vortexing for 30 sec
3) Centrifuge extracts for 5 min at 14,000 rpm at room temperature
4) Transfer supernatants from step 3 into new labeled 1.5 ml snap-cap tubes
5) Set spectrophotometer at 562 nm.
6) Add 900 µL of 1 mM CPRG to 100 µl of water to a plastic cuvette for the blank. Set
spec reference with the blank (water sample + CPRG).
7) Transfer 100 µl of each fly extract to an individual plastic cuvette. Add 900 µL of 1
mM CPRG to each of the fly extracts. Stagger the addition of CPRG to coincide with
the order and timing of absorbance measurements.
8) Record absorbance of each cuvette every minute for 6 mins

CPRG
*CPRG is more sensitive than X-GAL and product measurement at 562 not interfered
with by fly pigment
*CPRG solution is only good for 24 hours
Final volume
of 1mM
CPRG (mL)
10
15
35

CPRG
added
(g)
0.005
0.008
0.0205

Protease inhibitor cocktail
Stored in the -20
Sigma (P8340)
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Simple Locomotor Assay
A. Day before assay
1. Collect experimental flies (reared for behavioral assays) in groups of 11 (single sex)
under brief CO2 following standard procedures for behavioral assays. A maximum of 24
vials, 6 groups of 4, can be tested during the assay. You will need to collect 4 additional
vials of controls flies to be the vortexed group.
2. Allow flies to recover overnight in non-yeasted food vials in the environmental
chamber.
B. Day of assay – Flugged Vial Experiment
1. Turn on humidifier(s) and allow relative humidity in testing room to become/remain
between 55-65%.
2. Prior to the experiment, print the locomotor test log sheet. For each vial of flies to be
tested, you will need: a clean, empty testing vial and a new Flug
3. Transfer flies from all food vials into matched testing vials one at a time and
immediately insert Flugs into testing vials until the bottom of the Flugs are just below the
vial tops. For vials used for vortexing, use “The Fluginator” to force Flugs further down
into vials until the tape is in contact with the vial.
4. Vortex the control vials for 4 minutes. Up to four vials will be vortexed at once. In
order to prevent vial destruction during the vortex, use a couple of rubber bands on
each vial and a few rubber bands to hold all four vials together. (See Below)
5. Have someone else in the lab assign a unique code to each vial for each genotype
and—IMPORTANTLY—record the code for later*. Place coded vials with flies in testing
room to acclimate.
6. Label empty testing vials to match codes on fly vials from B5
7. Using the Test Log as a guide, arrange coded food vials with flies and empty testing
vials into matching arrays in the testing room. It is possible to test 6 sets of 4 vials
simultaneously, so arrange 24 vials (maximum) in 6 sets or rows containing 4 vials
each. Then transfer flies from food vials to the matching testing vials.
8. Time 0 assessment (# dead): For each vial individually: grasp with thumb and
forefinger, tap the vial on the table three times to knock flies to the bottom of the vial,
wait 30 seconds and then count the number of flies that are dead (no movement
whatsoever). Record this number of flies for each vial at time 0 in the printed Testing
Log.
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9. Hereafter, each row of four vials will be handled as a set at staggered one-minute
intervals.
Start timer counting up at time 0 upon completion of recording the number of dead flies.
10. At time 6 minutes, test the first set of 4 vials by grasping each vial individually with
thumb and forefinger, tapping on the table three times to knock flies to the bottom of the
vial. Then wait 30 seconds to count and record the total number of flies that are on the
bottom.
The specific schedule is:
Vial
1
2
3
4

Tap
6 min 0 s
6 min 5 s
6 min 10 s
6 min 15 s

Assess
6 min 35 s
6 min 40 s
6 min 45 s
6 min 50 s

At times 7, 8, 9, 10 and 11 minutes, test the second, third, fourth, fifth and sixth sets of
vials, respectively, as done for the first set.
11. At time 12 minutes, test the first set of 4 vials again as described in B10 and
continue testing the second, third, fourth, fifth and sixth sets of vials at 13, 14, 15, 16
and 17 minutes, respectively.
Continue testing flies as described in B10 and B11 for 60 minutes.
12. Record the total number of flies in each vial on the locomotor assay sheet.
13. Fill out the locomotor assay file. Percent Active flies will be automatically calculated.
Compile the data as directed on the sheet to calculate aggregate percent active and
fraction alive for each vial and sort the data by group in the Sorted Data worksheet.
Clean-up is (a) turn off humidifier, (b) discard vials containing flies, (c) remove any trash
from and straighten up testing room, and (d) turn off light in testing room.
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Tyramine feeding assay
1. Make tyramine vials. Pipet 100mL of 100 mg/mL of tyramine onto vials. Tyramine
will readily dissolve in diH20. Control vials only contain 100 mL of diH20
2. Let vials dry in environmental chamber overnight

3. Sedation, sort and place 11 female flies in each tyramine or vehicle treated vial (as
you would for a sedation assay). Store vials food-side down in environmental
chamber for two nights
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Yohimbine administration protocol
Day before experiment:
1. Collect flies (10-20) and place in food vials in the environment chamber
Day of experiment:
2. Place 5 pieces of Whatman filter paper in bottom of vial
3. Administer drug (400uL??) to filter paper:
 Control = 5% sucrose
 Drug = 5% sucrose, 10mg/mL yohimbine
4. Flip flies from food vials into vials with treatment
5. Let flies consume treatment for 2 hours
6. Test flies in sedation assay
For a 16 vial experiment: Make 8mL sucrose solution
 5% sucrose = 8mL diH20, 0.4g sucrose
4mL of sucrose solution = control
4mL of sucrose solution = Add 10mg/mL yohimbine
 Add 40mg yohimbine to the 4mL of 5% sucrose solution
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